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ABSTRACT 
Haemophilia A is a common X-linked recessive bleeding disorder, affecting about 
1 in 5000 males worldwide. It is caused by a deficiency of functional coagulation 
Factor VIII (FVIII), resulting in prolonged or abnormal bleeding episodes. The 
severity of the disease is related to the level of functional FVIII in the plasma. The 
FVIII gene is a large gene, located at Xq28 with a complex genomic organisation. 
It contains 26 exons spanning 186kb of genomic DNA, and produces a 9kb 
transcript, resulting in a functional protein of 2332 amino acids. 
Over 900 mutations, which span a wide variety of categories, including 
rearrangements; complete or partial gene deletions; large insertions; duplications; 
frameshift mutations; splicing defects; nonsense and missense mutations, have 
been identified in the FVIII gene. Most mutations are rare or family specific, except 
for the intron 22 inversion mutation, which is reported to account for 45-50% of 
mutations in severe haemophilia A patients in most populations. A second 
inversion mutation, in intron 1, accounts for approximately 3.8% of haemophilia A 
patients in the UK. In South Africa, diagnostic mutation testing is currently only 
available for the intron 22 inversion mutation. Linked marker analysis is used to 
track high risk alleles in families where the disease-causing mutation is unknown. 
This study aims to evaluate an mRNA-based method to identify disease-causing 
mutations in South African haemophilia A patients and improve the diagnostic 
service. Blood samples from 120 patients were tested first for the intron 22 and 
then for intron 1 inversion mutations. Inversion negative patients were analysed 
further using mRNA. 
A mutation has been identified in 73.3% (88/120) of all patients. 30% (36/120) of 
patients had the intron 22 inversion, 2.5% (3/120) an intron 1 inversion and 40.8% 
(49/120) of patients had a mutation identified by mRNA analysis. A mutation was 
not identified in the remaining 26.7% (32/120) due to sample and technical 
difficulties. 
Of the 49 mutations identified through mRNA analysis, 28 patients (57.1%) have a 
point mutation (17 missense (34.7%), 9 nonsense (18.4%) and 2 splice-site 
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mutations (4.1%)), 9 patients (18.4%) have a deletion and 7 patients (14.3%) have 
an insertion. Another 5 patients (10.2%) have a complex mutation (including 
patients where an exon deletion was detected on mRNA analysis, but no mutation 
was identified on DNA analysis). One mutation, c.3637insA, was found recurrently 
in 14% (6/43) of patients from the white population. This single base insertion 
results in a frameshift mutation with a premature stop codon at amino acid 1221 
(only translating about half the normal FVIII protein). This common mutation, 
together with haplotype analysis, suggests a founder effect for this mutation. 
mRNA analysis of the FVIII gene is a novel technique in mutation detection for 
haemophilia A. It decreases the costs involved in sequencing the coding region 
and it offers improved mutation detection compared to DNA analysis. 
Diagnostic testing in South Africa should be extended from the current intron 22 
inversion mutation to include DNA analysis for the intron 1 inversion and the 
founder mutation (c.3637insA) in white patients, followed by mRNA testing, 
starting with the analysis of the fragments spanning exon 14. mRNA analysis 
identifies an additional 55.7% of mutations compared to conventional diagnostic 
testing for the intron 22 inversion alone. 
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1 INTRODUCTION 
1.1 INTRODUCTION TO THE CHAPTER 
This chapter includes an introduction to haemophilia A, including the general 
background and history of the disorder, inheritance and prevalence, clinical 
symptoms and a description of the different severities. The current treatment 
options for haemophilia and potential side effects from treatment are also 
discussed. 
The role of factor VIII in the blood coagulation pathway is discussed. The FVIII 
gene and the wide variety of mutations occurring within the gene are reviewed. 
The different methods for DNA testing and the current DNA testing options 
available in South Africa are explained. 
The aim of this project is to optimise and implement an mRNA approach for 
mutation detection for haemophilia A in South Africa, with the intention of 
improving the diagnostic service, and assisting female relatives at risk of 
haemophilia by offering them conclusive carrier testing and prenatal diagnosis.  
 
1.2 HISTORY OF HAEMOPHILIA A 
Haemophilia A is one of the most common inherited bleeding disorders, caused by 
a deficient or non-functional coagulation Factor VIII (FVIII) (reviewed in Bhopale & 
Nanda, 2003). 
Haemophilia encompasses both haemophilia A and haemophilia B. Although the 
two are clinically similar, they can be differentiated by laboratory testing, as 
described in section 1.6 below. This study focuses on haemophilia A. 
The clinical manifestations of haemophilia have been recognised for many 
centuries. During the second century, the Talmud stated that male babies with two 
brothers, who died after excessive bleeding after being circumcised, need not 
undergo the procedure themselves. However, the first medical report of 
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haemophilia was only in 1803 by Otto in which he described a family showing 
symptoms spanning three generations (reviewed in McKusick, 1965). 
Although the specific type was unknown, haemophilia was well documented in the 
European royal family. Queen Victoria of England (1837-1901) passed on a 
mutation to the royal families of Spain, Germany and Russia (reviewed in 
McKusick, 1965). The pedigree of the European royal family (reviewed in Stevens, 
1999) can be seen in Figure 1.1 below. A paternal age effect may have been 
responsible for the disease as there was no other family history of the disorder, 
and Queen Victoria’s father was 52 years old when she was born (McKusick, 
1965). 
 
1.3 INHERITANCE AND PREVALENCE OF HAEMOPHILIA A 
Haemophilia A is a common X-linked recessive bleeding disorder that affects 
about 1 in 5000 males worldwide, with no ethnic or geographical predisposition 
(reviewed in Pandey & Mittal, 2001). The high prevalence of haemophilia is due to 
the X-linked mode of inheritance and the high mutation rate of the FVIII gene 
(Strauss, 1967; Vogel, 1977). Although the prevalence does not vary much 
between populations, it could be underestimated in developing countries due to 
poor diagnosis (reviewed in Graw, Brackmann, Oldenburg, et al., 2005). 
The majority (approximately 60%) of haemophilia A cases have a family history, 
however, the remainder are sporadic due to de novo mutations (reviewed in Graw, 
et al., 2005). In 90% of these families, the mutation has arisen in the parents or 
grandparents (Becker, Schwaab, Möller-Taube, et al., 1996). It has been reported 
that mutations causing haemophilia A originate 3.6 times more frequently in male 
germ cells than female germ cells. However, this sex ratio of mutation frequencies 
differs for each type of mutation. The mutation rate for point mutations is 5-10-fold 
higher and inversions more than 10-fold higher in male germ cells, while deletions 
are more than 5-fold higher in female germ cells (reviewed in Oldenburg, 
Ananyeva & Saenko, 2004b). Therefore a mother of a sporadic case of 
haemophilia has a high risk of being a carrier of the disorder. 
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As with all X-linked recessive conditions, there is a 50% chance that a female 
carrier will pass the defective gene to her child (male or female) (refer to Figure 
1.2a). While all female offspring born to a haemophiliac father are obligate 
carriers, all his sons will be unaffected (refer to Figure 1.2b). 
 
 
Figure 1.2: Inheritance of Haemophilia A, from an obligate carrier female (a) and 
an affected male (b). 
 
Although haemophilia A is an X-linked recessive condition, females can present 
with symptoms in the following instances: skewed X inactivation (e.g. Coleman, 
Genet, Harper, et al., 1993); inheritance of two mutant FVIII genes, one from each 
parent (e.g. Pola & Svojitka, 1957; Windsor, Lyng, Taylor, et al., 1995); X-
autosome translocation disrupting the FVIII gene (e.g. Migeon, Axelman, Jan de 
Beur, et al., 1989) or leading to preferential inactivation of the unaffected X-
chromosome; or a female with Turner Syndrome and a mutation in the FVIII gene 
on her only X chromosome. 
In developing countries, most patients with haemophilia are in the paediatric age 
group as they seldom reach adulthood due to inadequate treatment (Evatt & 
Robillard, 2000). They suffer from the pain of bleeding, the morbidity of 
orthopaedic deformity and finally death (reviewed in DiMichele, Chuansumrit, 
London, et al., 2006). 
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In South Africa in 2007, there were more than 1760 haemophilia patients on the 
National Haemophilia Register (Mahlangu & Gilham, 2007). In 2003, Hazewinkel, 
Hoogerwerf, Hesseling, et al., recorded the incidence of the disorder in the 
Western Cape as 7/100 000. They also describe the mean age of diagnosis for 
severe patients as 9 months, while moderate haemophiliac patients were 
diagnosed at 11 months. In addition, they state that, even with therapy, 
haemophilia causes significant morbidity in South African patients and their 
families. However, little is known about care of patients outside of the haemophilia 
treatment centres. 
 
1.4 CLINICAL SYMPTOMS OF HAEMOPHILIA A 
Haemophilia A is characterised by a deficiency or decrease in function of factor 
VIII which results in prolonged bleeding episodes. Typical clinical symptoms 
include: delayed bleeding and prolonged oozing after injuries, surgeries or tooth 
extractions, or renewed bleeding after initial bleeding has stopped (Arun & 
Kessler, 2001). 
The clinical presentation and severity of the disease is directly related to the level 
of functional FVIII activity (reviewed by Kulkarni & Lusher, 2001). The severity is 
greatly influenced by the mutations in the FVIII gene (reviewed in Pandey & Mittal, 
2001) and the proportion of severe, moderate and mild haemophilia A cases are 
about 50%, 10% and 40% respectively (Antonarakis, Rossiter, Young, et al., 
1995). However, Rizza, Spooner & Giangrande (2001) suggests a bias towards 
patients with severe haemophilia A in most studies as they are likely to attend 
clinic more frequently. The three types of haemophilia A are described in more 
detail below.  
 
1.4.1 Severe Haemophilia A 
Severe haemophilia A patients present with less than 1% factor VIII levels and 
frequently present with spontaneous bleeds into joints, muscles and internal 
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organs or abnormal bleeding after minor injuries. These patients are usually 
diagnosed in the first year of life and have an average of two to five spontaneous 
bleeding episodes per month (reviewed by Johnson & Thompson, 2005). 
 
1.4.2 Moderate Haemophilia A 
Moderately severe patients have between 1% and 5% factor VIII levels and have 
prolonged bleeding or delayed oozing after minor trauma or surgery, but seldom 
have spontaneous bleeding episodes. These patients are usually diagnosed 
before the age of five or six years and the frequency of the bleeding episodes can 
vary from once a month to once a year (reviewed by Johnson & Thompson, 2005). 
 
1.4.3 Mild Haemophilia A 
Mildly affected patients do not have spontaneous bleeding episodes but have 
abnormal bleeding only after significant trauma, surgery and major injuries. 
Individuals with mild haemophilia A have 5-35% of residual factor VIII activity and 
the frequency of bleeding may vary from once a year to once every ten years. 
These patients are often not diagnosed until later in life (reviewed by Hoyer, 1994; 
Johnson & Thompson, 2005). 
 
1.5 BLOOD COAGULATION PATHWAY AND ROLE OF FACTOR VIII 
Factor VIII is a plasma glycoprotein cofactor that serves as an essential 
component in the intrinsic blood coagulation pathway (Kaufman, 1992; Spiegel, 
Murphy & Stoddard, 2004). The blood coagulation pathway is an intricate process 
involving a cascade of coagulation factors and proteins which eventually form a 
blood clot. Essentially, an injury stimulates vasoconstriction and platelets to 
adhere to the damaged blood vessel wall and to each other at the site of injury 
(primary haemostasis), mediated by von Willebrand factor. The aggregating 
platelets release chemicals that initiate blood clotting via the intrinsic or extrinsic 
Improved Mutation Detection for Haemophilia A in South Africa 7 
pathways of the coagulation cascade to create a fibrin network to seal the damage 
in the blood vessel (secondary haemostasis) (summarised by Nathwani & 
Tuddenham, 1992; Voet & Voet, 1995). 
Upon activation, and in the presence of calcium ions and phospholipid surfaces, 
factor VIII and factor IX form an active complex, which activates factor X. 
Subsequent stages of the cascade proceed, resulting in the deposits of fibrin, the 
structural polymer of the blood clot (reviewed in Bowen, 2002). A schematic 
representation of the coagulation cascade is shown in Figure 1.3 below (Bowen, 
2002). If any of the factors involved in the coagulation pathway are deficient or 
defective, this would result in a condition of abnormal bleeding, as discussed in 
section 1.6 below. 
 
 
Figure 1.3: A schematic representation of the intrinsic and extrinsic pathways of 
the coagulation cascade leading to fibrin formation. 
Reviewed in Bowen (2002) 
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1.6 TREATMENT OF HAEMOPHILIA A 
1.6.1 Current Treatment Options 
As haemophilia A is caused by an absence or functionally abnormal FVIII 
(reviewed in Bhopale & Nanda, 2003), treatment of haemophilia involves 
replacement with either plasma-derived or recombinant clotting factor 
concentrates. Recombinant factor concentrates are preferred over plasma-derived 
replacements as the infectious agent transmission risk is reduced (reviewed in 
DiMichele, et al., 2006). 
Treatment may be given for several reasons: in an attempt to keep the factor VIII 
at a normal level to prevent “spontaneous” bleeding episodes, given before 
surgery to prevent excessive bleeding or after trauma. 
Although factor concentrate provides effective haemostasis, there are some 
contra-indications to the product. Factor concentrates have a short half-life so they 
need to be intravenously injected 2-3 times per week and patients have a 20-30% 
chance of developing inhibitors to FVIII. Factor concentrates also involve very high 
life-long medical expenditure and restrictive global access (reviewed in DiMichele, 
2005; Srivastava, 2005). Tuddenham (2005) estimated the life time cost of 
replacement therapy for one haemophilia patient to be £5 000 000. 
Laurian (2005) reviewed the research aiming to develop better replacement 
therapies with an increased protein stability to facilitate prophylaxis of one injection 
per week, or less (Pipe & Kaufman, 1997; Ananyeva, Kouiavskaia, Shima, et al., 
2001; Lillicrap, 2005); to reduce inhibitor formation (Barrow, Healey, Gailani, et al., 
2000); for infused factor concentrate therapies (reviewed in Hoots, 2005) and the 
possibility of oral instead of intravenous administration (Hemker, Hermans, Muller, 
et al., 1980). Also, production of the factor concentrates in larger quantities may 
make haemophilia A treatment cheaper (Brettler, 2005). 
Haemophilia A treatment in the future may include gene therapy, cell-based 
treatments and the development of novel clotting factor molecules, with a variety 
of potential biological advantages (reviewed in DiMichele, et al., 2006). Research 
into the potential for gene therapy is discussed in section 1.6.2. 
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1.6.2 Gene Therapy for Haemophilia A 
Gene therapy involves the treatment of inherited disease by the addition, insertion 
or replacement of a normal gene (Mueller & Young, 1998). Gene therapy raises 
many ethical issues because current treatments are now much safer than 
previously and gene therapy carries an unknown risk of long-term adverse effects 
(reviewed in Laurian, 2005). However it has the potential to provide long-term 
endogenous production of FVIII, especially if made affordable to the majority of 
haemophilia patients (reviewed in DiMichele, 2005). 
In theory, gene therapy offers potential cost savings with fewer treatments versus 
a life time cost for one patient’s replacement therapy (reviewed in Tuddenham, 
2005) and haemophilia gene therapy does not require organ specificity to achieve 
sufficient protein expression (White & Samulski, 2005). However, inhibitor 
development is unlikely to change with gene therapy (Brettler, 2005). 
Many gene therapy trials for haemophilia A have used vectors like adeno-
associated viruses, adenoviruses and retroviruses. Adeno-associated viral vectors 
show long-term positive results in mouse and dog models but human trials have 
been disappointing, with low levels of circulating FVIII and only transient efficacy 
(Snyder, Miao, Meuse, et al., 1999; Scallan, Lillicrap, Jiang, et al., 2003; 
Giangrande, 2004; Negrier, 2004; reviewed in Laurian, 2005). DiMichele, et al. 
(2006) and Tuddenham (2005) reviewed gene therapy with adenovirus and 
retrovirus vectors. Adenoviruses have been associated with acute negative effects 
including hepatotoxicity and thrombocytopenia and even death in a patient with 
ornithine transcarbamylase deficiency treated with an adenovirus vector 
(DiMichele, et al., 2006; Tuddenham, 2005). Retrovirus vectors are relatively well 
tolerated by the immune system but there are concerns about the long-term risk of 
insertional mutagenesis by integration into the host genome (DiMichele, et al., 
2006; Tuddenham, 2005). For example, there is a report of leukaemia 
development in three children treated for X-linked severe combined 
immunodeficiency, due to insertional mutagenesis by a retrovirus vector, one of 
whom subsequently died (Hacein-Bey-Abina, Von Kalle Schmidt, et al., 2003). In 
two recent reviews (Gabrovsky & Calos, 2008; Mannucci, 2008), no successful 
gene therapy trials have been reported. 
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Most gene therapy trials to date have involved adult subjects (White, 2001), 
although the ultimate goal is to develop treatments for children (reviewed in 
DiMichele, et al., 2006). Ethicists believe that children and young adults below the 
age of 25, should not be recruited into gene therapy trials as safety, especially 
long-term, has not been demonstrated and is not guaranteed (Brettler, 2005). 
 
1.6.3 Haemophilia A Treatment in South Africa 
In South Africa, patients attending clinics at a haemophilia treatment centre (in one 
of the 16 centres in Johannesburg, Cape Town, Port Elizabeth, East London, 
Durban, Pretoria, Bloemfontein, Potchefstroom, Mthatha and Polokwane) are 
treated with prophylactic factor replacement therapy. The amount of factor 
administered at each treatment is dependent of the weight of the patient. The 
recommendations are as follows: for less than 20kg require 300U, 20-40kg need 
800U, 40-54kg requires 1000U, 55-67kg need 1300U and patients between 67kg 
and 80kg requires 1500U. This treatment regimen facilitates the appropriate 
management of haemophilia and reduces the associated complications such as 
musculoskeletal deformities and death (Mahlangu & Gilham, 2007). 
Treatment products available for patients without inhibitors include: plasma-
derived, solvent detergent-treated FVIII (such as Haemosolvate Factor VIII 
concentrate from National Bioproducts Institute), desmopressin for mild/moderate 
haemophilia patients (such as 1-deamino-8-D-arginine vasopressin (DDAVP) from 
Stimate®), antifibrinolytic and adjunctive agents (Mahlangu & Gilham, 2007). 
Recombinant human FVIII, Kegonate (FVIII), was registered with the South African 
regulatory authority in October 2008 (Dr Mahlangu, personal communication, 
2009). 
In South Africa the 2008/2009 cost for 1000U of Haemosolvate factor VIII is 
R1986.19 (2008/2009 price list obtained from National Bioproducts Institute). As 
per current guidelines, an average adult male with severe haemophilia A, weighing 
between 67kg and 80kg would require 1500U per treatment (at R3007.82). 
Discovery Health, the biggest medical aid insurer in South Africa, only covers a 
maximum of R14 000 per month in their chronic illness benefits for 2009 
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(https://www.discovery.co.za/contentSources/logged_out/pdfs/2007_cib_formulary.pdf). 
This means that a patient is only covered for just over 4 treatments per month.  
For patients with FVIII inhibitors, treatment products available are recombinant 
FVIIa (for example, NovaSeven® from Novo Nordisk) or an activated prothrombin 
complex concentrate known as FEIBA® (Factor Eight Inhibitor Bypassing Agent by 
Adcock Ingram Critical Care) together with antifibrinolytic and adjunctive agents 
(Mahlangu & Gilham, 2007). 
Hazewinkel, et al. (2003) reported the majority of haemophilia patients (73%) in 
the Western Cape are treated with factor “on demand” after a bleed. Some 
patients (20%) with recurrent severe bleeds in joints are given clotting factor three 
times a week as “periodic prophylaxis” until the joint has improved and a few 
patients (7%) receive “continuous prophylaxis” with Factor from shortly after birth. 
 
1.7 FACTOR VIII INHIBITORS 
Approximately 20-35% of severe haemophilia A patients, and occasionally patients 
with a milder phenotype, develop antibodies to exogenous FVIII derived from FVIII 
replacement therapy (Lusher, Arkin, Abildgaard, et al., 1993; Hay, 1998; Darby, 
Keeling, Spooner, et al. 2004). These antibodies, or inhibitors, bind to infused FVIII 
and reduce its half-life and neutralise the coagulation activity (Mannucci & 
Tuddenham, 2001). 
Inhibitor formation is a complex process and is reviewed by Astermark (2006). 
Several factors (genetic, environmental and treatment-related) are thought to 
influence inhibitor development. These are described in more detail below. 
 
1.7.1 Genetic Factors 
Genetic factors are believed to be involved in inhibitor development as siblings 
have a higher risk (50%) of developing inhibitors than members of an extended 
haemophiliac family (9%) (Gill, 1999). The Malmö International Brother Study 
Improved Mutation Detection for Haemophilia A in South Africa 12 
(MIBS) found that inhibitor concordance was 78% in siblings, significantly higher 
than in unrelated patients (Astermark, Berntorp, White, et al., 2001). Interestingly, 
a study by Scharrer, Bray & Neutzling (1999) found that the inhibitor incidence was 
51.9% in African-Americans compared to 25.8% in Caucasians, suggesting 
patients with African heritage are at higher risk of developing inhibitors. 
Genetic factors which influence inhibitor development with FVIII replacement 
therapy include: the type of causative FVIII gene mutation (Oldenburg, Schroder, 
Brackmann, et al., 2004a); the MHC class I and II phenotype (and polymorphisms 
in the genes encoding cytokines and immune regulatory molecules (reviewed in 
Astermark, 2006).  
 
1.7.2 Environmental and Treatment Related Factors 
In monogenic conditions, it is expected that monozygotic twins will present with the 
same phenotype. However, this is not the case for inhibitor development in 
haemophilia A, indicating that non-genetic factors influence inhibitor risk 
(Astermark, et al., 2001). Some of these environmental factors include age when 
treatment was initiated, immune system challenges, type of factor concentrate 
used and mode of administration. 
 
1.8 LABORATORY DIAGNOSIS OF HAEMOPHILIA A 
There are other disorders that are clinically similar to haemophilia A, for example 
haemophilia B (factor IX deficiency) or von Willebrand disease (due to a deficiency 
of von Willebrand factor). It is important to accurately diagnose and differentiate 
between the specific types of bleeding disorders, to determine the therapeutic 
intervention required and for accurate genetic counselling. A diagnosis is made 
using the following tests. 
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1.8.1 Coagulation Screening Test 
This involves a platelet count, bleeding time or a platelet function analysis, 
activated partial thromboplastin time (aPTT, to measure the intrinsic pathway) and 
prothrombin time (PT, to measure the extrinsic or tissue-factor pathway) (reviewed 
by Dahlbäck, 2000; Johnson & Thompson, 2005). The diagnostic interpretation of 
the coagulation screening test results as suggested by the World Federation of 
Haemophilia (2005) can be found in Table 1.1.  
 
Table 1.1: Interpretation of the coagulation screening test for different bleeding 
disorders. 
Possible condition Platelet count Bleeding time PT aPTT 
Normal Normal Normal Normal Normal 
Haemophilia A or B Normal Normal Normal Prolonged 
Von Willebrand 
disease 
Normal or 
reduced 
Normal or 
prolonged  
Normal Normal or 
prolonged 
Platelet defect Normal or 
reduced 
Normal or 
prolonged 
Normal Normal 
 
1.8.2 Coagulation Factor Assays 
Since haemophilia A and B are indistinguishable on coagulation screening tests, 
their diagnosis must be confirmed using coagulation factor assays. These assays 
measure the amount of a specific coagulation factor, for example factor VIII, factor 
IX or von Willebrand factor. The normal range for factor VIII clotting activity is 50-
150%. In haemophilia A, the factor VIII activity is less than 35% with normal factor 
IX and von Willebrand factor levels. Severe haemophilia A is diagnosed with less 
than 1% factor VIII activity, while moderate and mild patients have a factor VIII 
clotting activity of 1-5% and 5-35%, respectively. About 10% of female 
haemophilia A carriers have a factor VIII clotting activity less than 35%, indicating 
that coagulation factor assays are unreliable in detecting the majority of female 
carriers (reviewed by Johnson & Thompson, 2005). The FVIII:vWF ratio is often 
decreased in female haemophilia A carriers and was routinely used for carrier 
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detection, however, the accuracy of this test is limited and variable among 
individual laboratories (Rimoin, Connor, Pyeritz, et al., 2007). 
 
1.8.3 Molecular Genetic Testing 
Coagulation screening tests and coagulation factor assays are generally sufficient 
to make a clinical diagnosis of haemophilia A. However, the detection of carrier 
females for haemophilia A (as with most X-linked recessive conditions) is relatively 
difficult because most females are asymptomatic and the information provided by 
a coagulation assay can be equivocal due to random X-chromosome inactivation 
(reviewed in Pandey & Mittal, 2001). DNA based analysis (using either direct 
mutation detection or indirect/linked marker analysis, discussed in section 1.11.1 
and 1.11.2 respectively) is able to accurately detect carriers and provide prenatal 
testing for at risk individuals with 95% confidence (reviewed in Pandey & Mittal, 
2001). 
Although DNA testing is a more costly diagnostic tool, the benefits include: a 
definitive diagnosis, accurate carrier testing, prenatal diagnostic options and 
identifying symptomatic carriers that may require treatment (Sorenson, Jennings-
Grant & Newman, 2003; Ludlam, Pasi, Bolton-Maggs, et al., 2005). Knowledge of 
the disease-causing mutation may be useful in predicting the disease severity, the 
likelihood of inhibitor formation and even selecting the best candidates for different 
gene therapies in the future (reviewed in DiMichele, et al., 2006). 
 
1.9 THE FACTOR VIII GENE AND PROTEIN 
1.9.1 The FVIII Gene 
The factor VIII gene (FVIII) is a large gene with a complex genomic organisation 
(reviewed in Pandey & Mittal, 2001). The gene was cloned between 1982 and 
1984 by Gitschier, Wood, Goralka, et al. (1984), and is located in the most distal 
band of the long arm of the X chromosome (Xq28) (Poustka, Dietrich, 
Langenstein, et al. 1991; Freije & Schlessinger, 1992) (refer to Figure 1.4, 
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obtained from http://www.genecards.org/pics/loc/GC0XM153717.F8.png). The 
Human Genome Organisation (HUGO) database (http://www.genenames.org/) 
uses the F8 gene symbol, however, the Haemophilia A Mutation, Structure, Test 
and Resource Site (HAMSTeRS) (http://europium.csc.mrc.ac.uk/Main/main.htm) uses 
FVIII. The FVIII symbol will be used in this dissertation. 
 
 
Figure 1.4: A schematic representation of the position of the FVIII gene (arrow) on 
the X chromosome. 
 
The FVIII gene spans 186kb of genomic DNA and consists of 26 exons encoding 
an mRNA transcript of approximately 9kb (Toole, Knopf, Wozney, et al., 1984; 
Wood, Capon, Simonsen, et al., 1984). It encodes a 2351 amino acid polypeptide 
(Vehar, Keyt, Eaton, et al., 1984), from which 19 amino acids are cleaved off the 
N-terminal, to produce the mature, functional protein of 2332 amino acids 
(reviewed in Graw, et al., 2005). The genomic organisation of the FVIII gene is 
represented schematically in Figure 1.5.  
 
 
Figure 1.5: A schematic representation of the FVIII gene.  
The relative positions and sizes of the exons (green) and introns (white) of the FVIII gene, 
and the F8A and F8B genes in intron 22 (in red and blue respectively) with their 
transcription orientation are shown (adapted from Graw, et al., 2005). 
 
The FVIII gene is unusual in that within intron 22 (IVS22) a CpG island exists that 
is associated with two additional transcripts, F8A (Levinson, Kenwrick, Lakich, et 
al., 1990) and F8B (Levinson, Kenwrick, Gamel, et al., 1992) as can be seen in 
Figure 1.5. F8B is a 2.7kb transcript and is transcribed in the same direction as the 
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FVIII gene, using a private exon and FVIII exons 23 to 26. The function of the F8B 
transcript and its potential translated product remains unknown (reviewed in Graw, 
et al., 2005). The F8A gene spans 2kb, contains no introns and is transcribed in 
the opposite orientation to the FVIII gene. It encodes a 40-kDa Huntingtin-
associated protein (Peters & Ross, 2001), which is thought to be involved in the 
aberrant nuclear localisation of the huntingtin protein in Huntington Disease 
(reviewed in Graw, et al., 2005). Two homologous copies of F8A have been found 
approximately 400kb telomeric to the FVIII gene (Levinson, et al., 1990). The 
significance of the F8A transcript and its homologues will be described in more 
detail in section 1.10.1.1 below. 
Although most factor VIII protein synthesis takes place in the liver, other tissues do 
contain detectable levels of FVIII mRNA (Wion, Kelly, Summerfield, et al., 1985). 
 
1.9.2 Activation of the FVIII Protein 
FVIII is a large glycoprotein with three distinct domain types, in the arrangement 
(NH2)-A1-A2-B-A3-C1-C2-(COOH) (Vehar, et al., 1984; Lenting, van Mourik & 
Mertens, 1998; O’Brien, Mastri & Fay, 2000), as can be seen in Figure 1.6. 
Activation of FVIII involves proteolysis by thrombin or FXa, which cleaves the FVIII 
protein at Arg1689 (between the B and A3 domain), producing a heavy (A1-A2-B) 
and light (A3-C1-C2) polypeptide chain (Eaton, Rodriguez & Vehar, 1986). The 
heavy and light chain heterodimers are covalently bound to a copper ion, although 
the role of the copper in the structure and function of FVIII is unclear (reviewed in 
Bhopale & Nanda, 2003; Fang, Wang & Wang, 2007). 
The heavy chain is cleaved further at Arg740 (between A2 and B domain) 
releasing the B domain from the polypeptide and at Arg372 (between the A1 and 
A2 domains) to produce the A1 and A2 polypeptides of 50 and 43kDa in size, 
respectively. The light chain is 73kDa (Eaton, et al., 1986). The presence of the 
50, 43 and 73kDa polypeptides correlates with weak thrombin activation (Fulcher, 
Roberts & Zimmerman, 1983; Eaton, et al., 1986). 
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Figure 1.6: A schematic representation of the FVIII protein.  
The translated native/precursor protein is shown, which after cleavage by thrombin, 
becomes activated into the mature FVIII protein (adapted from Graw, et al., 2005). 
 
The inactive precursor form of FVIII binds to and circulates with von Willebrand 
factor (vWF). Cleavage at the Arg1689 residue releases FVIII from vWF (Pittman 
& Kaufman, 1988) and permits the interaction of vWF with a phopsholipid surface 
(Walker, Chavin & Fay, 1987; Brandstetter, Bauer, Huber, et al., 1995) and FVIII 
with platelets (reviewed in Fang, et al., 2007) (refer to the blood coagulation 
pathway in section 1.6). 
 
1.10 MUTATIONS IN THE FVIII GENE 
Over 900 mutations causing haemophilia A have been identified in the FVIII gene. 
These were obtained from the results of genetic analysis of over 2500 DNA 
samples from haemophilia A patients examined for molecular defects using a 
variety of methods. These results were compiled into a database of FVIII gene 
mutations and published by Tuddenham, Cooper, Gitschier, et al. (1991). This 
database is summarised, continually updated and available online at the 
Haemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS) at 
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http://europium.csc.mrc.ac.uk/Main/main.htm (Tuddenham, Schwaab, Seehafer, et al., 
1994).  
Haemophilia A disease-causing mutations span a wide variety of categories, 
including rearrangements; complete or partial gene deletions; large insertions; 
duplications; frameshift mutations; splicing defects; nonsense and missense 
mutations (Tuddenham, et al., 1994). In a review, Antonarakis, et al. (1995) 
analysed data from an international consortium and found that point mutations 
account for 46% of FVIII mutations, inversions for 42% and deletions account for 
8% of severe haemophilia A cases. 
Many of these mutations are rare or family specific, except for two relatively 
common recurrent inversion mutations occurring in intron 22 and intron 1 of the 
FVIII gene. These two inversion mutations, which occur fairly frequently, are 
described in section 1.10.1 below. 
 
1.10.1 Gene Rearrangements 
Large gene rearrangements are responsible for 40-50% of all severe Haemophilia 
A cases (Antonarakis, et al., 1995). 
1.10.1.1 Intron 22 Inversion 
While studying the mRNA from haemophilia A patients, Naylor, Brinke, Hassock, 
et al., (1993) found that approximately half of the patients in their cohort did not 
have amplification across intron 22. It was later determined that this non-
amplification was due to an inversion mutation. As discussed in section 1.9.1, 
intron 22 of the FVIII gene contains an additional transcript, the F8A gene (int22h-
1). Two additional copies of the F8A gene, a distal or telomeric copy (int22h-3) and 
a proximal or centromeric copy (int22h-2), are located approximately 400kb and 
500kb telomeric to the FVIII gene (Lakich, Kazazian, Antonarakis, et al., 1993; 
Naylor, et al., 1993; Naylor, Buck, Green, et al., 1995). The intron 22 inversion 
mutation results from an intrachromosomal crossover event between the 
intragenic copy (int22h-1) and one of the two extragenic copies (int22h-2 or int22h-
3) (Lakich, et al., 1993; Naylor, et al., 1993; Bagnall, Waseem, Green, et al., 
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2002). As a result, the FVIII gene is separated into two parts in opposite 
orientations, causing the mRNA to be interrupted so that synthesis of the FVIII 
protein is incomplete (Maugard, Tuffery, Aguilar-Martinez, et al., 1998). 
This intron 22 inversion mutation accounts for approximately 45-50% of severe 
haemophilia A patients’ mutations (Lakich, et al., 1993; Naylor, et al., 1993; 
Bagnall, et al., 2002). In a study of 2093 severe haemophilia A patients, 
Antonarakis, et al. (1995) found that the distal copy (int22h-3) is involved in 35% of 
cases, the proximal copy (int22h-2) in 7%, while just over 1% of cases involved an 
additional abnormal pattern. Although most inversion mutations involve int22h-1 
and either int22h-2 or int22h-3, rare, atypical inversions have been reported 
(Lakich, et al., 1993; Naylor, Nicholson, Goodeve, et al., 1996; Yamazaki, Mohri, 
Inaba, et al., 1997). These atypical inversions are thought to be due to a 
rearrangement between int22h-1 and a third, truncated copy of the F8A gene 
within the FVIII gene (reviewed in Bowen, 2002). 
For many years, it was believed that int22h-2 and int22h-3 were orientated in the 
same direction as each other, but in opposite orientation to int22h-1, because 
either copy can be involved in the intron 22 inversion mutation (Lakich, et al., 
1993). Sequencing of the human genome, especially the X chromosome, revealed 
that int22h-2 and int22h-3 are actually in opposite orientations to each other, and 
that int22h-2 (the proximal copy) is in the same orientation as int22h-1 (Ross, 
Grafham, Coffey, et al., 2005). 
It has subsequently been found that int22h-2 and int22h-3 are part of an imperfect 
palindrome (as illustrated in Figure 1.7a, adapted from Bagnall, Giannelli & Green, 
2006). Bagnall, et al. (2006) noted that if all X chromosomes had the arrangement 
suggested by Ross, et al. (2005), recombinations between int22h-1 and int22h-2 
would result in deletions or duplications due to intra-chromosomal 
rearrangements. Bagnall, et al. (2006) proposed that the arms of this palindrome 
undergo intra-chromosomal recombination, thereby changing the orientation of 
int22h-2 and int22h-3 relative to int22h-1 (refer to Figure 1.7b and c). They further 
suggested that this int22h-2 and int22h-3 rearrangement is polymorphic. 
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Figure 1.7: The proposed mechanism causing the palindrome inversion 
polymorphism between int22h-2 and int22h-3.  
(a) shows the common arrangement, while (b) shows the proposed intra-chromosomal 
recombination resulting in the inverted palindrome configuration (c). Obtained from 
Bagnall, et al. (2006) 
 
Bagnall, Giannelli, Green, et al. (2005) also illustrated the possible results of 
recombinational events between the different int22h copies, with respect to the 
int22h-2 and int22h-3 palindromic polymorphism. The distal (type I) and proximal 
(type II) intron 22 inversion mutations resulting from intra-chromosomal 
recombinations are illustrated in Figure 1.8A and B below. Inter-chromosomal 
rearrangements between mis-aligned int22h copies may cause deletions or 
duplications, as illustrated in Figure 1.8C and D below. 
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Figure 1.8: An illustration of the possible recombinational events between the 
different int22h copies.  
(A) and (B) show the proposed intra-chromosomal rearrangements causing int22h-related 
inversions. (C) and (D) show the inter-chromosomal or intra-chromosomal recombinations 
between mis-aligned int22h repeats causing deletions or duplications. The left panel 
shows the mode of rearrangement while the right panel shows the structure of wild type 
and mutant alleles. Obtained from Bagnall, et al. (2005). 
 
Family studies have found that the intron 22 inversion occurs almost exclusively 
during spermatogenesis from a normal male (Rossiter, Young, Kimberland, et al., 
1994), usually the patient’s maternal grandfather (Antonarakis, et al., 1995). 
In South Africa, Dangerfield, Manga, Field, et al. (1997) found the intron 22 
inversion mutation to account for 43% (6/14) of black and 32% (13/41) of white 
haemophilia A cases. All six of the black patients had the type I type inversion, 
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while in the white group, 69% (9/13) were of the type I type and 31% (4/13) were 
type II inversions. The frequency of the intron 22 inversion mutation in the South 
African white population group is one of the lowest reported (Antonarakis, et al., 
1995). The type II inversion has subsequently been identified in black South 
African patients and these results will be presented in section 3.2.1.2. 
1.10.1.2 Intron 1 Inversion 
An intrachromosomal inversion between a 1kb sequence in intron 1 (int1h-1) of the 
FVIII gene and a second sequence (int1h-2), repeated in the reverse orientation 
approximately 140kb telomeric to the FVIII gene occurs in about 4.8% of families 
with severe haemophilia A in the United Kingdom (Bagnall, et al., 2002). This 
mutation was found in 3.0% of Chinese patients (Liang, Yan, Xioa, et al., 2008); 
2.7% of Indian patients (Ahmed, Ivaskevicius, Kannan, et al., 2005), and 15% of 
severe haemophilia A patients in the Netherlands (Boekhorst, Verbruggen, 
Lavergne, et al., 2005). 
 
1.10.2 Single Base Substitutions 
Single base mutations or point mutations include missense mutations (which result 
in a single amino acid change), nonsense mutations (change an amino acid into a 
stop codon) and mRNA splice site or splice junction mutations (which change the 
true splice site or create a new one, resulting in exon skipping or the insertion of 
intronic sequence into the mRNA sequence) (reviewed in Bowen, 2002). In August 
2007, there were 615 different single base substitutions reported, of which, 75% 
were missense mutations, 15% were nonsense mutations and 10% splice junction 
alterations (HAMSTeRS database). 
 
1.10.3 Deletions 
In a 2003 review of the molecular pathology of haemophilia A on the HAMSTeRS 
mutation database, the database lists over 270 deletion mutations in the FVIII 
gene. These deletions may be micro-deletions of 1bp or more (causing a frame 
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shift mutation), partial gene deletions or deletions of 210kb (deleting the entire 
gene). Most of these mutations result in frameshift mutations which are associated 
with severe haemophilia A (HAMSTeRS database; reviewed in Bowen, 2002). 
 
1.10.4 Insertions 
The 2003 review of the mutation database describes over 57 different insertions 
varying in size from 1bp up to 2.1kb as well as a 3.8kb retrotransposon or LINE 
element (Kazazian, Wong, Youssoufian, et al., 1988). Single base insertions are 
most common. All insertions are associated with severe disease as they either 
result in a frameshift mutation or gross insertions which adversely affect the gene 
product (HAMSTeRS database; reviewed in Bowen, 2002). 
 
1.11 MOLECULAR GENETICS TESTING FOR HAEMOPHILIA A 
DNA testing for haemophilia A, using either direct mutation detection (section 
1.11.1) or indirect or linked marker analysis (section 1.11.2), is used for 
confirmation of diagnosis (in affected patients), carrier testing (in at risk female 
relatives) and prenatal testing. Direct mutation detection provides a more accurate 
diagnosis of haemophilia A than coagulation screening tests and coagulation 
factor assays, particularly in carriers and for prenatal diagnosis. However, the 
highly heterogeneous nature of mutations and the complexity of the FVIII gene can 
make direct mutation detection difficult (reviewed in Pandey & Mittal, 2001). 
Indirect detection or linked marker analysis may be more useful in these cases. 
DNA mutation results must be interpreted with caution, as there is a potential risk 
of somatic mosaicism in families with sporadic haemophilia A of approximately 
10% which could cause uncertainty regarding recurrence risks in mothers who 
appear to be mutation negative (Leuer, Oldenburg, Lavergne, et al., 2001; 
reviewed in Peyvandi, Jayandharan, Chandy, et al., 2006). 
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DNA testing is important for prenatal diagnosis, as it influences obstetric decisions, 
delivery options, and early care of haemophilia, even if the family decide not to 
terminate the pregnancy (Baty, Drayna, Leonard, et al., 1986). 
 
1.11.1 Direct Mutation Detection 
Direct detection (detecting the disease-causing mutation) is used in haemophilia A 
with high accuracy and a high detection rate in haemophilia A families. It is able to 
detect mutations in familial and sporadic cases, even if the proband is unavailable 
(reviewed in Peyvandi, et al. 2006). 
Currently in South Africa, direct mutation analysis is only available for the intron 22 
inversion mutation in the FVIII gene (refer to section 1.10.1.1). Detection of this 
mutation involves the use of Southern blot analysis as described in Lakich, et al. 
(1993). Genomic DNA is digested with the Bcl I restriction enzyme and the 
fragments of interest are detected using the p482.6 probe, labelled with 32P 
(Oldenburg, Rost, El-Maarri, et al., 2000). All three copies of int22h are 
distinguished as different sized fragments as follows: int22h-1 (FVIII gene 
fragment) is 21.5kb; int22h-2 (proximal copy) is 14kb; while int22h-3 (distal copy) 
is 16kb (Naylor, et al., 1995). The type of inversion can be determined by the band 
patterns observed by Southern blotting (reviewed by Goodeve, 1998), as shown in 
Figure 1.9.  
Bagnall, et al. (2006) recently developed a single-tube, long-range PCR assay to 
test for the intron 22 inversion mutation. Primers were specifically designed to 
amplify each copy of int22h (int22h-1, int22h-2 and int22h-3) in 10kb, 11kb and 
12kb fragments respectively, which are resolved on a 0.5% agarose gel. This 
assay is able to distinguish between the different types of inversions in patients 
and carrier females, and is able to identify deletions and duplications resulting 
from recombinations between int22h sequences. 
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Figure 1.9: A diagrammatic representation of the intron 22 inversion mutation, 
showing schematic results obtained from Southern blot analysis after digestion 
with Bcl I, with the expected sizes for both types of inversion mutation.  
 
1.11.1.1 Mutation Detection Strategies 
Many centres perform mutation pre-screening that rely on heteroduplex formation 
and the subsequent detection of mismatched heteroduplexes (reviewed by 
Keeney, Mitchell & Goodeve, 2003). The three main heteroduplex detection 
methods include denaturing gradient gel electrophoresis (DGGE) (Higuchi, 
Antonarakis, Kasch, et al., 1991); conformational sensitive gel electrophoresis 
(CSGE) (Ganguly, Rock, & Prockop, 1993) and denaturing high performance liquid 
chromatography (dHPLC) (Oefner & Underhill, 1995). Another method of pre-
screening includes protein truncation testing (PTT) which detects truncating 
mutations at the protein level (Maugard, et al. 1998); however, missense 
mutations would not be detected using this method.  
Aberrant products obtained from these pre-screening techniques are then resolved 
by DNA sequencing, the gold standard for mutation detection (reviewed by 
Keeney, et al., 2003).  
Multiplex ligation-dependent probe amplification (MLPA) is a relatively new 
technique that detects copy number quantification, such as deletion or duplication 
mutations. As mutations and/or polymorphisms very close to the probe ligation site 
may result in a false positive MLPA result, all apparent single exon 
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deletions/duplications require confirmation using a different technique. Point 
mutations would not be detected using MLPA 
(http://www.mlpa.com/WebForms/WebFormProductDetails.aspx?Tag=tz2fAPIAupLo0TRB
qtiGHA||&ProductOID=kZ3txtB8eJg|) 
Another method of mutation detection involves the analysis of mRNA. This method 
has proved successful in previous studies, for example Naylor, et al. (1992) 
detected mutations in all 28 subjects studied, and the study also resulted in the 
discovery of the intron 22 inversion mutation. A mRNA-based approach to assess 
the transcribed FVIII gene, will therefore detect a wide range of mutations such as 
large rearrangements, deletions, insertions, mutations affecting splicing and point 
mutations at a reduced cost due to the large size of the FVIII gene at a DNA level. 
 
1.11.2 Indirect Detection or Linked Markers 
Linked marker analysis uses two types of markers, namely: those that can be 
detected using a restriction enzyme (or RFLP markers) and short tandem repeat 
sequences (STRs). STR markers result from repeat differences in a stretch of di- 
or tri-nucleotide repeats and are distributed randomly throughout the whole 
genome (reviewed in Pandey & Mittal, 2001). 
Certain polymorphic markers within or close to the FVIII gene (to reduce the 
chance of recombination between the gene and the marker) are used to track the 
inheritance of the high-risk X chromosome in families affected with haemophilia A 
(reviewed in Pandey & Mittal, 2001). Linkage needs DNA from an affected 
proband to determine the high-risk X-chromosome, and the mother of the proband 
must be informative (heterozygous) for at least one of the polymorphic linked 
markers tested. 
Linkage analysis is rapid, relatively inexpensive to perform and 99% reliable in 
familial cases of haemophilia A. However, linkage analysis can only exclude a 
female relative from being a carrier in sporadic cases (which account for up to 
40% of haemophilia A cases) (reviewed in Peyvandi, et al. 2006) as a high risk 
allele cannot detect where the mutation arose in a sporadic case. Also some 
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families may not be informative for any of the linked markers tested, and 
depending on the marker, there may be a chance of recombination between the 
gene and the marker (reviewed in Pandey & Mittal, 2001). 
In South Africa, the Diagnostic Molecular Genetics Laboratory at the Division of 
Human Genetics, National Health Laboratory Service (NHLS) and School of 
Pathology, the University of the Witwatersrand in Johannesburg uses three STR 
markers for haemophilia A linked marker analysis, namely two intragenic markers 
(in introns 13 and 22 of the FVIII gene) (Lalloz, McVey, Pattinson, et al., 1991; 
Lalloz, Schwaab, McVey, et al., 1994) and one extragenic marker (p39), 500kb 3’ 
to the FVIII gene (Wehnert, Reiner & Caskey, 1993). 
A study by Dangerfield, et al. (1997) found the combination of the two intragenic 
markers (intron 13 and intron 22) to be 100% informative in black families (5 
families) and 67% (24 families) informative in the white group. When the p39 
extragenic marker was included, the linked marker informativity increased to 91% 
of white South African patients (McKibbin, 2002). 
Further, the findings of Dangerfield, et al. (1997) suggested the presence of a 
founder haemophilia A haplotype in the Afrikaner population of alleles 20 and 26 
repeats for the intron 13 and intron 22 markers respectively, thereby suggesting a 
possible common founder mutation. However, no common founder mutation was 
identified by sequencing the coding region of the FVIII gene (Dangerfield & 
Manga, unpublished data). The high incidence of other disorders such as 
porphyria variegata (Dean, 1971) and familial hypercholesterolemia (Jenkins, 
Nicholls, Gordon, et al., 1980) in the Afrikaner population has been attributed to 
founder effect. 
 
1.12 AIMS OF THE PROJECT 
1.12.1 Motivation for the Project 
Currently, the Diagnostic Molecular Genetics Laboratory, Division of Human 
Genetics, NHLS and School of Pathology, the University of the Witwatersrand, 
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Johannesburg is only able to offer direct mutation detection for the intron 22 
inversion mutation for haemophilia A. As this mutation only accounts for 32-43% of 
mutations in patients with haemophilia A in South Africa (section 1.10.1.1), the 
disease-causing mutation in the remaining patients remains unidentified. This 
impacts on carrier testing and prenatal diagnosis options for family members at 
risk of haemophilia A, especially if the family is uninformative on linked marker 
analysis. 
Knowledge of the disease-causing mutation may have clinical significance for 
appropriate patient management, as it may indicate disease severity, may help 
predict patients at risk of developing inhibitors to FVIII replacement therapy 
(section 1.7) and in the future, could identify prospective candidates for gene 
therapy (section 1.6.2). 
mRNA analysis for haemophilia A has proved successful in previous studies of 
haemophilia A mutation detection, for example Naylor, et al. (1992) detected 
mutations in all 28 subjects studied, and the study also resulted in the discovery of 
the intron 22 inversion mutation. mRNA analysis has also proved useful in 
mutation detection in other diseases such as Duchenne and Becker Muscular 
Dystrophy (for example, Roest, Bout, van der Tuijn, et al., 1996), breast and 
ovarian cancers (examples include Spearman, Sweet, Zhou, et al., 2008; Rhei, 
Bogomolniy, Federici, et al., 1998), and neurofibromatosis (an example described 
in Pros, Gómes, Martín, et al., 2008). 
As DNA-based analysis has not been as useful as was expected (Dangerfield & 
Manga, unpublished data) and is very expensive because of the large size of the 
FVIII gene, it is hoped that an mRNA-based approach to assess the transcribed 
FVIII gene, will detect a wide range of mutations such as large rearrangements, 
deletions, insertions, mutations affecting splicing and point mutations at a reduced 
cost. 
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1.12.2 The Specific Aims of the Project 
1. To develop and assess an mRNA-based mutation detection strategy for FVIII 
gene mutations. 
2. To improve the molecular genetic diagnostic service available to haemophilia 
A patients and their families. 
3. To identify the potential founder mutation in the Afrikaans population.  
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2 SUBJECTS AND METHODS 
2.1 INTRODUCTION TO THE CHAPTER 
This chapter describes the subjects obtained for the project and the methods used 
to analyse the samples. Fresh blood from which mRNA and DNA was extracted 
for analysis was collected from patients with haemophilia A. The patients were 
analysed for the intron 22 inversion mutation. The mRNA was reverse transcribed 
into more stable cDNA, amplified by PCR and sequenced. All sequences were 
compared to a reference sequence to detect mutations. These mutations were 
compared to an online mutation database to determine whether they were 
previously reported mutations or polymorphisms. An attempt was made to confirm 
all mutations on the patients’ DNA sample. 
 
2.2 SUBJECTS 
Ethics approval for this study was obtained from the Human Research Ethics 
Committee (Medical) at the University of the Witwatersrand, Johannesburg, with 
the protocol number of M040801. A copy of the ethics clearance certificate can be 
found in Appendix A1. 
Data were collected and analysed from 120 haemophilia A patients. The majority 
of the subjects used in this study were ascertained through the Haemophilia Clinic 
at the Johannesburg Hospital. The distribution of where the samples were 
collected from is as follows: 
110 patients from the haemophilia clinic at the Johannesburg Hospital 
4 patients from the haemophilia clinic at Chris Hani Baragwanath Hospital 
4 patients through private practice (Dr D. Brittain, Mayo Clinic, Floracliff) 
2  patients from Groote Schuur Hospital, Cape Town. 
A blood sample of 5-10ml fresh blood was collected from these patients after 
informed consent was obtained from either the patients or the parents of the 
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patients if the patient, was under 16 years of age. The consent and assent forms 
can be found in Appendices A2 and A3 respectively. 
Samples were collected from all South African population groups. Due to the small 
sample size of the Indian and mixed ancestry patients, they were grouped together 
as “others” for ease of analysis, as, separately, the sample numbers were too 
small to draw any conclusions. The population breakdown of the patient cohort 
was as follows:  
56 white patients 
56 black patients 
4 Indian patients  
4 mixed ancestry patients. 
As suggested by Rizza, et al. (2001) there is a bias towards sample collection from 
patients with severe haemophilia as they are likely to attend clinics more 
frequently. This is evident in the distribution of the disease severity in these 
patients. The severity of haemophilia A in this cohort is: 
97 severe disease 
13 moderate disease 
5 mild disease and  
5 unknown severity. 
In a pilot study, 34 intron 22 inversion negative patients from the diagnostic cohort 
were tested for the intron 1 inversion mutation, and consisted of 25 white patients, 
seven black patients and two patients from the Indian and mixed ancestry 
populations. These patients will be referred to as the diagnostic haemophilia A 
cohort (refer to section 3.2.2). 
Screening for the c.3637insA mutation was undertaken in all 30 of the white 
families from the diagnostic cohort who tested negative for the intron 22 inversion 
mutation, however, mutation results were only obtained for 23 of these patients. 
These patients will be referred to as the white haemophilia A families in the 
diagnostic database (refer to section 3.2.6.2).  
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2.3 METHODS 
The composition of all reagents and solutions used in the techniques below can be 
found in Appendix D, unless otherwise stated. 
 
2.3.1 DNA Extraction 
DNA was extracted from 3-10ml of patient blood, collected in EDTA Vacutainers, 
using a modified protocol of the salting-out method, as described by Miller, Dyk, 
Pelesky, et al. in 1988. The detailed protocol can be found in Appendix B1. DNA 
samples were stored at 4C. 
 
2.3.2 RNA Extraction 
RNA was extracted within 24 hours of sample collection from 1ml of fresh patient 
blood, collected in EDTA Vacutainers, using the QiAamp RNA Blood Mini kit 
(QIAGEN) using the protocol supplied with the kit. A detailed description of the 
extraction process can be found in Appendix B2. All the RNA samples were stored 
at -70C. These samples were found to be stable for up to one year. 
An mRNA extraction was attempted on a single blood sample stabilised with 
TRIzol (Invitrogen Life Technologies). The protocol for stabilising RNA in blood 
using TRIzol was supplied by Dr Marius Coetzee (Department of Haematology 
and Cell Biology, University of the Free State, Bloemfontein) and can be found in 
Appendix B2. The TRIzol extraction protocol can also be found in Appendix B2. 
The mRNA extracted from the TRIzol stabilised blood amplified for all the cDNA 
fragments, and therefore offers a viable option for sample transport of samples 
from other centres around the country (discussed further in section 4.3.2.1.1). 
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2.3.3 Detection of the Intron 22 Inversion Mutation 
The detection of the intron 22 inversion is performed routinely in the Diagnostic 
Molecular Genetics Laboratory, Division of Human Genetics, NHLS and School of 
Pathology, the University of the Witwatersrand, Johannesburg using Southern Blot 
analysis as described by Levinson, et al. (1990). Inversion testing using Southern 
blot analysis was performed as part of the study for all 120 patients. 
Southern blotting studies the organisation of genes within genomes. Genomic 
DNA is digested with one or more restriction enzymes and the resulting fragments 
are separated, according to size, by agarose gel electrophoresis. The DNA is 
denatured in situ and transferred from the gel to a nylon membrane and the 
relative positions of the DNA fragments are preserved. The DNA, attached to the 
membrane, is hybridised to a labelled oligonucleotide probe and the bands 
complementary to the probe are located by the autoradiography (reviewed by 
Sambrook & Russell, 2001). 
2.3.3.1 Digestion of Genomic DNA 
To detect the intron 22 inversion, approximately 10µg of genomic DNA was 
digested with 30U Bcl I restriction enzyme (Roche) in a reaction containing 1x 
reaction buffer M (Roche) and 0.05M spermidine, with a final volume made up to 
50µl with ddH2O. This reaction was incubated overnight at 50°C. 5µl of the 
digested products were checked on a trial gel to ensure adequate DNA 
concentration and sufficient digestion of the DNA. Once this was confirmed, the 
remaining digested sample (45µl) was mixed with 5µl Ficoll dye and loaded on a 
0.6% agarose gel without ethidium bromide. A 1kb marker and a MWMII marker 
(Roche) were used as the size standards. The gel was run at 1.6V/cm for two 
nights to ensure adequate separation of the products of interest. The progress of 
the gel was checked after the first night by staining the gel in a solution of 100ml 
1x TBE buffer containing 10µl ethidium bromide. After sufficient separation of the 
products (between 16kb and 20kb) was obtained, the gel was prepared for 
Southern transfer. 
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2.3.3.2 Southern Transfer 
The gel was soaked in depurinating solution for 15 minutes, rinsed in ddH2O and 
soaked in depurinating solution for another 15 minutes. The gel was then soaked 
in denaturing solution for 30 minutes, followed by neutralising solution for 30 
minutes. The gel was finally soaked in 20x SSC for a minimum of 10 minutes, or 
until ready to blot. The DNA in the gel was transferred using upward capillary 
action onto a positively charged nylon membrane (HybondTM-N, Amersham) for 2 
to 3 nights. The membrane was baked at 80°C for 1 hour to immobilise the DNA 
on the membrane. 
2.3.3.3 Southern Hybridisation 
The membrane was soaked in 15-20ml of prehybridisation buffer containing 100µl 
of heat denatured DNA from fish sperm (Roche) at 65°C for at least 1 hour. The 
fish sperm DNA is a blocking agent which reduces the levels of background 
hybridisation on the membrane. 
The p482.6 probe, inserted in the pUC19 plasmid vector containing an Ampicillin 
resistance gene, is grown in E. coli bacterial cells. The probe is a 1kb fragment of 
a 9.6kb insert from intron 22 of the FVIII gene, and excised from the vector using 
an Eco RI and Sst I restriction enzyme (Roche) double digest. 
The p482.6 probe was labelled with 32P-dCTP using the Megaprime DNA labelling 
kit (Amersham) (refer to Appendix B3 for the detailed labelling protocol). The 
labelled probe was heat denatured, added to the prehybridisation buffer, then to 
the membrane. The membrane was incubated in this solution at 65°C in the 
Maxi14 hybridisation oven (Hybaid) for approximately 72 hours. 
After hybridisation, excess and non-specifically bound probe was washed off the 
membrane by increasing the stringency of the washes. The washes performed 
were as follows: 2 washes in a 2x SSC, 0.1% SDS solution for 10 minutes each at 
room temperature; 2 washes of a 1x SSC, 0.1% SDS solution for 20 minutes each 
at 65°C; 1 wash of a 0.5x SSC, 0.1% SDS solution for 10 minutes at 65°C; 2 
washes of a 0.1x SSC, 0.1% SDS solution for 20 minutes each at 65°C; and finally 
3 short rinses with a 0.1x SSC solution. 
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The membrane was exposed to Hyperfilm MP (Amersham) and stored in an X-ray 
cassette and kept at -80°C for 3-21 days before the X-ray film was developed in 
the XP400 automated X-ray film processor (AXIM). 
2.3.3.4 Stripping of Labelled Southern Blots 
If the labelling process was unsuccessful, the blots were stripped of the radioactive 
label which involved washing the membrane in denaturing solution for 10 minutes, 
followed by 2 washes of special neutralising solution for 10 minutes each and the 
membranes were stored in 2x SSC. Freshly labelled probe was hybridised to the 
stripped blot as described in section 2.3.3.3 above. 
 
2.3.4 Detection of the Intron 1 Inversion Mutation 
The detection of the intron 1 inversion was performed using a PCR protocol as 
described by Bagnall, et al. (2002), which involves the amplification of 1l genomic 
DNA, 1x Amplitaq polymerase buffer (Perkin Elmer), 1.25mM MgCl2 (Perkin 
Elmer),  0.125mM dNTP mix (Promega), 5% DMSO (Merck), 20pmol/l of primers 
9F, 9R and int1h-2F (IDT), 2.5U Amplitaq polymerase (Perkin Elmer) and made up 
to a final volume of 25l with ddH2O. Primer sequences can be found in Appendix 
C, Table C1. 
The reaction was placed in an Applied Biosystems 2720 PCR machine with the 
following conditions: 94°C for 5 minutes, followed by 30 cycles of 94°C for 30 
seconds, 63°C for 30 seconds and 72°C for 2 minutes. The reaction was 
completed with a final extension of 72°C for 5 minutes. Once the PCR was 
complete, 15µl of the PCR product was mixed with Ficoll dye and detected on a 
1.5% agarose gel using the GeneSnap software (SynGene) and the G:box gel 
documentation system (Syngene). 
The expected PCR product size is 1.5kb in a normal individual and 1.0kb in a gene 
with an intron 1 inversion. The detailed protocol for the intron 1 inversion PCR can 
be found in Appendix E1. 
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2.3.5 Reverse Transcription 
RNA was reverse transcribed into cDNA in order to create a stable working stock 
of patient material, using the ImPromIITM Reverse Transcription System 
(Promega). The detailed protocol for reverse transcription can be found in 
Appendix B4. 
Three different primer options can be used for cDNA synthesis, namely random 
hexamer, gene specific and oligo(dT)15 primers. The random hexamer primer 
amplifies all RNA through random primer binding, the gene specific primer 
amplifies only the gene of interest, while the oligo(dT)15 primer amplifies all mRNA. 
The oligo(dT)15 primer was used to amplify the FVIII mRNA to allow the entire 
FVIII mRNA to be reverse transcribed in one piece. This method would exclude 
non-amplification due to potential polymorphisms or mutations in the gene specific 
primer. 
 
2.3.6 Polymerase Chain Reaction for FVIII cDNA 
2.3.6.1 Primer Selection and Design 
The primer sequences used to amplify the FVIII cDNA fragments were obtained 
from Dr Peter Green, Kings College London (personal e-mail, 2004). They were 
checked against the September 2004 FVIII mRNA sequence download from 
www.genome.ucsc.edu (accession number: NM_000132) to confirm that the 
sequences and orientations of the primers were correct and the sequences were 
modified where needed.  
As it was initially intended to perform protein truncation testing (PTT) on the 
overlapping FVIII fragments, special PTT primers were ordered and used during 
the optimisation phase of each fragment. However, it was later decided not to 
perform PTT due to the costs and direct sequencing was performed on the 
individual fragments instead (refer to section 4.3.1.1). For PTT, the forward and 
reverse primers needed certain additions that would allow for in vitro translation of 
the amplified products. The forward primers required a T7 promoter, a Kozac 
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(Eukaryotic translation initiation sequence) sequence and a start codon. A stop 
codon followed by a polyA tail needed to be incorporated into the reverse primers. 
As primers were ordered for different applications, they were given different 
prefixes to avoid confusion. The cDNA primers had a prefix of HPA-RNA-, PTT 
primers with the prefix HPA-PTT- and internal sequencing primers with the prefix 
HPA-PTT-seq-. Sequences for all the primers used can be found in Table C2 in 
Appendix C. Some primers were used for other applications other than for what 
they were originally ordered. 
2.3.6.2 PCR Optimisation and Final Protocols 
Due to the large size of the FVIII transcript (approximately 9kb), the cDNA was 
initially divided into six overlapping segments as described in Naylor, Green, 
Rizza, et al. (1992), with each fragment spanning several exons. During 
optimisation of the PCR amplification conditions for these fragments, it was 
decided to amplify three fragments (namely fragment 1, 4 and 6) in smaller parts 
(fragment 1a & 1b, fragment 4a & 4b and fragment 6a & 6b) using the internal 
sequencing primers to reduce the size of the fragment thereby allowing for 
improved amplification of these regions. Thus there were nine fragments in total. 
These fragments and the exons covered by each fragment are shown 
schematically in Figure 2.1 and in more detail in Table C3 in Appendix C. 
 
 
Figure 2.1: A schematic representation of the relative position and sizes of the 
overlapping cDNA fragments amplified in relation to the FVIII gene 
 
After numerous attempts at optimisation, the final PCR conditions for each cDNA 
fragment were determined. Certain fragments, namely fragments 1b, 2, 5 and 6b, 
required a nested PCR for a better product yield. For this project, a standard PCR 
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mix for each fragment contained 1-2µl of cDNA or nested PCR products (where 
applicable) added to a reaction containing a final concentration of 1x buffer 2 of 
the Expand High Fidelity PCR System (Roche), 1.25mMol dNTPs (Promega), 
20ρmol of both the forward and reverse primer (IDT), 1U of Expand High Fidelity 
Taq polymerase (Roche) made up to a final volume of 25µl with ddH2O 
The reaction was placed in an Applied Biosystems 2720 PCR machine with the 
following conditions: 95°C for 10 minutes, followed by 35 cycles of 95°C for 1:30 
minutes, annealing temperature for 1:30 minutes and 72°C for 2:30 minutes. The 
reaction was completed with a final extension of 72°C for 20 minutes. The 
annealing temperatures were specific for each fragment. Once the PCR was 
complete, the entire volume (25µl) of PCR product was mixed with Ficoll dye and 
checked for amplification on a 1.5% agarose gel using the GeneSnap software 
(SynGene) and the G:box gel documentation system (Syngene). The bands were 
excised from the gel and sequenced as described in section 2.3.8 below. 
Some of the conditions for the fragments varied slightly from the standard PCR 
conditions above, to optimise the product yield. The primers used to amplify each 
fragment, annealing temperatures and expected product sizes can be found in 
Table 2.1. This table also includes any additional PCR components added to the 
reaction and the primers used for internal sequencing, where applicable. The 
primer sequences can be found in Table C2 of Appendix C below. The final 
versions and detailed protocol sheets for each fragment can be found in 
Appendices E2 to E10. 
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2.3.7 Polymerase Chain Reaction for FVIII DNA 
The FVIII gene spans 186kb of genomic DNA and consists of 26 exons (Toole, et 
al., 1984; Wood, et al., 1984). Once a mutation was detected in a cDNA fragment, 
an attempt was made to confirm the mutation at the DNA level by sequencing the 
specific exon/exons and flanking sequences involved. 
Primer sequences for all 26 exons of the FVIII gene were obtained from Dr Peter 
Green, Kings College London (personal e-mail, 2004). The primer sequences 
were mapped to the genomic DNA of the FVIII gene (September 2004 download 
from www.genome.ucsc.edu, accession number: NC_000023.9) to confirm that 
the sequences and orientations of the primers were correct. Exon 14 was 
amplified in four reactions (namely 14a1, 14a2, 14b1 and 14b2) due to the large 
size of the exon (approximately 3.1kb). The primer sequences for all the exons 
can be found in Table C4 in Appendix C. They span the exon, exon/intron 
boundaries and at least 50bp of intronic sequence on either side of the exon. 
A semi-standard PCR was used to optimise the individual exons, differing in the 
primers, annealing temperature and number of cycles used. These conditions 
were as follows: 1µl genomic DNA added to a reaction containing 1.25mM dNTP 
mix (Promega), 1x Amplitaq Gold buffer (Perkin Elmer), 2.5mM MgCl2 (Perkin 
Elmer), 10mol of each primer (IDT), 1U Amplitaq Gold polymerase (Perkin 
Elmer), made up to a final volume of 25µl with ddH2O. The cycling conditions were 
95°C for 5 minutes followed by a variable number of cycles of 95°C for 1 minute, 
respective annealing temperature for 1 minute, 72°C for 1 minute. A final 
extension at 72°C for 10 minutes completed the PCR conditions. The 
corresponding annealing temperatures, number of cycles and expected PCR 
product sizes for each exon are found in Appendix C, Table C4, while the protocol 
sheet can be found in Appendix E11. 
For one patient, HPA020, primers were specially designed to amplify a region of 
intron 13 (namely 74701bp to 75082bp of the FVIII DNA sequence), 
encompassing the region where a suspected mutation was thought to occur. The 
PCR conditions were the same as the DNA PCR conditions and used primers 
HPA20-int13F and HPA20-int13R (refer to Appendix C, Table C4 for more details). 
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All 25µl of the PCR products were checked for amplification on a 3% agarose gel. 
The products excised from the gel and sequenced in an attempt to confirm the 
mutation at a DNA level (detailed in section 2.3.8) 
 
2.3.8 Sequencing 
DNA sequencing can be used as a tool to identify variants and mutations in genes 
of particular interest. One of two techniques can be used for DNA sequencing, 
namely the dideoxy or chain termination method of Sanger (Sanger, Nicklen & 
Coulson, 1977) and the chemical degradation method (Maxam & Gilbert, 1977). 
Both methods are based on high resolution electrophoresis to resolve their 
products (reviewed in Wilson & Walker, 1997; Sambrook & Russell, 2001). 
The principle of the Sanger method requires an oligonucleotide to anneal to a 
single stranded DNA template and act as a primer for the reaction. All four dNTPs 
must be present in the reaction, together with a ddNTP. ddNTPs contain a 3’-H 
atom instead of the 3’-OH group of the dNTPs, which prevents the phosphodiester 
bond formation with the succeeding dNTP. There is a chance that a ddNTP will be 
incorporated into the growing DNA strand instead of a normal dNTP, and 
termination of chain elongation occurs at that site. The products are resolved on a 
polyacrylamide gel and as termination will occur at every position along the DNA 
strand, the order of the bands determines the sequence of the DNA (reviewed by 
Wilson & Walker, 1997; Sambrook & Russell, 2001). 
Prior to automated sequencing technology, each ddNTP was added into a 
separate reaction and one dNTP was radioactively labelled with either 32P or 35S. 
The products were resolved in four adjacent lanes of a polyacrylamide gel, and 
detected by autoradiography. Using automated sequencing, four ddNTPs, each 
with a different coloured fluorescent label, are added in a single reaction and the 
products are resolved using an automated DNA sequencing machine (reviewed by 
Wilson & Walker, 1997; Sambrook & Russell, 2001). 
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The PCR products obtained from both the cDNA fragments and DNA exons were 
checked for amplification using agarose gel electrophoresis, and the products 
were excised from the gel using a clean scalpel and placed in a clean eppendorf 
tube. The agarose and excess primers and dNTPs were removed using 
NucleoSpin® Extract II columns (Macherey-Nagel). Cycle sequencing was 
performed on these cleaned PCR products using the ABI Prism® BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and either the forward 
or reverse primer. All unincorporated ddNTPs and primers were removed from the 
cycle sequencing products using either the DyeExTM 2.0 Spin Kit (Qiagen) or the 
BigDye® X-TerminatorTM Purification Kit (Applied Biosystems) clean up method. 
The detailed NucleoSpin® Extract II protocol can be found in Appendix B5 while 
the DyeEx® and X-TerminatorTM protocols can be found in Appendix B6. 
The cleaned cycle sequencing products were analysed using the ABI3130xl 
genetic analyser (Applied Biosystems). The parameters used for sequencing in the 
Foundation Data Collection software, v3.0 (Applied Biosystems), were as follows: 
Instrument Protocol 1 was RapidSeq36_POP7_Z or BDX_RapidSeq36_POP7_Z 
(depending on the cycle sequencing clean up method and for products larger than 
500bp), and the Analysis protocol 1 was 3130POP7_BDTv3-KB-Denovo-v5.2 
(POP7 is the polymer used for sequencing and microsatellite analysis). Samples 
were analysed using the sequence analysis software v5.2 (Applied Biosystems). 
These results were compared to a normal reference sequence to detect variations 
using the Seqman application of DNAstar (Lasergene). 
Any variations identified in the cDNA fragments were named using standard 
nomenclature based on the recommendations of den Dunnen & Antonarakis 
(2000). To determine whether the variation was pathogenic or polymorphic, we 
accessed the HAMSTeRS mutation and polymorphism databases 
(http://europium.csc.mrc.ac.za/WebPages/Main/main.htm), a paper by Green, 
Bagnall, Waseem, et al. (2008) and a paper by Viel, Machiah, Warren, et al. 
(2007). Novel changes, possibly affecting splicing, were checked on one of two 
web-based splice site predictor programs, either NetGene2 server 
(www.cbs.dtu.dk/services/NetGene2) or Berkeley Drosophila Genome project 
Splice Site Predictor (www.fruitfly.org/seq_tools/splice.htlm). 
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2.3.9 Flow Chart of Mutation Analysis Process 
Figure 2.2 shows a flow chart demonstrating the basic methods followed to identify 
the disease-causing mutation in the haemophilia A patients in this project. The 
different strategies used to determine the type of disease-causing mutation are 
illustrated in more detail for point mutations (missense and nonsense mutations in 
Figure 2.3), deletions (Figure 2.4) and insertions (Figure 2.5). The approach used 
to identify polymorphisms and benign variants can be found in Figure 2.3. As no 
rearrangement was detected in this study, the approach used to determine the 
type of rearrangement has not been elucidated. 
 
 
Figure 2.2: Flow chart of the methods followed to determine the disease-causing 
mutation in the haemophilia A patients in this project. 
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Figure 2.3: Flow chart of the methods followed to identify missense and nonsense mutations in the haemophilia A patients in this project. 
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Figure 2.4: Flow chart of the methods followed to identify deletions at the cDNA level in haemophilia A patients in this project. 
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2.3.10 Haplotype Analysis 
Haplotype analysis was undertaken on all patients who tested positive for the 
c.3637insA mutation using polymorphic linked markers in intron 13 and intron 22 
of the FVIII gene and p39, an extragenic marker 500kb telomeric to the FVIII gene, 
as described below. The PCR products were sized more accurately using 
microsatellite analysis (refer to section 2.3.10.4). 
2.3.10.1 Diagnostic Protocol for the Intron 13 Linked Marker 
The diagnostic protocol for the intron 13 polymorphic STR marker can be found in 
Appendix E12. Primer 1A is fluorescently labelled with FAM (a blue fluorescent 
label) and both primer sequences can be found in Appendix C in Table C5. The 
expected PCR product sizes range from 137bp to 155bp. Intron 13 results were 
reported as AC repeat numbers. To convert the PCR product size into the number 
of AC repeats, the following formula was used: AC repeat number = (PCR product 
size – 108bp)  2. 
2.3.10.2 Diagnostic Protocol for the Intron 22 Linked Marker 
The diagnostic protocol for the intron 22 polymorphic STR marker can be found in 
Appendix E13. Primer 1B is fluorescently labelled with HEX (a green fluorescent 
label) and both primer sequences can be found in Appendix C in Table C5. The 
expected PCR product sizes range from 69bp to 87bp. The intron 22 results are 
also reported as AC repeat numbers. To convert the PCR product size into the 
number of AC repeats, the following formula was used: AC repeat number = (PCR 
product size – 32bp)  2. 
2.3.10.3 Diagnostic Protocol for the p39 Linked Marker 
The diagnostic protocol for the p39 polymorphic STR marker can be found in 
Appendix E14. Primer p39F is fluorescently labelled with HEX (a green fluorescent 
label) and both primer sequences can be found in Appendix C in Table C5. The 
expected PCR product sizes range from 152bp to 166bp. Unlike intron 13 and 
intron 22 results, the p39 marker results are reported as PCR product size and not 
repeat number.  
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2.3.10.4 Microsatellite Analysis using the ABI3130xl Genetic Analyser 
Microsatellite analysis allows for accurate size determination of fluorescently 
labelled PCR products, which are run on the ABI3130xl Genetic Analyser (Applied 
Biosystems), using the GeneMapper v4.0 software. A detailed description of the 
protocol used for microsatellite analysis is given below. 
To prepare the samples for analysis, 1l of PCR product was mixed with 9l of a 
ROX-HiDi Formamide solution, heat denatured at 94 for 2 minutes and placed on 
ice until ready to run on the genetic analyser. The sample sheet was created with 
the applications GeneMapper-Generic or GeneMapper-ABI_3130XL, and the 
following parameters were selected: sample type was set to standard, the size 
standard was GS500(-250), the individual microsatellites panel was selected, 
analysis method was set to Microsatellite Default, and the instrument protocol 1 
was microsatellites. 
The raw data results were analysed using the GeneMapper v4.0 software (Applied 
Biosystems). This software compares the peak sizes of the alleles of interest to 
the scored alleles of the ROX500 size standard to accurately size the peaks of 
interest. After analysis, each sample was analysed to check that the ROX500 size 
standard peaks were scored correctly and that the required alleles were called and 
sized appropriately. 
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3 RESULTS 
3.1 INTRODUCTION TO THE CHAPTER 
This chapter describes the results obtained for the analysis of FVIII mRNA, 
together with the intron 22 and intron 1 inversion mutations. Previous studies for 
other disorders in our laboratory using mRNA have been unsuccessful, but the 
results obtained from this project show mRNA is a valuable tool for mutation 
detection, especially in analysis of the FVIII gene. Using this fairly novel technique, 
a modified and improved mutation detection method has been developed for 
diagnostic use for haemophilia A in South Africa. 
 
3.2 FVIII MUTATIONS IDENTIFIED 
Of the 120 patients analysed, a causative mutation has been identified in 88 
patients (73.3%). Although the disease-causing mutation was not identified in 32 
patients (26.7%) this is most likely due to poor mRNA quality, time restrictions of 
the project or technical problems related to amplification of some mRNA fragments 
(as discussed further in section 4.3.2.2). Of these 32 patients, 16 of them tested 
negative for the intron 22 inversion mutation. An intron 22 inversion result was not 
obtained on the remaining 16 patients, either due to technical reasons involving 
Southern blot analysis or poor DNA quality. A summary of the patients that were 
tested for the different mutations in this study can be found in Figure 3.1.  
Patients in whom no mutation was identified could have a large deletion (i.e. a full 
or partial FVIII gene deletion) or insertion that would hinder the PCR amplification 
of the respective fragments. As this possibility cannot be ruled out in the 
unsuccessful patients, large deletions and rearrangements could be 
underestimated in this study. The patients in whom no mutation was identified will 
be excluded from further analysis. 
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Figure 3.1: A flow chart showing the breakdown of patients tested at each stage 
of the project and a summary of the mutations identified. 
 
3.2.1 Intron 22 Inversion Mutation Results 
3.2.1.1 Intron 22 Inversion Frequency  
The intron 22 inversion mutation was tested for in all patients, however, Southern 
blot results were only obtained for 84 patients. Southern blot results were 
unsuccessful for the remaining 36 patients, although a result can be inferred as 
negative in an additional 20 patients in whom a pathogenic mutation was identified 
(no reports of two pathogenic mutations in one patient have been found either in 
the HAMSTeRS database or in various papers). Of the 104 patients with an intron 
22 inversion result (either direct or inferred), the population distribution is as 
follows: 51 white, 45 black and eight patients from the Indian and mixed ancestry 
populations. 
This intron 22 inversion accounts for 27.5% (14/51) of mutations in white patients, 
42.2% (19/45) of mutations in black patients and 37.5% (3/8) of mutations in the 
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Indian and mixed ancestry patients (graphically represented in Figure 3.2). The 
frequency in the white population corresponds to previous data obtained by 
Dangerfield, et al. (1997) and remains one of the lowest reported frequencies in 
the world (Antonarakis, et al., 1995). Green, et al. (2008) found the intron 22 
inversion to account for 16.6% of all mutations in haemophilia A patients in the 
United Kingdom, and 38% of patients affected with severe disease. 
 
 
Figure 3.2: The percentages of the intron 22 inversion mutation across the 
different population groups in South Africa compared to the expected worldwide 
percentages reported by Antonarakis, et al. (1995) and Green, et al. (2008). 
In this study, patients from the Indian and mixed ancestry populations have been 
combined as “Other” for ease of analysis, as individually, their sample sizes are too small 
to draw statistical conclusions. 
 
The frequencies of both the white and black intron 22 positive haemophilia A 
patients were compared individually to the world frequency, using a binomial 
distribution. The binomial distribution analyses two independent sample sets (or 
populations) with two types of data in one population (Clarke, 1997). A probability 
of less than 0.05 would indicate a significant difference between the observed and 
expected frequencies. It was found that the probability of such a binomial 
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distribution in the white patients is p=0.008, which is significantly different from the 
expected frequency. As for the black patients, p=0.413, which does not deviate 
significantly from the expected frequency. 
3.2.1.2 Type I and Type II Intron 22 Inversion Frequencies 
The different types of intron 22 inversions were analysed in the whole South 
African population as the sample sizes for the individual population groups were 
too small to draw any conclusions. The type I inversion accounts for 19.2% 
(20/104 patients), the type II inversion mutation accounts for 13.5% (14/104 
patients) and an atypical intron 22 inversion pattern for 1.9% (2/104 patients) of all 
mutations. The worldwide frequencies reported in Antonarakis, et al. (1995) are as 
follows: the type I inversion accounts for 35%, the type II for 7% and an atypical 
pattern accounts for just over 1% of all mutations. 
Of the intron 22 inversion mutations, the type I inversion accounts for 55.6% 
(20/36), the type II inversion for 38.9% (14/36) and the atypical pattern for 5.6% 
(2/36). In the Antonarakis, et al. (1995) study, the type I inversion accounted for 
82% (740/905) of intron 22 inversion mutations, while 15% (140/905) were the 
type II inversion and an unusual or aberrant pattern accounting for the remaining 
3% (25/905) of intron 22 inversion mutations. A chi-squared statistical comparison 
of the frequencies of the different types of intron 22 inversions between the South 
African population and world frequencies as reported by Antonarakis, et al. (1995) 
was undertaken, and showed a significant difference (p<0.0001).  
A comparison of the relative frequencies of the different types of the intron 22 
inversion mutation in the different population groups is shown in Figure 3.3. The 
type II inversion appears to account for more intron 22 inversion mutations in all 
the South African population groups studied, compared to those reported by 
Antonarakis, et al. (1995). The breakdown of the frequencies per population 
results in small sample size for all population groups and could not be compared 
statistically. However, it is interesting to note that Dangerfield, et al. (1997) did not 
find the type II inversion in the black population, whereas this study found the type 
II inversion accounting for 42.1% (8/19) of intron 22 inversions in the black 
population. 
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Figure 3.3: The population distribution of the type I, type II and atypical intron 22 
inversions in the South African populations compared to the world frequencies 
reported by Antonarakis, et al. (1995). 
Patients from the Indian and mixed ancestry populations have been combined as “Other” 
for ease of analysis, as individually, their sample size is too small to draw statistical 
conclusions. 
 
3.2.2 Intron 1 Inversion Mutation Results 
In a pilot study (not part of this study), 34 intron 22 inversion negative patients 
from the diagnostic haemophilia A cohort were tested for the intron 1 inversion 
mutation. All patients tested negative for this mutation. 
In this study, screening was undertaken on all patients for the intron 1 inversion 
mutation using PCR analysis. This mutation was identified in three patients, two of 
whom were black patients and the third patient was of Indian ancestry. This 
equates to approximately 5.3% (2/38) of mutations in black patients and 25% (1/4) 
in Indian patients. It is interesting that this mutation was not found in any white 
patients in this project (n=49) or the preliminary screen (n=25), whereas it 
accounts for approximately 4.8% of severe haemophilia A mutations in the United 
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Kingdom (Bagnall, et al., 2002). A summary of these results can be found in 
Appendix F in Table F1, highlighted in turquoise. 
 
3.2.3 Mutations Identified by mRNA Analysis 
By analysing the mRNA of haemophilia A patients, a wide variety of mutations 
have been detected in the FVIII gene and mutations were identified in 55.7% 
(49/88) additional patients. mRNA analysis significantly improves the mutation 
detection rate compared to the testing strategy currently offered by the Diagnostic 
Molecular Genetics Laboratory, Division of Human Genetics, NHLS and School of 
Pathology, the University of the Witwatersrand, Johannesburg for the intron 22 
inversion mutation only. 
Sections 3.2.3.1, 3.2.3.2, 3.2.3.3 and 3.2.3.4 present the mutations in haemophilia 
A patients by type and give an example in each case of the strategy used to 
identify mutations. A comprehensive breakdown of the mutations identified in all 
88 of the patients, in whom a mutation was identified in this project, together with 
their severity and inhibitor status are summarised in Table F1 (Appendix F). This 
table includes any polymorphisms and benign variants identified in these patients. 
 
3.2.3.1 Nonsense Mutations 
Nonsense mutations were determined as described in the flow diagram in Figure 
2.3 and a summary of these mutations are highlighted in pink in Table F1 
(Appendix F). 
Nonsense mutations in the FVIII gene accounted for 18.4% (9/49) of mutations 
identified using an mRNA approach and 10.2% (9/88) of the total mutations 
identified in this study. Four nonsense mutations (R427X, R795X, R1696X and 
W2271X) were previously reported in the HAMSTeRS point mutation database 
(http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/PointMutationsA.htm for mutations 
between amino acid 1 and 740, and for mutations in amino acids 741 to 2326, 
http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/PointMutationsB.htm). One patient 
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in this study tested positive for a double amino acid change, namely WD393-
394XH, the pathogenic change (W393X) was previously reported by Green, et al. 
(2008). The remaining four mutations (Q744X, K1012X, L1229X and Q1629X) 
were novel. 
3.2.3.1.1 An Example of a Previously Reported Nonsense Mutation 
In patient HPA184, a G to A transition was identified in fragment 6b on cDNA 
analysis at position 6879bp of the FVIII cDNA. This mutation was confirmed by 
sequencing exon 25 of the FVIII DNA. This mutation caused a tryptophan to be 
replaced with a stop codon at amino acid position 2271. This is illustrated in Figure 
3.4. This nonsense mutation is clearly pathogenic. It was also found in the 
HAMSTeRS database as having been previously reported by Laprise, Mak, 
Killoran, et al. (1998). The disease-causing mutation in this patient is thus 
W2271X. 
 
 
Figure 3.4: Raw data and interpretation of results obtained on patient HPA184 
showing the previously reported nonsense W2271X mutation.  
The electropherogram data are shown for part of the cDNA fragment 6b (A) and DNA 
exon 25 (B), with the G to A transition visible below the red arrows. The amino acid 
translation (C) is given below the electropherogram for both a normal sequence and the 
patient. Sequence alignment obtained using the Seqman application of the DNAstar 
software (LaserGene). 
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3.2.3.2 Missense Mutations 
Missense mutations were identified in this project using the approach outlined in 
Figure 2.3, and are indicated in Table F1 (Appendix F), highlighted in green. 
Missense mutations may be assessed using bioinformatics tools to examine cross 
species conservation and protein domain changes; however, this analysis has not 
been assessed in this project. Missense mutations in the FVIII gene accounted for 
34.7% (17/49) of mutations identified using an mRNA approach and 19.3% (17/88) 
of the total mutations identified in this study. 
A total of 17 missense mutations were identified by mRNA analysis, one of which 
was found in 2 patients (namely G450E). Of the 16 different missense mutations, 
six mutations (namely V162M, R372C, A704T, R2209G, W2229C and P2300L) 
were previously reported on the HAMSTeRS point mutation database (for 
mutations in amino acids 1 to 740, 
http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/PointMutationsA.htm, and 
http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/PointMutationsB.htm for amino 
acids 741 to 2326), while one mutation, E1829K was previously reported by 
Green, et al. (2008). The following nine mutations were novel: D125V, T395C, 
G450E, N467T, M614T, H979Q, D1568N, E1766K and W1942R. The G450E 
mutation was found in two patients, both of whom had the M2238V polymorphism, 
although they appear to be unrelated. One patient (HPA183) also had the A544A 
novel variant; however, the second patient (HPA084) was not tested for this 
variant. 
3.2.3.2.1 An Example of a Previously Unreported Missense Mutation 
In patient HPA186, an A to T transversion was identified in fragment 1a on cDNA 
analysis at position 431bp of the FVIII cDNA and confirmed by sequencing exon 4 
of the FVIII DNA. This mutation caused an aspartic acid to be replaced with a 
valine at amino acid position 125. This is illustrated in Figure 3.5. This specific 
missense mutation has not been previously reported on the HAMSTeRS point 
mutation database. However, there were four reports of substitutions of aspartic 
acid at amino acid position 125, once to tyrosine, and three substitutions to 
asparagine (HAMSTeRS point mutation database for amino acids 1 to 740, 
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http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/PointMutationsA.htm). This 
mutation is likely to be pathogenic as aspartic acid is a polar, negatively charged 
amino acid and valine is a non-polar hydrophobic amino acid, while both tyrosine 
and asparagine are polar, hydrophilic amino acids. The disease-causing mutation 
in this patient is thus D125V. 
 
 
Figure 3.5: Raw data and interpretation of results obtained on patient HPA186 
showing a novel D125V missense mutation.  
The electropherogram data are shown for part of the cDNA fragment 1a (A) and DNA 
exon 4 (B), with the A to T transversion visible below the red arrows. The amino acid 
translation (C) is given below the electropherogram for both a normal sequence and the 
patient. Sequence alignment obtained using the Seqman application of the DNAstar 
software (LaserGene). 
 
3.2.3.3 Deletion and Insertion Mutations 
Deletion mutations were determined using the approach outlined in the flow 
diagram in Figure 2.4 and insertion mutations were identified using the approach 
outlined in the flow diagram in Figure 2.5. All deletion and insertion mutations 
identified in this study are summarised in Table F1 in Appendix F and are 
highlighted in tan and yellow respectively. 
Of the nine deletion mutations detected using FVIII mRNA analysis, the following 
five mutations were previously reported: ΔF652, c.3548delAA, c.3637delA, 
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c.4321delAGAA and c.4379delA (for large deletions of more than 50bp 
http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/LargeDeletions.htm and 
http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/SmallDeletions.htm for small 
deletions less than 50bp). This project identified three novel deletion mutations, 
namely: c.3745delCTGA, c.4118delA and c.4920delA (this mutation is described 
in more detail in section 3.2.3.3.1). The breakpoints of the exon 10-11 deletion in 
patient HPA202 were unable to be determined due to time constraints of the 
project and difficulty in amplifying exon 10 and 11 at the DNA level because of the 
presence of the deletion spanning these two exons. This mutation was confirmed 
on repeat sequencing of cDNA fragment 2. It cannot therefore be determined if 
this mutation was previously reported or if it is novel.  
Two different insertion mutations were identified in this project in seven patients. 
One mutation (c.3637insA) was previously reported and one (c.4201insC) was 
novel (HAMSTeRS insertion mutation database at 
http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/Insertions.htm). The 
c.3637insA mutation was identified in 6 white patients which lead to the hypothesis 
of this being the founder mutation in this population group, and is described in 
more detail in section 3.2.6. 
All the deletion and insertion mutations in this project resulted in a frameshift 
mutation, except for two in-frame deletion mutations: namely the single amino acid 
deletion (ΔF652 in patient HPA258) and the deletion of exon 10 and 11 (patient 
HPA202). 
Green, et al. (2008) found that 47.7% of the small insertions and deletions 
identified in their study occurred in a string of six or more adenines. Of the 10 
different small insertion or deletion mutations identified in this study, three (30%) 
occurred in a stretch of six or more adenines. This is most likely due to replication 
slippage (Becker, et al., 1996). 
3.2.3.3.1 An Example of a Novel Deletion Mutation 
In patient HPA128, an A deletion was identified in exon 14 on DNA analysis at 
position 4921bp of the FVIII cDNA and confirmed by repeat sequencing of exon 
14. This mutation caused a frameshift mutation from the glutamic acid at amino 
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acid 1621, and a stop codon at 1622. This is illustrated in Figure 3.6. This specific 
deletion mutation has not been previously reported on the HAMSTeRS deletion 
mutation database. However, this mutation is likely to be pathogenic as the 
resulting protein is prematurely truncated at amino acid 1622 (just over half of the 
2332 amino acids are translated). The disease-causing mutation in this patient is 
thus c.4920delA. 
 
 
Figure 3.6: Raw data and interpretation of results obtained on patient HPA128 
showing the novel deletion mutation, c.4920delA. 
The electropherogram data are shown for part of the DNA sequencing of exon 14b2 (A) 
compared to the reference sequence (B). The amino acid translation (C) is given for both 
the normal sequence and the patient. Sequence alignment obtained using the Seqman 
application of the DNAstar software (LaserGene). The apparent gap in the 
electropherogram (a) is a program artefact to highlight missing bases. 
 
3.2.3.4 Mutations Affecting Splicing 
Mutations affecting splicing were broadly divided into two sections: splice site 
mutations and complex mutations (refer to the approach outlined in Figure 2.4 and 
Figure 2.5) and are summarised in Table F1 in Appendix F (highlighted in purple 
and orange respectively). 
Of the two splice site mutations, both were novel mutations (IVS13-1GC and 
c.2111CT which caused a deletion of exon 13, as discussed in section 
3.2.3.4.1). Five complex mutations were identified in this project, and were defined 
as mutations where the exact DNA change was not identified at a DNA level, and 
are likely to be cryptic splice site or deep intron mutations. Due to the cost and 
time constraints of this project, sequencing of the entire intronic sequence for 
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these patients was not performed. We were therefore unable to determine whether 
these complex mutations were previously reported or novel. These mutations 
included a deletion of exon 10 (discussed in section 3.2.3.4.2), an insertion of 
113bp of part of intron 13 into the FVIII mRNA at position 2120bp, a partial 
deletion of exon 16 (deletion of amino acids 1779-1788, and is discussed in 
section 3.2.3.4.3), and two deletions of exon 19. 
3.2.3.4.1 An example of an Unreported Splice Site Mutation 
In patient HPA236, a 209bp deletion was found on analysis of the FVIII cDNA 
fragment 2 (illustrated in Figure 3.7A). This deletion corresponds to a deletion of 
exon 13 and results in an in-frame deletion of 71 amino acids. DNA sequencing of 
exon 13 identified a C to T transition at cDNA position 2111bp (3bp from the end 
of exon 13, just before the exon/intron splice site) (as shown in Figure 3.7B). 
This base change appears to substitute a proline at amino acid 687 with a leucine, 
a previously unreported mutation on the HAMSTeRS mutation database (Figure 
3.7C). However, this C to T transition is more likely to affect splicing, based on the 
mRNA evidence. This mutation was checked on two internet based splice site 
predictor websites (http://www.fruitfly.org/cgi-bin/seq_tools/splice.pl and 
http://www.cbs.dtu.dk/services/NetGene2), and both websites predict that this C to 
T change does not affect splicing. Perhaps this mutation alters the competency of 
splicing of exon 13 or has a subtle effect on an exon splice site enhancer 
sequence, rather than affecting the actual splice site, although no normal transcript 
was seen in this patient. 
Repeat sequencing of cDNA fragment 2 confirmed the deletion of exon 13. 
Therefore, according to the cDNA sequence data, this mutation does alter splicing 
and is likely to be pathogenic. The disease-causing mutation at a DNA level in this 
patient is thus 2111CT which causes the deletion of exon 13 on cDNA, 
presumably by aberrant splicing. 
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Figure 3.7: Raw data and interpretation of results for patient HPA236 showing an 
unreported exon 13 deletion resulting from the c.2111CT splicing mutation. 
The electropherogram data are shown for part of cDNA fragment 2 (A) showing a deletion 
corresponding to a deletion of exon 13. The electropherogram data obtained from DNA 
sequencing for part of exon 13 (B), with the T to C transition visible below the red arrow. 
The amino acid translation for a normal sequence and the patient are shown in (C). 
Sequence alignment obtained using the Seqman application of the DNAstar software 
(LaserGene). The apparent gap in the electropherogram (a) is a program artefact to 
highlight missing bases. 
 
3.2.3.4.2 An Example of a Complex Mutation 
In patient HPA219, a 199bp deletion was identified in fragment 2 on cDNA 
analysis (from position 1445bp to 1538bp of the FVIII cDNA), corresponding to a 
deletion of exon 10. At the protein level, this deletion caused a frameshift from the 
isoleucine at amino acid 464, and produced a stop codon at the next amino acid 
(position 465), and is therefore likely to be the pathogenic mutation in this patient. 
However, no mutations were identified by DNA sequencing of exon 10 and the 
intron/exon boundaries (230bp into intron 9 and 126bp into intron 10), thereby 
eliminating obvious donor and acceptor splice site mutations. This is illustrated in 
Figure 3.8. Sequencing of the entire intron 9 and intron 10 were not practical within 
the time and cost confines of this study as these two introns are over 4800bp and 
3900bp in size respectively. Thus the specific mutation at the DNA level has not 
been identified and is assumed to be a deep intronic mutation or a cryptic splice 
site. The effect of the disease-causing mutation in this patient is a deletion of exon 
10, detectable on cDNA analysis, causing a truncated protein. 
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3.2.3.4.3 An Example of Alternative Splicing Resulting in Two Transcripts 
In patient HPA223, a 47bp deletion was identified in cDNA fragment 5 (from 
5373bp to 5419bp of the FVIII cDNA), which corresponded to a partial deletion of 
exon 16 (illustrated in Figure 3.9A). At the protein level (Figure 3.9B), this deletion 
caused a frameshift from the valine at amino acid 1773, and produced a stop 
codon at amino acid 1793, and is therefore likely to be the pathogenic mutation in 
this patient. No mutation was identified on DNA sequencing of exons 15, 16 and 
17 and their intron/exon boundaries (69bp 5’ of exon 15, 77bp 3’ of exon 15, 67bp 
5’ of exon 16, 101bp 3’ of exon 16, 60bp 5’ of exon 17 and 63bp 3’ of exon 17), 
except for a T deletion 37bp into intron 16 (IVS16+37delT) (shown in Figure 3.9C). 
This IVS16+37delT could possibly be an unreported variant or a mutation affecting 
splicing. The http://www.cbs.dtu.dk/services/NetGene2 splice predictor website 
predicted a splice site at cDNA position 5420bp for both the normal sequence and 
patient HPA223 (including the IVS16+37delT mutation). 
On closer inspection of the electropherogram data of fragment 5 (Figure 3.9A), 
there appears to be a second sequence 5’ to the deletion (this reverse sequence 
is reverse complemented and reads in the 3’ to 5’ direction), which corresponds to 
the normal sequence (highlighted by the blue arrow). This patient therefore seems 
to have two transcripts, although the normal transcript occurs at a much lower 
level than the alternate transcript. 
Thus the specific mutation at the DNA level has not been identified and is 
assumed to be a deep intronic mutation creating an alternate splice site. The 
disease-causing mutation in this patient therefore causes a partial deletion of exon 
16, detectable on cDNA analysis. The pathogenicity of the IVS16+37delT is 
unclear, but could be used as a linked marker. 
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Figure 3.9: The raw data obtained for patient HPA223 showing alternate splicing 
of part of exon 16 on cDNA analysis 
The electropherogram data for part of cDNA fragment 5 (A) showing a deletion that 
corresponds to part of exon 16 (the red horizontal arrow). The normal amino acid 
sequence (B) compared to the predicted amino acid sequence in this patient. The 
electropherogram data for part of intron 16 (117940bp-117962bp) obtained from DNA 
sequencing of exon 16 (C) showing a T deletion (below the red vertical arrow), the 
pathogenicity of which is unknown. The alternate transcript is seen in the reverse 
complemented cDNA sequence (A) as messy or “frameshift” sequence and is highlighted 
by the blue arrow. Sequence alignment obtained using the Seqman application of the 
DNAstar software (LaserGene). The apparent gap in the electropherograms in (a) and (c) 
are a program artefact to highlight missing bases. 
 
3.2.4 Polymorphisms 
Any change that was suspected to be a polymorphism or benign variant was either 
checked against the HAMSTeRS polymorphism database (available at 
http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/Polymorphisms.htm) or a paper 
describing FVIII polymorphisms by Viel, et al. (2007). In this study, five 
polymorphisms or benign variants were identified, four of which were previously 
reported (D1241E, S1269S, P1481P and M2238V). In the South African 
haemophilia A patient group as a whole, these polymorphisms were found at a 
frequency of 0.44 (23/52), 0.11 (5/47), 0.02 (1/43) and 0.18 (5/28) respectively. 
The novel variant, namely A544A, was only found in one patient from the black 
population (n=28). Table 3.1 shows the population distribution of the different 
polymorphisms and variants and their frequencies. The frequencies were 
determined for the specific polymorphism and variant for those patients for whom 
data were available. Data were not available for each patient for each 
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polymorphism or variant as complete cDNA sequencing was not undertaken in 
patients once a mutation was detected due to costs. Also note that the sample 
sizes of the Indian and mixed population group are too small to draw any 
significant conclusions. 
 
Table 3.1: Population distribution and frequencies of the different polymorphisms 
and benign variants found.  
Population A544A  D1241E S1269S P1481P M2238V 
White Not found 
(0/39) 
0.22  
(5/23)  
0.13  
(3/24) 
Not found 
(0/18) 
0.10  
(1/14) 
Black 0.04  
(1/28) 
0.68 
(17/25) 
0.10 (2/20) 0.05 (1/22) 0.25 (3/12) 
Indian/Mixed 
ancestry 
Not found 
(0/6) 
0.25  
(1/4) 
Not found 
(0/3) 
Not found 
(0/3) 
0.50 (1/2) 
Except for the novel variant, A544A, all polymorphisms are previously reported by Viel, et 
al. (2007). 
 
3.2.5 Implication of Mutations in Family Members 
To date, in the Diagnostic Molecular Genetics Laboratory, Division of Human 
Genetics, NHLS and School of Pathology, the University of the Witwatersrand, 
Johannesburg, linked marker analysis has involved the use of 2 polymorphic STR 
markers in intron 13 and intron 22 of the FVIII gene and one extragenic marker, 
the p39 marker (as discussed in section 1.11.2). Even if informative, linked marker 
analysis remains an indirect method of mutation detection. It would only determine 
if a female is carrying the high risk X chromosome. It does not take into account 
the possibility of new mutations or germline mosaicism. Knowledge of the disease 
causing mutation in the proband would allow a female’s carrier risk to be refined 
and determined more accurately through direct mutation detection. Three 
examples are illustrated in section 3.2.5.1, 3.2.5.2 and 3.2.5.3 below, where 
mutation analysis has either confirmed or altered the carrier risk determined by 
linked marker analysis. 
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3.2.5.1 Confirmed Carrier Status as Determined by Linked Marker Analysis 
A novel mutation, c.4201insC, was identified in the patient HPA029. Direct 
mutation analysis was undertaken on the patient’s mother and sister who were at 
high risk of being carriers based on linked marker analysis (refer to Figure 3.10A). 
Linked marker analysis could not determine if this was a new mutation in the 
patient nor exclude the mother from being a germline mosaic for the mutation. 
Direct mutation detection in the mother and sister confirmed them both to be 
carriers of the c.4201insC mutation, as shown in Figure 3.10C and D.  
 
 
Figure 3.10: An illustration of a family where direct mutation detection confirmed 
the carrier status obtained from linked marker results.  
The pedigree and haplotype results for family HPA029 (A), shows that the high risk 
chromosome has been inherited by II2. Partial electropherogram data obtained from DNA 
sequencing of exon 14b1 in family HPA029 in the patient (B) showing the c.4201insC 
mutation, his mother (C) and sister (D). Although the sequences are reverse 
complemented, the frameshift in the mother and sister is “before” the point of the 
mutation. The carrier status of the mother and sister can be confirmed. Sequence 
alignment obtained using the Seqman application of the DNAstar software (LaserGene). 
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3.2.5.2 Mother with Germline Mosaicism or New Mutation in Patient 
In patient HPA184, a previously reported c.6879GA mutation was identified in 
the cDNA causing a W2271X mutation (refer to section 3.2.3.1) (Laprise, et al., 
1998). Linked marker analysis found that the patient’s unaffected brother shared 
the high-risk X chromosome (refer to Figure 3.11). This would mean that the 
mothers’ carrier risk would be significantly decreased, although she could still be 
at risk of being a germline mosaic. Direct detection for the c.6879GA mutation 
was carried out on the mother and brother in an attempt to refine their status. Both 
the mother and brother tested negative for the mutation, as can be seen in Figure 
3.12. Although the results cannot distinguish if this is a new mutation in the patient 
or whether the mother is a germline mosaic, future definitive prenatal diagnosis by 
mutation analysis can be offered to the mother. 
 
 
Figure 3.11: The pedigree and haplotype results for family HPA184 before direct 
mutation detection. 
The haplotype results identified the high-risk X chromosome in the affected proband (II1). 
It has also been inherited by the unaffected brother (II2). This result does not resolve the 
mother’s carrier status although it decreases her carrier risk.  
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Figure 3.12: Direct mutation detection results for family HPA184 for the 
c.6879GA mutation. 
Partial electropherogram data for exon 25 from the patient (A), his mother (B) and brother 
(C) are shown. (D) is the normal reference sequence. The mother and brother tested 
negative for the c.6879GA mutation, suggesting a new mutation in the patient or 
germline mosaicism in the mother. Sequence alignment obtained using the Seqman 
application of the DNAstar software (LaserGene). 
 
3.2.5.3 Inconclusive Linked Markers Resolved on Mutation Analysis. 
In family HPA112, linked marker results identified the high risk allele in the patient. 
His unaffected uncle (II1) shared this high risk allele, as is seen in Figure 3.13. 
The patient’s grandmother (I2) could possibly be a germline mosaic or this could 
be a new mutation in the patient’s mother (II1) or even in the patient. There is also 
a possibility that his mother could be a germline mosaic. Therefore the carrier risk 
for the mother and aunt (II2) was difficult to define using these results. 
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Figure 3.13: A pedigree diagram showing the linked marker results for family 
HPA112.  
The high-risk X chromosome present in the patient is marked in red. 
 
The proband in this family was found to have a novel c.1898TC mutation in exon 
12, resulting in a M614T missense mutation (refer to Figure 3.14). Direct mutation 
detection for this mutation was able to resolve the haplotype data and refine the 
carrier risk for the mother, aunt and grandmother. DNA sequencing data for the 
family can be found in Figure 3.15. It shows that the aunt and grandmother are 
negative for the disease-causing mutation, thereby reducing their high risk of being 
a carrier to 0%. It also proves that the unaffected uncle is negative for the M614T 
mutation. The risk for the mother of the patient being a carrier has been 
significantly reduced; however, it cannot be determined if she is a germline mosaic 
or if this is a new mutation in the patient. Either way, definitive prenatal testing is 
available to her using direct mutation analysis for future pregnancies. 
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Figure 3.14: Partial electropherogram data for cDNA fragment 2 in the proband of 
family HPA112 corresponding to the M614T missense mutation.  
It shows the c.1898TC mutation below the red arrow. Sequence alignment obtained 
using the Seqman application of the DNAstar software (LaserGene). 
 
 
Figure 3.15: The DNA sequencing data for family HPA112 showing the 
c.1898TC (M614T) mutation. 
The DNA electropherogram for exon 12 showing the absence of the c.1898TC (M614T) 
mutation in the patients mother (A), aunt (B), grandmother (C) and unaffected uncle (D). 
The normal reference sequence is below (E). Sequence alignment obtained using the 
Seqman application of the DNAstar software (LaserGene). 
 
3.2.6 Common Mutation in the White Population 
The c.3637insA mutation (described in section 3.2.6.1) was found in 14% of white 
patients (6/43), four of whom have Afrikaans surnames (66.7%). In most 
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conditions, especially X-linked recessive disorders such as haemophilia A, it is 
difficult to determine Afrikaans ancestry just based on surnames, as the mutation 
is passed down the maternal line while surnames are passed down the paternal 
lineage. Also Afrikaans ancestry is poorly defined when based on only one 
generation. This mutation will therefore be referred to as the common white 
founder mutation. It would be practical in the future to screen all white patients with 
haemophilia A, who test negative for the intron 22 inversion mutation, for the 
c.3637insA mutation. 
Together with the fact that the intron 22 inversion mutation has one of the lowest 
reported frequencies in the world (Antonarakis, et al., 1995) and that a potential 
founder haplotype was proposed by Dangerfield, et al. (1997) and McKibbin 
(2002), these data suggest that the c.3637insA mutation may be the elusive 
Afrikaans founder mutation. The suspicion of the founder haplotype is based on 
the many at-risk female relatives in big families who are uninformative on linked 
marker analysis and that the suspected founder mutation occurs on a common 
microsatellite haplotype. Further investigations to determine the frequency of this 
mutation in white haemophilia A patients from the diagnostic cohort and haplotype 
analysis were undertaken to confirm this hypothesis as described in sections 
3.2.6.2 and 3.2.6.4. 
 
3.2.6.1 The c.3637insA Mutation 
The insertion of an A nucleotide at cDNA position 3637-3638 (shown in Figure 
3.16) causes a frameshift mutation from the isoleucine at amino acid position 
1194, with a premature stop codon occurring at amino acid position 1221 (Figure 
3.17). The normal FVIII protein is 2351 amino acid in length, therefore in the 
presence of this mutation, only about half of the FVIII gene is translated. According 
to the HAMSTeRS insertion mutation database (available at 
http://europium.csc.mrc.ac.uk/WebPages/PublicFiles/Insertions.htm), this mutation has 
been reported 16 times previously. 
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Figure 3.16: The raw electropherogram data obtained for a patient with the 
c.3637insA mutation. 
A partial electropherogram of the forward sequence of exon 14b1 (A) and reverse 
complemented sequence of exon 14a2 (B) obtained from a patient with the mutation, 
while (C) is the electropherogram data obtained from a normal individual. The normal 
reference sequence is seen in (D). The c.3637insA mutation is highlighted by the red 
arrows. Sequence alignment obtained using the Seqman application of the DNAstar 
software (LaserGene). The apparent gap in the (c) and (d) electropherograms are a 
program artefact to highlight missing bases. 
 
 
Figure 3.17: The amino acid sequence for the normal FVIII protein (A) and 
c.3637insA mutation (B), terminating at amino acid position 1221.  
The difference from the normal sequence is shown in red, with X indicating the premature 
stop codon. 
 
3.2.6.2 Frequency of c.3637insA Mutation in the White Population 
Screening for the c.3637insA mutation was performed on all 30 of the white 
haemophilia A families in the diagnostic database who previously tested negative 
for the intron 22 inversion mutation. Results were obtained for 23 unrelated 
individuals and the mutation was found in three (13%). This frequency is 
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consistent with the frequency found in the study sample of 43 white patients (of 
14%). 
 
3.2.6.3 Pedigree of a Family Positive for c.3637insA Mutation  
Most of the patients who tested positive for the c.3637insA mutation have a family 
history of haemophilia A which can be traced back a number of generations. 
Family HPA11 is an example of one such family. After the c.3637insA mutation 
was identified in the proband (IV6), a few other family members whose DNA 
samples were available in the Diagnostic Molecular Genetics Laboratory, Division 
of Human Genetics, NHLS and School of Pathology, the University of the 
Witwatersrand, Johannesburg were tested for this mutation. Figure 3.18 shows the 
pedigree of the members of the HPA11 family. Mutation analysis for the 
c.3637insA mutation found a second affected individual (IV3) to be positive, 
individuals II2, III2 and IV7 were found to be carriers and individuals III1 and III3 
tested negative for the mutation and are therefore not carriers of haemophilia A. 
 
3.2.6.4 Haplotype Analysis for c.3637insA Mutation in Patients 
More conclusive haplotype analysis was required in c.3637insA positive patients to 
determine if this mutation is indeed a founder mutation or just a common recurrent 
mutation, especially as it has been reported 16 times in the HAMSTeRS database 
(section 3.2.6.1). Haplotype analysis was undertaken on all nine patients who 
tested positive for the c.3637insA mutation (six patients collected for mutation 
analysis for this project and the three additional patients from the diagnostic white 
patient screen), using polymorphic microsatellite markers within or close to the 
FVIII gene (section 3.2.6.4.1). Single nucleotide polymorphisms (SNPs) within the 
FVIII gene (section 3.2.6.4.2) were tested for in three patients. If a rare allele had 
been detected, the remaining patients would have been tested for this SNP.  
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Figure 3.18: A pedigree of family HPA11, positive for the c.3637insA mutation. 
Mutation testing for the c.3637insA mutation (for patients marked with a tick) found the 
proband (IV6) and individual IV3 positive for the mutation. Individuals II2, III2 & IV7 were 
found to be carriers for the mutation, and individuals III1 & III3 tested negative for the 
mutation. 
 
3.2.6.4.1 Microsatellite Markers 
Haplotype analysis was undertaken using polymorphic microsatellite markers in 
intron 13 and intron 22 of the FVIII gene and the p39 marker, an extragenic marker 
500kb telomeric to the FVIII gene (described in section 2.3.10). These are the 
linked markers used in routine analysis undertaken by the Diagnostic Molecular 
Genetics Laboratory, Division of Human Genetics, NHLS and School of Pathology, 
the University of the Witwatersrand, Johannesburg to track the high risk X 
chromosome in haemophilia A families. 
The results from the microsatellite markers show a common haplotype in 8 of the 9 
patients in association with the c.3637insA mutation (refer to Table 3.2). This 
mutation tracks with the intron13-intron22-p39 haplotype of 20 repeats, 26 
repeats, 160bp respectively. The one patient (HPA118) that did not share this 
common haplotype was found to have a haplotype of 20 repeats, 27 repeats and 
160bp respectively.  
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Table 3.2: The haplotype analysis results for the intron 13, intron 22 and p39 
microsatellite markers for patients positive for the c.3637insA mutation. 
Patient/family Intron 13  
(repeat numbers) 
Intron 22 
(repeat numbers) 
p39 
(bp) 
HPA005 20 26 160 
HPA011 20 26 160 
HPA015 20 26 160 
HPA034 20 26 160 
HPA050 20 26 160 
HPA118 20 27 160 
HPA192 20 26 160 
HPA230 20 26 160 
HPA249 20 26 160 
 
3.2.6.4.2 Single Nucleotide Polymorphism Markers 
A number of polymorphisms have been reported on the HAMSTeRS 
polymorphism database and by Viel, et al. (2007) (refer to section 3.2.4). It was 
decided to investigate 11 of these polymorphisms spanning the entire FVIII gene. 
These polymorphisms and the results obtained for three of the nine c.3637insA 
patients can be found in Table 3.3. 
No rare single nucleotide polymorphisms were found in the three patients and 
therefore the SNP data does not further define or elucidate the founder haplotype. 
However, population frequencies for some of these SNPs have been determined 
in this project (refer to section 3.2.4) and the statistical analysis of the chance of 
finding this haplotype, together with the microsatellite haplotype in section 
3.2.6.4.1, in the random population is calculated in section 3.2.6.4.3. 
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Table 3.3: Results from the single nucleotide polymorphism screen of the FVIII 
gene in 3 patients positive for the c.3637insA mutation. 
Results Polymorphism Protein 
change 
FVIII 
position HPA011 HPA050 HPA230 
25610GA - intron 2 G G G 
29567CT - intron 3 C C C 
61534TC - intron 9 T T T 
61620GA R484H exon 10 G G G 
91317AG R776G exon 14 A A A 
92555CT H1188H exon 14 C C C 
92714CG D1241E exon 14 C C C 
92798AC S1269S exon 14 A A A 
92927GA K1312K exon 14 G G G 
120776TA - intron 19 T T T 
162161AG M2238V exon 25 A A A 
 
3.2.6.4.3 Statistical Analysis of the c.3637insA Mutation Haplotypes  
Previous studies to determine the allele frequency for each of the microsatellite 
markers in the white South African population found allele 20 of the intron 13 
marker to have a frequency of 0.52 (84/161) (Dangerfield, et. al, 1997), allele 26 of 
the intron 22 marker to have a frequency of 0.58 (93/161) (Dangerfield, et. al, 
1997) and allele 160 of the p39 marker to have a frequency of 0.17 (12/71) 
(McKibbin, 2002). The statistical analysis of the chance of finding this haplotype, 
together with the SNP haplotype in section 3.2.6.4.2, in the random population is 
calculated using the Fisher’s exact test as shown in Table 3.4. The Fisher’s exact 
test is used in the analysis of data for small sample sizes (n<10) and examines the 
significance of an association between two variables in a 2x2 contingency table 
(http://udel.edu/~mcdonald/statfishers.html). 
As there were no haplotype data for control samples, each marker had to be 
compared separately. These probabilities indicate that the allele observed at each 
microsatellite loci occurs far more commonly than expected (p=0.000001 to 0.053) 
and is therefore likely to be a founder mutation. The SNP haplotype data do not 
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differ significantly from the expected frequencies from the control samples (p=0.5 
to 0.8), however, the sample size for the patient group was extremely small (n=3). 
 
Table 3.4: The statistical probabilities of the common c.3637insA haplotype 
occurring in the South African white population. 
Marker Patients Controls Exact 
probability1 
Exact 
probability2 
Intron 13 9/9 84/161 0.004 0.004 
Intron 22 8/9 93/161 0.061 0.053 
p39 9/9 12/71 0.000001 0.000001 
D1241E 3/3 18/23 * 0.512 0.5 
S1269S 3/3 21/24 * 0.692 0.7 
M2238V 3/3 13/14 * 0.824 0.8 
1 The Fisher’s exact probability obtained from http://www.langsrud.com/fisher.htm 
2 The Fisher’s exact probability determined from http://www.physics.csbsju.edu/cgi-
bin/stats/exact 
* Allele frequencies obtained from the white patients this study (section 3.2.4) 
 
3.2.7 Mutation Summary 
Of the 120 patients analysed, a causative mutation was identified in a total of 88 
patients (73.3%). In 32 patients (26.7%) the disease-causing mutation was not 
identified. This was most likely due to technical problems related to poor mRNA 
quality, however, large deletions and rearrangements cannot be excluded. 
DNA analysis identified the intron 22 inversion in 40.9% (36/88) patients and the 
intron 1 inversion in 3.4% (3/88) patients, while mRNA analysis identified a 
mutation in 55.7% (49/88) patients. Of the 49 mutations identified through mRNA 
analysis, 28 patients (57.1%) have a point mutation (17 missense (34.7%), 9 
nonsense (18.4%) and 2 splice-site mutations (4.1%)), 9 patients (18.4%) have a 
deletion and 7 patients (14.3%) have an insertion. Another 5 patients (10.2%) 
have a complex mutation where an exon was deleted on mRNA analysis, but no 
mutation detected on DNA analysis. 
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In this study, it was found that the intron 22 inversion frequency accounted for 
32.5% (14/43) of mutations in the white population, 50% (19/38) of mutations in 
the black population and 42.8% (3/7) of mutations in the Indian and mixed 
ancestry populations (as discussed in section 3.2.1.1). An illustration of the 
breakdown of the different mutation types identified per population group can be 
found in Figure 3.19. It is likely that the increase in the frequency of insertion and 
deletion mutations in the white population is due to the presence of the c.3637insA 
founder mutation (described in section 3.2.6). 
 
 
Figure 3.19: A graphical illustration of the different mutation types identified per 
population group. 
 
The distributions of the different types of mutations, identified by mRNA analysis, 
in the FVIII gene can be found in Figure 3.20. The intron 1 and intron 22 inversion 
mutations have been excluded from this figure. It is evident that most mutations 
(24/49 = 48.9%) are found in exon 14 of the FVIII gene. This is not surprising as 
this exon is about 3.1kb in length – almost a third of the mRNA transcript. 
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Figure 3.20: A schematic representation of the different types of mutations 
identified by mRNA analysis in the FVIII gene in this study. 
The intron 22 and intron 1 inversions have been excluded from this analysis. 
 
A comparison of the frequencies of the different types of mutations in the South 
African population identified by mRNA analysis versus studies undertaken by 
Green, et al. (2008); Oldenburg, et al. (2004b) and Astermark, Oldenburg, 
Escobar, et al. (2005) can be found in Figure 3.21. Green, et al. (2008) studied a 
third of the haemophilia A patients in the UK; Oldenburg, et al. (2004b) reviewed 
all mutations referenced in the HAMSTeRS mutation database and the Astermark, 
et al. (2005) study used data from the Malmö international brothers study. Our 
study, together with the Green et al. (2008) and Oldenburg. et al. (2004b) studies 
determined the frequencies, using mutation data from patients with all severities of 
haemophilia A. The Astermark, et al. (2005) study, however, only assessed 
patients with severe haemophilia A. 
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Intron 22 inversion, insertion/deletion and complex mutations appear to occur at a 
higher frequency in the South African population when compared to the rest of the 
world, whereas missense mutations appear to be lower in the South African 
patients. Missense mutations occur less frequently in patients with severe 
haemophilia A compared to other severities (Astermark, et al., 2005), and the 
patient cohort of this study has a large number of patients with severe haemophilia 
A. This bias in severe haemophilia A patients could explain the increased 
frequency of the intron 22 inversion mutation in the South African population as a 
whole. While the increase in insertions is not unexpected due to the presence of 
the c.36937-3638insA founder mutation in the white population (refer to section 
3.2.6). A statistical comparison of these study groups is difficult as they were 
collected under different conditions and therefore has not been performed. 
 
3.2.7.1 Novel and Previously Reported Mutations 
The novel and previously described mutations are described for each mutation 
type as follows: for nonsense mutations (section 3.2.3.1), for missense mutation 
(section 3.2.3.2), for deletion and insertion mutations (section 3.2.3.3) and for 
mutations affecting splicing (section 3.2.3.4). 
To summarise, of the 49 non intron 22 or intron 1 inversion mutations identified in 
this project by mRNA analysis, 23 (46.9%) were previously reported (6 of which 
are the common white mutation, c.3637insA) and 20 (40.8%) were novel 
mutations not previously reported on the database. As we were unable to identify 
the exact DNA change resulting in 6 mutations (12.2%), we were unable to 
determine if they were novel or previously reported. 
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4 DISCUSSION 
4.1 INTRODUCTION TO THE CHAPTER 
In this chapter, the results of this project and the implications of these findings will 
be discussed. It will also discuss aspects of the project such as mRNA analysis 
(including technical issues, cost effectiveness, advantages and disadvantages), 
and make suggestions about the implementation of this new technique into the 
Diagnostic Molecular Genetics Laboratory, Division of Human Genetics, NHLS 
and School of Pathology, the University of the Witwatersrand, Johannesburg. 
mRNA analysis has proved to be an important technique to identify an increased 
number of mutations in Haemophilia A patients. 
 
4.2 FVIII MUTATIONS IDENTIFIED IN THE PROJECT 
4.2.1 Intron 22 Inversion 
In this study, the intron 22 inversion mutation was found in 34.6% (36/104) of 
South African haemophilia A patients. The world frequency of this mutation is 42-
50% in severe haemophilia A (Lakich, et al., 1993; Naylor, et al., 1993; 
Antonarakis, et. al, 1995). The patients in this study were not selected for 
haemophilia A severity, although there was a bias towards patients with severe 
disease due to sample ascertainment. 
Analysis of the intron 22 inversion mutation at a population level, found the 
mutation in 27.5% (14/51) of white patients, 42.2% (19/45) of black patients and 
37.5% (3/8) of the Indian and mixed ancestry patients. The frequency of the intron 
22 inversion mutation is significantly lower (p=0.008) in the white population. 
Although it remains one of the lowest reported frequencies, it is similar to that 
reported in severe haemophilia A patients in France (28%) (Antonarakis, et al., 
1995). The frequency of this mutation in the black population does not deviate 
(p=0.413) from the expected world frequency of 45%. The frequency of the intron 
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22 inversion mutation in the black population in this study (42.2%) is similar to that 
previously reported by Dangerfield, et al. (1997) as 43% (6/14) in South Africa. 
In the South African population studied in this project, the type I inversion accounts 
for 55.6% (20/36) of intron 22 inversion mutations, the type II inversion for 38.9% 
(14/36) and the atypical pattern of the inversion accounts for 5.6% (2/36). In the 
Antonarakis, et al. (1995) study, the type I inversion accounted for 82% (740/905) 
of intron 22 inversion mutations, while 15% (140/905) were the type II inversion 
and an atypical pattern account for the remaining 3% (25/905) of intron 22 
inversion mutations. The type I inversion is lower in the South African population, 
while the type II inversion is higher than the reported world frequencies. A chi-
squared statistical comparison of these differences was assessed (2=835) and 
resulted in a probability of <0.0001.  
The sample sizes were too small to draw any conclusions as to whether there are 
differences in the distribution of the different types of the intron 22 inversion 
mutation between the different South African populations. However, the type II 
inversion was found in 42.1% (8/19) of the intron 22 inversion mutations in the 
black population. Previously, the type II inversion was not found in this population 
(Dangerfield, et al., 1997), but this could have been due to a small sample size, in 
the previous study. 
As the intron 22 inversion mutation is still the commonest mutation in haemophilia 
A, it is important to test for this mutation first in any mutation analysis. 
 
4.2.2 Intron 1 Inversion  
Direct testing for the intron 1 inversion mutation by PCR analysis was undertaken 
on all patients. This mutation was identified in three patients, two of whom are 
black patients (5.3% of all mutations) and the third patient is of Indian ancestry 
(25% of all mutations). A study of haemophilia A patients from India found the 
intron 1 inversion mutation to account for 2.7% (2/75) of all mutations (Ahmed, et 
al., 2005). 
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It is surprising that this mutation was not found in any white patients in this project 
(n=49) nor in the preliminary screen of 25 white patients from the diagnostic 
haemophilia A cohort. This mutation accounts for approximately 4.8% (10/209) of 
severe haemophilia A mutations in the United Kingdom (Bagnall, et al., 2002) and 
15% (3/21) of mutations in severe haemophilia A patients in the Netherlands 
(Boekhorst, et al., 2005). 
The intron 1 inversion mutation is an important mutation to screen for in 
haemophilia A mutation analysis, even though it has not been identified in the 
white population as yet. As it is a rapid PCR assay, it should be performed as a 
second line mutation test, after testing for the intron 22 inversion mutation. 
 
4.2.3 Mutations Identified using mRNA Analysis 
mRNA analysis of haemophilia A patients identified mutations in an additional 
55.7% (49/88) patients, thus significantly improving the mutation detection rate 
compared to the conventional testing strategy currently offered by the Diagnostic 
Molecular Genetics Laboratory, Division of Human Genetics, NHLS and School of 
Pathology, the University of the Witwatersrand, Johannesburg, for the intron 22 
inversion mutation only. 
The mutation profile in intron 22 inversion negative patients in the South African 
population showed a wide variety of different types of mutations: 34.7% (17/49) 
missense mutations, 18.4% (9/49) nonsense mutations, 4.1% (2/49) splice-site 
mutations, 18.4% (9/49) deletion mutations and 14.3% (7/49) insertion mutations. 
The remaining 10.2% (5/49) patients had a complex mutation where an exon was 
deleted on mRNA, but no mutation was detected at the DNA level. 
When compared to other studies (such as Oldenburg, et al., 2004b; Astermark, et 
al., 2005; Green, et al., 2008), it was found that complex point mutations together 
with insertion/deletion mutations appear to occur at higher frequencies in the 
South African population compared to the rest of the world, whereas the frequency 
of missense mutations in the South African population is lower than expected. 
However, the fact that insertion/deletion mutations are higher in the South African 
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population may be explained by the presence of the c.3637insA founder mutation 
in white patients. In both this study and the Astermark, et al. (2005) study, the 
decrease in frequency of missense mutations, may be explained by the bias of 
severe haemophilia A patients. Missense mutations are lower in patients with 
severe haemophilia A than patients with other severities of haemophilia A 
(Astermark, et al., 2005). Astermark, et al. (2005) only studied severe haemophilia 
A patients, which also explains the high frequency of intron 22 inversion frequency 
in this patient group. 
In summary, a mutation was identified in 76.8% (43/56) of white patients, 67.9% 
(38/56) of black patients and 87.5% (7/8) of Indian and mixed ancestry patients. 
mRNA analysis of the FVIII gene allows for an increased mutation detection rate in 
patients. Mutation results have major implications for family members at risk of 
being carriers of haemophilia A as it can confirm or refute a high-risk result 
determined by linked marker analysis. There were no patients in whom a mutation 
was not found after full sequencing analysis of the FVIII mRNA, and the patients 
without results are more likely to be due to technical difficulties rather than the 
inability of the technique to identify the pathogenic mutation. However, some large 
deletions, insertions and rearrangements may have been missed in these patients. 
 
4.2.4 Novel and Previously Reported Mutations 
Of the 49 mutations identified on mRNA analysis, almost half, 46.9% (23/49) 
(including six copies of the c.3637insA white founder mutation), were previously 
reported on the HAMSTeRS mutation database or by Green, et al. (2008), while 
an additional 40.8% (20/49) were novel mutations. As the exact DNA change 
resulting in 12.2% (6/49) of mutations identified on mRNA analysis could not be 
identified, we can not comment on whether these mutations are novel. These 
mutations may be deep intronic mutations affecting splicing or deletions where the 
breakpoints could not be defined. Screening for the DNA cause of these mutations 
was only conducted by looking for mutations in the exons and the intron/exon 
boundaries of the PCR fragments described in 2.3.7. Due to the high costs 
involved and time constraints, it was not possible to screen the entire flanking 
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intronic sequences for mutations. Although, the exon 10-11 deletion in patient 
HPA202 could be confirmed using the haemophilia A MLPA kit available from 
MRC Holland, this has not been undertaken due to the costs involved in ordering 
and verifying the kit in this laboratory. 
A report by Cutler, Mitchell, Smith, et al. (2002) found that 50.6% (41/81) of 
mutations identified in their intron 22 inversion negative patient cohort were novel. 
Whereas a study by Green, et al. (2008) found that 27.7% (176/636) of mutations 
resulting from a screen of one third of the UK population to be novel. As about one 
third of haemophilia A patients are sporadic cases (reviewed in Graw, et al., 2005), 
the new mutation rate in the FVIII gene is high and therefore, many novel 
mutations would be expected. 
 
4.2.5 Clarification of Linked Marker Results 
Linked marker analysis is useful in cases where the mutation has not been 
identified as it is able to track the inheritance of the high risk allele within a family. 
However, it may be uninformative in a family and it does not take into account the 
possibility of a new mutation in the patient, or the risk of germline mosaicism in the 
mother. Direct mutation detection is optimal for accurate and informative carrier 
testing as it can confirm (example shown in section 3.2.5.1) or decrease the high 
risk (described in section 3.2.5.2) determined by linked markers in a female, and 
possibly reduce the need for testing in other family members or provide definitive 
testing in other family members. Even in cases where germline mosaicism, or a 
new mutation, cannot be determined, the mother can be offered conclusive 
prenatal diagnosis by mutation testing. Direct testing may also be useful in cases 
where linked marker results are uninformative (examined in section 3.2.5.3) or 
where key family members are unavailable for linked marker analysis. 
 
4.2.6 Polymorphisms 
Five polymorphisms or benign variants were identified in this project, four of which 
have been previously reported (Viel, et al., 2007). The white population shows 
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variation at three of these sites, namely D1241E, S1269S and M2238V. All five 
polymorphisms and variants were present in the black population. The Indian and 
mixed ancestry population sample size was too small to draw any conclusions. 
These polymorphisms and their frequencies may potentially be useful in linkage 
analysis in determining the high-risk X chromosome, especially in cases where the 
disease-causing mutation can not be identified and where other markers are 
uninformative. 
The novel variant, A544A was only found in one patient from the black population 
at a frequency of 0.04 (1/28). It is suggested that more individuals from the black 
population be screened for this variant to determine if it is indeed a polymorphism 
in the population or just a rare variant in patient HPA183, before using this variant 
as a linked marker in future linkage analysis. 
 
4.2.7 Common Founder Mutation in the White Population 
The c.3637insA mutation was found at a frequency of 14% (6/43) in patients from 
the white population. As this was the only mutation that occurred more than once 
in the white population, haplotype analysis was performed to determine if this 
mutation was the elusive founder mutation previously proposed (Dangerfield, et 
al., 1997; McKibbin, 2002), or just a common recurrent mutation as it has been 
previously reported 16 times in the HAMSTeRS mutation database. 
Using haplotype analysis for 3 polymorphic microsatellite markers (intron 13, intron 
22 and the p39 extragenic marker), a common haplotype of 20 repeats, 26 repeats 
and 160bp was found in 8/9 of patients positive for the c.3637insA mutation. The 
only patient that did not have this haplotype was found to have a haplotype of 20 
repeats, 27 repeats and 160bp. It is possible that this single repeat difference for 
the intron 22 marker may be due to replication slippage, or it may be an 
independent mutation in this patient. No rare SNP was found in three of these 
patients to refine the haplotype further, but they also share the same SNP 
haplotype. 
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The control group used microsatellite frequencies obtained by Dangerfield, et al. 
(1997) and McKibbin (2002). As haplotype data were not available for the control 
group, each marker had to be compared separately. The probabilities indicate that 
the allele observed at each of the microsatellite loci in the c.3637insA patients 
occurs far more commonly than expected (p=0.000001 to 0.0530). The SNP 
haplotype data in the patient group did not differ significantly from the expected 
frequencies from the control samples (p=0.5 to 0.8), which may be explained by 
the fact that no rare alleles were observed in the patient cohort. The microsatellite 
data therefore provide strong evidence that the common haplotype identified in the 
patients is likely to be a founder mutation and not a common recurrent mutation. 
It is interesting to note that together the c.3637insA mutation (14%) and the intron 
22 inversion mutation (32.5%) account for 46.5% of disease-causing mutations in 
the white population. This is comparable to the frequency of the intron 22 inversion 
alone in most world populations (Antonarakis, et al., 1995). 
The c.3637insA mutation can be added to the list of other founder mutations in the 
South African white population, such as porphyria variegata (Dean, 1971), familial 
hypercholesterolemia (Jenkins, et al., 1980), pseudoxanthoma elasticum (Le 
Saux, Beck, Sachsinger, et al., 2002); BRCA1 in breast/ovarian cancer (Reeves, 
Yawitch, van der Merwe, et al., 2004); Fanconi Anaemia (Tipping, Pearson, 
Morgan, et al., 2001) and autosomal recessive polycystic kidney disease 
(unpublished data). These founder effects are all autosomal dominant or recessive 
disorders, whereas the haemophilia A founder mutation is the first report of an X-
linked founder mutation in the white population of South Africa. However, this is 
not the first case of a founder mutation causing haemophilia A. Santacrose, 
Santoro, Sessa, et al. (2008) report on a founder mutation in the FVIII gene in mild 
and moderate haemophilia A patients in southern Italy. 
It is suggested that the Diagnostic Molecular Genetics Laboratory, Division of 
Human Genetics, NHLS and School of Pathology, the University of the 
Witwatersrand, Johannesburg, include testing for this mutation into their routine 
mutation testing strategy, especially for white patients that test negative for the 
intron 22 inversion (refer to section 4.4). 
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4.3 THE USE OF MRNA FOR MUTATION DETECTION  
Analysis of mRNA for haemophilia A mutation detection has proved successful in 
previous studies. For example, in the identification of the common intron 22 
inversion mutation (Naylor, et al., 1992) and the intron 1 inversion mutation 
(Bagnall, et al., 2002). mRNA analysis has proved useful in finding deep intronic 
mutations and in assessing the functional impact of such mutations on the gene, 
and determining the consequences of some mutations (Green, et al., 2008).  
mRNA analysis is useful for genes with large intronic sequences or for large genes 
as it assesses the transcript which is normally smaller in size. Some disorders in 
which mRNA analysis has proved useful include Duchenne and Becker Muscular 
Dystrophy (Roest, et al., 1996), breast and ovarian cancers (Rhei, et al., 1998; 
Spearman, et al., 2008), and neurofibromatosis (Pros, et al., 2008). FVIII is also a 
perfect candidate for mRNA analysis as it is a large gene (186kb of genomic DNA) 
and DNA analysis was not previously as successful as expected (Dangerfield & 
Manga, unpublished data). Also, there are a large number of rearrangements in 
the FVIII gene that would not be identified by analysing the DNA alone. The 9kb 
FVIII mRNA transcript can be assessed in nine overlapping fragments, compared 
to analysis of DNA which would require the 26 exons to be amplified in 29 
reactions. Analysis of mRNA would therefore be expected to be more cost 
effective than DNA analysis, because fewer fragments are amplified and it is able 
to detect a wider variety of mutations, such as large rearrangements, deletions, 
insertions and cryptic mutations that would be missed by studying the exonic DNA. 
mRNA analysis also detects mutations readily detected by DNA analysis such as 
obvious splice site and point mutations.  
Studying the gene at the mRNA level would not be able to detect mutations within 
the promoter region which would affect the regulation of gene expression rather 
than the actual protein produced (Mueller & Young, 1998). There is also a report of 
a patient with severe haemophilia A, who tested negative for the intron 22 and 
intron 1 inversion mutations and the coding sequences at a DNA level, and in 
whom there was no detectable mRNA for the FVIII gene. This mutation causing 
haemophilia A in the patient is therefore likely to be due to the absence or rapid 
degradation of the F8 mRNA (El-Maarri, Singer, Klein, et al., 2006). 
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The main aim of the project was to assess an mRNA based approach to develop a 
more effective mutation detection system that would detect more mutations and 
reduce the costs of DNA mutation analysis. Initially, this project intended to use 
PTT as a mutation detection technique, however, it was decided this technique 
was too costly and limited as it would not detect all types of mutations (as 
discussed in section 4.3.1.1). PTT only detects mutations that truncate the protein 
of interest. 
 
4.3.1 Advantages of mRNA Analysis 
mRNA has numerous benefits over DNA as a medium for analysis for example, 
the cost benefits and the mutation detection rate. These are discussed in sections 
4.3.1.1 and 4.3.1.2. 
4.3.1.1 Cost Effectiveness of Different Mutation Analysis Methods 
mRNA analysis for the FVIII gene analyses nine overlapping fragments in 24 
sequencing reactions (two sequencing reactions each for fragments 1a, 1b, 4a, 
4b, 6a and 6b, and four sequencing reactions each for fragments 2, 3 and 5) (refer 
to section 2.3.6). DNA analysis of the 26 exons of the FVIII gene, requires 58 
sequencing reactions (two sequencing reactions for each exon, except for exon 14 
which requires eight sequencing reactions to cover this large exon) (refer to 
section 2.3.7). mRNA analysis therefore drastically reduces the sequencing cost to 
approximately half, compared to DNA mutation analysis for haemophilia A, as 
seen in Table 4.1, and also reduces the analytical work required, thereby reducing 
the time required for analysis. Further, full mRNA analysis may not be required in 
all patients. A few examples where fewer mRNA sequencing reactions may be 
required are illustrated below: 
1. If a patient’s PCR product differs from the expected size, it is likely to 
indicate an insertion or deletion at the RNA level and only this fragment 
would be sequenced initially. However, the genomic cause could be an 
insertion, deletion or point mutation resulting in abnormal splicing.  
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2. Once a pathogenic mutation has been identified in a patient, further 
mutation analysis on other fragments may be discontinued. 
3. As many mutations were identified in exon 14, analysis of this exon may be 
done first (either at a DNA or mRNA level) and if a mutation is identified, 
analysis of the remaining FVIII gene may not be required. 
 
Table 4.1: A cost comparison of mRNA versus DNA analysis for the FVIII gene 
per patient. 
Analysis Technique Approximate cost 
per patient 
Total cost per 
patient 
RNA extraction R95 
Reverse transcription R65 
mRNA 
Sequencing (24 reactions) R2300 
R2620 
DNA extraction R40 DNA 
Sequencing (58 reactions) R5670 
R5710 
 
Originally this project intended to use the protein truncation testing technique 
which selectively identifies certain mutations that result in premature protein 
truncation (including nonsense mutations, insertions, deletions, gene 
rearrangements, various splicing mutations) and possibly even detection of 
mutations that affect protein folding. This technique involves reverse transcription 
of mRNA, PCR amplification followed by in vitro transcription and translation of the 
PCR products. The protein products are analysed using SDS-PAGE (reviewed by 
Den Dunnen & van Ommem, 1999). Any truncated proteins would be analysed 
further, usually by sequencing analysis, to determine the exact nature of the 
mutation. Maugard, et al. (1998) found the protein truncation test identified the 
disease-causing mutation in 66% of inversion 22 negative, severe haemophilia A 
patients in France.  
After much consideration, it was decided not to use the protein truncation test in 
this project, mainly for cost reasons. Not only does protein truncation testing 
require amplification of the nine overlapping cDNA fragments, but it also requires 
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nine reactions of the in vitro transcription/translation kit (containing cell-free 
extracts of prokaryotic or eukaryotic cells with all the machinery components and 
polymerases required for coupled transcription and translation). Further, this 
technique does not detect missense mutations or mutations that may affect protein 
function rather than protein structure. In these cases, mRNA sequence analysis 
would still be required in addition to the protein truncation test to identify the 
disease-causing mutation, thus adding costs. A comparison of the costs is broadly 
shown in Table 4.2. The costs for the protein synthesis kit and sequencing are 
based on the suppliers’ 2009 prices.  
 
Table 4.2: Comparison of the broad cost estimates per patient for protein 
truncation testing versus sequencing analysis of FVIII mRNA. 
Situation Technique Approximate costs Total 
RNA extraction R95 
Reverse transcription R65 
Protein synthesis kit R611/reaction x 9 = R5500 
PTT identifies 
mutation  
Sequencing R200 
R5860 
RNA extraction R95 
Reverse transcription R65 
Protein synthesis kit R611/reaction x 9 = R5500 
PTT does not identify 
mutation  
Sequencing R2300 
R7960 
RNA extraction R95 
Reverse transcription R65 
mRNA sequencing 
only 
Sequencing R2300 
R2460 
 
4.3.1.2 Detection of Additional Mutations using mRNA Analysis 
Another major benefit for mRNA analysis includes the detection of additional 
mutations (deletions, insertions and deep intronic mutations that affect splicing) 
that would otherwise have been missed using DNA analysis.  
In this study, the disease-causing mutation would have been missed in 12.2% 
(6/49) of patients if testing was only conducted using DNA analysis. These 
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mutations include partial, single or multiple exon deletions (discussed in sections 
4.3.1.2.1, 4.3.1.2.3 and 4.3.1.2.4) and insertions of intron sequence into the mRNA 
transcript. Some other mutations may have been misclassified as missense 
mutations instead of mutations affecting splicing (discussed in section 4.3.1.2.2). 
Some of these cases are described below. 
4.3.1.2.1 Example of a Deep Intron Site Mutation 
In patient HPA219 (refer to section 3.2.3.3), a deletion of exon 10 was detected on 
mRNA analysis; however DNA analysis of exon 10 did not detect the disease 
causing mutation within exon 10 or the intron/exon boundaries. It is assumed that 
there is a deep intronic or cryptic splice site mutation that causes exon 10 to be 
spliced out of the mRNA sequence. This mutation would have been missed using 
DNA analysis alone. 
4.3.1.2.2 Example of a Cryptic Splice Site Mutation 
Patient HPA236 was found to have a deletion of exon 13 on mRNA analysis (refer 
to section 3.2.3.4.1). In this case, although DNA analysis of exon 13 found a 
c.2111CT mutation which appears to cause a P687L substitution, mRNA 
analysis proved that this mutation would actually affect the splicing of exon 13. 
Here the effect of the mutation would have been misinterpreted as a missense 
mutation rather than a splice site mutation and the severity perhaps may have 
been underestimated. This mutation was not predicted by the online splice site 
predictor programs and emphasises the importance of mRNA analysis in 
determining the effect of a mutation. 
4.3.1.2.3 Example of Alternative Splicing 
DNA sequencing of patient HPA223 of exon 16 found no mutation, except for a 
IVS16+37delT (the pathogenicity of which is unknown). Initial mRNA analysis 
showed a partial deletion of exon 16. Closer inspection of the sequencing result 
provided evidence of alternative splicing of exon 16 (refer to section 3.2.3.4.3). 
This mutation is therefore only able to be detected using mRNA analysis. The 
IVS16+37delT may be used at least, as an additional linked marker to track the 
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high-risk X chromosome in this family, even though the pathogenic mutation 
remains unknown. 
4.3.1.2.4 Example of a Multi-exon Deletion 
In patient HPA210, exons 10 and 11 were found to be deleted on mRNA analysis. 
Using DNA analysis the two exons could not be amplified. This was strongly 
suggestive of a deletion spanning these two exons. If DNA analysis was used in 
isolation, it may have been assumed that amplification of these two exons was 
problematic. However, the breakpoints of this mutation have not been defined due 
to the large size of introns 9 and 11 and time and cost constraints of the project. 
Once the breakpoints are defined, a PCR for this family may be specifically 
designed to aid in carrier testing and prenatal diagnosis. MLPA analysis could be 
used as an alternate mutation detection method, or DNA amplification of exon 10 
and 11 using a dosage assay, however, this technique would need careful 
analysis and at least 5 control samples. Currently, testing of other family members 
can only be offered using mRNA analysis, which appears to be the best method at 
present. 
 
4.3.1.3 Detection of Carriers using mRNA 
For mutations such as large deletions, rearrangements or complex mutations, 
direct mutation detection can be offered to family members at risk of haemophilia 
A by using mRNA, as these mutations are either unable to be detected using DNA, 
or are easier to detect at an mRNA level. An alternate method of detection would 
need to be optimised before carrier testing and prenatal diagnosis could be offered 
to family members. Other possible methods of mutation detection of such 
mutations in female relatives include: use of linkage analysis which may reveal 
loss of heterozygosity for the markers in the deleted region; gene dosage analysis 
and MLPA could be applied to the FVIII gene as suggested by Keeney, et al. 
(2005). However, these methods would not be useful if the deletion is not present 
at the DNA level. 
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4.3.2 Disadvantages of mRNA Analysis 
4.3.2.1 Stability of mRNA 
mRNA is less stable than DNA. This is mainly due to the fact that RNA is single 
stranded and highly prone to relatively rapid degradation. This is important in the 
transport and storage of patient samples. 
4.3.2.1.1 Transport of Patient Samples 
The stability of mRNA is a major consideration in transportation of samples for 
diagnostic testing. In this project, it was found that it is best to extract mRNA within 
24 hours of sample collection, which may not always be possible when the sample 
is being transported from a remote location. 
To overcome this limitation, there are two potential options available. The first is 
the PAXgene product (Qiagen) and the other involves the addition of TRIzol 
(Invitrogen) to the blood sample immediately after collection. Both possibilities are 
described below. 
4.3.2.1.1.1 PAXgene Blood RNA kit 
PAXgene Blood RNA kit is a joint kit that includes blood collection tubes and the 
extraction kit. It allows stabilisation of RNA for 3 days at 18-25C or 5 days if 
stored at 2-8C. After extraction, the cellular RNA is stable for 6 months at -20C 
to -70C (product catalogue and details are available from the Qiagen website 
http://www1.qiagen.com/Products/RnaStabilizationPurification/DSP/PaxGeneBloodRnaKit
.aspx?r=3710). Although it is reported that this kit is compatible with systems 
previously optimised using the QIAamp RNA blood mini kit, it was not tested in this 
project. It would be important to try this option as it would allow an easy alternative 
to overcome the limitations with mRNA stability and allow transport of samples 
from other centres around the country to be sent in for diagnostic testing. 
It would need to be ensured that haemophilia centres around the country had 
access to these blood tubes and the shelf-life of the tubes would need to be 
determined. Also the cost of the tubes is apparently high, and may increase the 
cost of the test. 
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4.3.2.1.1.2 TRIzol stabilisation 
TRIzol is a chemical that is added to a blood sample to stabilise the RNA and it is 
used in the extraction process. Unfortunately, TRIzol contains phenol and 
guanidine isothiocyanate, meaning that special safety precautions are required 
when working with this solution (further information is available at the Invitrogen 
website at http://www.invitrogen.com/site/us/en/home/brands/Product-Brand/Trizol.html). 
The TRIzol method requires some processing in a laboratory at the site of sample 
collection, and the samples need to be transported frozen, both of which may be 
problematic when blood needs to be sent from distant locations. In addition, TRIzol 
requires a different method of extraction to that of the QIAamp RNA blood mini kit 
(the protocol for mRNA extraction from TRIzol stabilised blood can be found in 
Appendix B). A sample of TRIzol stabilised blood from a normal individual was 
obtained from Dr Marius Coetzee (Department of Haematology and Cell Biology, 
University of the Free State, Bloemfontein) to determine if TRIzol stabilised 
samples would be able to be used in this project. Amplification of the RNA 
fragments works well without further optimisation. 
4.3.2.1.2 Long Term Storage of Patient Samples 
DNA samples from patients are still viable after many years if stored in TE buffer 
at 4C, however, during this study it was found that mRNA was only stable for a 
year at -70C (also stated in the QIAamp RNA Blood Mini kit manual). The mRNA 
samples of haemophilia A patients can not be banked to be used as a positive 
control at a later stage, should other at-risk family members require testing, 
especially for those patients where the disease-causing mutation is only 
detectable on mRNA analysis. The long-term stability of cDNA has not been 
assessed in this project. 
 
4.3.2.2 Failure Rate of mRNA Analysis 
In this project, mutations were not detected in 26.7% patients (32/120) using the 
mRNA approach. Although this is relatively high, this could be due to several 
factors. mRNA is only stable for a year at -70C (as discussed in section 4.3.2.1.2) 
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and some samples took longer than a year to try to identify the disease-causing 
mutation, and therefore made it difficult to complete analysis in these samples. 
This should be kept in mind for diagnostic testing and it may not be possible to 
batch samples for testing. Other factors could involve poor mRNA quality of the 
initial sample, a deletion of the entire FVIII transcript or even large or partial gene 
deletions. In cases where amplification of one or more fragments failed, it would 
be difficult to determine if this was due to a full or partial gene deletion, large 
rearrangements or technical difficulties with the amplification of the cDNA 
fragment/s. A possible resolution to this limitation in some patients could be to test 
the patient’s DNA, especially in the region were mRNA amplification was 
unsuccessful. Rearrangements are however, difficult to determine and identify. If 
the PCR runs are carefully controlled, deletions of the entire fragment should be 
detectable or at least suspected on repeat runs.  
For those patients in whom no mutation was detected, none had amplification of 
all 9 fragments and were found to be negative on sequencing analysis for these 
fragments. These patients were therefore unsuccessful for technical reasons. The 
mutation detection rate is likely to increase if the technical issues are resolved or 
at least minimised. 
Other options to reduce the failure rate of mRNA analysis could be to improve the 
primer and PCR conditions of the reactions, and perhaps to even optimise the 
systems so that all the fragments can be amplified under the same conditions or 
even adding universal sequencing tags to allow for sequencing using a single 
primer. 
 
4.4 IMPLEMENTATION OF FINDINGS INTO THE DIAGNOSTIC LABORATORY 
This project shows that inclusion of mRNA analysis for the FVIII gene detected a 
further 55.7% (49/88) of mutations. Although certain limitations related to mRNA 
analysis (stability, transportation of samples, and the failure rate of analysis) need 
to be overcome, mRNA analysis offers a significantly improved method for 
analysis, and is likely to result in an even higher detection rate in a controlled 
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diagnostic setting. A step-wise approach to mutation detection may be the most 
cost effective option, however, it may be more time consuming. 
Currently, the Diagnostic Molecular Genetics Laboratory, Division of Human 
Genetics, NHLS and School of Pathology, the University of the Witwatersrand, 
Johannesburg, only offers direct mutation detection for the intron 22 inversion 
mutation, which detects mutations in 40.9% (36/88) of patients. However, the 
frequency of the intron 22 inversion mutation varies across the different population 
groups: 32.6% (14/43) of the white patients, 50% (19/38) of the black patients and 
42.9% (3/7) of patients from the Indian and mixed ancestry patients (refer to 
section 3.2.1.1). Currently, the intron 22 inversion mutation is detected using 
Southern blot analysis, which is costly, time consuming and requires the use of 
hazardous radioactive labelling. It is highly recommended that long range PCR for 
the intron 22 inversion mutation (Bagnall, et al., 2005) be optimised and 
implemented into the Diagnostic Molecular Genetics Laboratory, Division of 
Human Genetics, NHLS and School of Pathology, the University of the 
Witwatersrand, Johannesburg. 
Secondly, as the c.3637insA mutation accounts for 14% of mutations in white 
patients (refer to section 3.2.5 and 4.2.7), it is recommended that testing for this 
mutation be included into routine diagnostic testing, prior to mRNA analysis. 
Together, the intron 22 inversion mutation and the c.3637insA mutation account 
for 46.5% (20/43) of disease-causing mutations in the white patients. This 
c.3637insA mutation is detected by sequencing analysis of exon 14b1. This 
sequencing would also detect other mutations in this part of exon 14. 
The third recommendation would be to include testing for the intron 1 inversion 
mutation in patients who test negative for the intron 22 inversion mutation. The 
intron 1 inversion mutation accounts for 3.4% (3/88) of disease-causing mutations 
in the South African haemophilia A population. Although this mutation has not 
been detected in white South African patients, it accounts for 4.8% (10/209) of 
severe haemophilia A mutations in the United Kingdom (Bagnall, et al., 2002) and 
15% (3/21) of mutations in severe haemophilia A patients in the Netherlands 
(Boekhorst, et al., 2005). As detection is via a single PCR, it is advisable to test for 
this mutation before mRNA analysis. 
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Screening of exon 14 of the FVIII gene should be considered for patients who test 
negative for the intron 22 inversion and intron 1 inversion mutations, and for white 
patients who test negative for the c.3637insA mutation. Excluding the c.3637insA 
founder mutation, 36.7% (18/49) of non-inversion mutations identified in this 
project were found to occur in exon 14. This result is not surprising as 
approximately one third of the FVIII transcript is comprised of exon 14. Exon 14 
can easily be tested in four amplified reactions using DNA, and three reactions if 
mRNA is available (fragment 3, 4a and 4b). It is recommended to sequence exon 
14 at the DNA level, as it would include the detection of obvious splice site 
mutations. Fragments 3, 4a and 4b are all within exon 14 and do not cover the 
exon/intron boundaries. These exon/intron boundaries are covered in fragment 2 
and 5. 
If the disease-causing mutation has still not been identified in a patient using this 
approach, mutation detection using the mRNA approach is likely to detect the 
disease-causing mutation. There are no recommendations for the order of 
screening of the remaining mRNA fragments. 
Further options for mutation detection could involve assessing the use of MLPA. In 
this project, this technique may only have aided in the detection of mutation in two 
patients, namely HPA202 with a deletion of exon 10-11 and HPA017 with a 
deletion of exon 19. If MLPA can be performed using mRNA, it may detect 
mutations which affect splicing. Such mutations (exon deletions, splice site 
mutations and complex mutations) were responsible for disease in 16.3% (8/49) of 
non-inversion patients in this project.  
A summary of the recommendations for the step-wise screening of the FVIII gene 
in haemophilia A in a diagnostic setting is outlined in Figure 4.1. 
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Figure 4.1: A schematic summary of the approach for step-wise mutation 
detection for haemophilia A patients in a diagnostic setting. 
 
4.5 FVIII ANALYSIS IN OTHER CENTRES 
Details of various laboratories from around the world, who offer mutation analysis 
for haemophilia A, were obtained from the Laboratory Directory on the GeneTests 
website (http://www.genetests.org). Five laboratories, who offer diagnostic testing 
for haemophilia A, were contacted via e-mail to enquire about their mutation 
detection methodologies. All five laboratories replied. A comparison of the 
techniques utilised for diagnostic FVIII analysis found that mRNA analysis was not 
routinely used in a diagnostic setting. mRNA is therefore a fairly underutilised tool 
for mutation detection for haemophilia A and possibly other conditions. It may be 
because of the technical difficulties entailed with handling mRNA (as already 
discussed in section 4.3.2) or the limited timescale and budget to undertake 
routine diagnostic testing (Bell, Bodmer, Sistermans, et al., 2007). These 
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laboratories may have bigger budgets and therefore the cost of sequencing DNA 
would not be a problem. 
The University Medical Centre, Utrecht, Netherlands performs diagnostic analysis 
on the genomic DNA using a PCR test for the inversion intron 22 and sequence 
analysis of the exons (including exonic splice regions) of the FVIII gene (Dr M.E. 
van Gijn, 2008, personal e-mail).  
Leiden University Medical Centre in Netherlands use DNA, not mRNA for 
haemophilia A analysis. They analyse the complete coding sequence by sequence 
analysis and use PCR analysis for detection of the intron 1 and intron 22 
inversions. They also can perform MLPA analysis for haemophilia A (Dr E.M.J. 
Boon, 2008, personal e-mail). 
The Department of Genetics at the University of Pennsylvania, Philadelphia use a 
step-wise mutation detection method. They start by testing for the intron 22 
inversion mutation using Southern Blot analysis, followed by full sequencing of all 
coding exons of the FVIII gene. If no mutations are found using these methods, 
intron 1 inversion testing, quantitative PCR and mRNA analysis to search for 
intronic mutations follow (Dr Ganguly, 2008, personal e-mail) 
The Sheffield Molecular Genetics Service in the United Kingdom uses long-range-
PCR for the intron 22 and intron 1 inversion mutations and direct DNA sequencing 
of all FVIII exons (Dr A. Goodeve, 2008, personal e-mail). 
The most comprehensive mutation analysis strategy appears to be performed at 
the City of Hope Medical Centre in California. Initially they perform a PCR assay 
for the intron 22 inversion, followed by comprehensive mutation analysis where all 
coding regions and splice junctions of the FVIII gene are analysed using direct 
DNA sequencing. This is followed by testing for the intron 1 inversion mutation 
also using a PCR assay. Patients who test negative for these testing strategies are 
further tested for von Willebrand factor Normandy mutations (sequence analysis of 
exon 18, 19 and 20 of the von Willebrand gene) as mutations here may impact on 
FVIII stability. And lastly, in patients where no mutations are found, they perform a 
dosage analysis for known large gene deletions (their assay tests for large 
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deletions in exon 1, 6, 7, 8, 10, 12-14, 16, 20-23, 25-26 of the FVIII gene) (Weiss, 
2008). 
Therefore the use of mRNA analysis for FVIII in this study is a novel approach and 
its benefits have been proved in this project as it has the potential to reduce costs 
and detect a broad range of mutations, including large deletions and 
rearrangements which may be missed by DNA sequencing. 
 
4.6 SUMMARY OF PROJECT FINDINGS 
mRNA is a useful method for mutation analysis, especially for haemophilia A, and 
it is recommended that the mutation detection strategy outlined in section 4.4 be 
implemented into the routine haemophilia A diagnostic service available at the 
Diagnostic Molecular Genetics Laboratory, Division of Human Genetics, NHLS 
and School of Pathology, the University of the Witwatersrand, Johannesburg. 
The advantages of mRNA include the reduced cost of mutation detection 
compared to DNA analysis (section 4.3.1.1) and detection of additional mutations 
that may have been missed using DNA analysis (section 4.3.1.2). The limitations 
of mRNA analysis include the stability of mRNA (section 4.3.2.1) and the failure 
rate of mRNA analysis (section 4.3.2.2). 
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5 CONCLUSION 
Knowledge of the haemophilia A disease-causing mutation may have clinical 
significance in determining the severity of the disease and in prediction of which 
patients are prone to developing inhibitors to FVIII replacement treatment or are 
potential candidates for gene therapy trials. Direct mutation detection is also useful 
in accurately determining the carrier status of at risk family members and in 
prenatal diagnosis.  
In this study, the intron 22 inversion mutation was found in 40.9% of South African 
patients (32.6% of white patients, 50% of black patients and 42.9% of the Indian 
and mixed ancestry patients). The inversion mutation in intron 1 of the FVIII gene 
accounts for 3.4% of all patients (0% of white patients, 5.3% of black patients and 
12.5% of patients from the Indian and mixed ancestry population). Analysis of the 
FVIII transcript identified an additional 55.7% of mutations (67.4% of white 
patients, 44.7% of black patients and 42.8% of Indian and mixed ancestry 
patients). The mutation profile of non-inversion patients was as follows: 34.7% 
missense, 18.4% nonsense, 4.1% splice-site mutations, 18.4% deletions, 14.3% 
insertions, while the remaining 10.2% patients had a complex mutation. 
In addition to the intron 22 and intron 1 inversion mutations, mRNA proves to be 
highly effective in identifying disease-causing mutations. Using this testing 
strategy, a mutation was identified in 73.3% of South African Haemophilia A 
patients (76.8% of white patients, 67.9% black patients and 87.5% Indian and 
mixed ancestry patients). A higher mutation detection rate is expected if the 
technical difficulties related to mRNA are minimised. 
Analysis of mRNA identified the c.3637insA mutation at a frequency of 14% in the 
white haemophilia A population, thereby providing further evidence for the 
presence of the previously suspected founder mutation in these patients.  
mRNA analysis is a cost effective method of mutation analysis (almost half the 
cost of DNA based analysis) and has a high mutation detection rate (able to detect 
a wide variety of mutations, including rearrangements, deletions, insertions, 
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mutations affecting splicing and point mutations). mRNA based analysis is also 
able to determine the effects of certain mutations simultaneously. 
Unfortunately, mRNA is less stable then DNA which may impact on the 
transportation of samples from remote locations and long term storage of 
diagnostic samples to be used as a positive control sample in future.  
The Diagnostic Molecular Genetics Laboratory, Division of Human Genetics, 
NHLS and School of Pathology, the University of the Witwatersrand, 
Johannesburg is the only laboratory in South Africa to offer mutation analysis for 
haemophilia A, thereby providing a diagnostic service to the whole country and the 
whole Southern African region. From the findings of this study, it is recommended 
that this laboratory implement a step-wise based approach to mutation detection 
for haemophilia A. Initially, testing for the intron 22 inversion mutations (by 
Southern blotting or ideally by long range PCR) is recommended, followed by the 
detection of the intron 1 inversion mutation and the c.3637insA mutation (in white 
patients). Thereafter, mutation analysis of exon 14 (either by DNA or mRNA 
analysis) would be recommended before full mutation analysis using an mRNA 
based approach is carried out.  
In summary, testing for a mutation using intron 1 and 22 direct detection and 
mRNA analysis identified a mutation in 76.8% (43/56) white patients, 67.9% 
(38/56) black patients and 87.5% (7/8) Indian and mixed ancestry patients. Thus a 
new mutation detection strategy has been developed that significantly improves 
the diagnostic service available to haemophilia A patients and their families in 
South Africa. 
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6 APPENDICES 
APPENDIX A 
ETHICS 
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A1 ETHICS CLEARANCE CERTIFICATE 
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A2 PATIENT CONSENT FORM 
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A3 PATIENT ASSENT FORM 
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APPENDIX B 
TECHNIQUE PROTOCOLS 
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B1 DNA EXTRACTION PROTOCOL 
Salting-out Procedure 
Modified from Miller, et al. (1988). 
 
1. Collect blood into purple-top EDTA or yellow-top ACD tubes 
2. Decant no more than 10ml whole blood into a 50ml polypropanol (NUNC) tubes. If 
only 3-5ml blood is available, halve the volumes of solutions in the protocol 
3. Freeze the blood at -20C for storage. Thaw the whole blood for about 1 hour 
before extraction 
4. The composition of all solutions used can be found in Appendix D 
Day 1: 
1. Fill each NUNC tube (up to 45-50ml mark) with cold sucrose-Triton-X lysing buffer 
(keep this solution cold during the procedure), and invert the NUNC tube several 
times to mix 
2. Centrifuge the NUNC tube for 10 minutes at 1000xg (~2400r.p.m.) at 4C in the 
Beckman GS-6R centrifuge 
3. A reddish-white pellet should be visible. Pour off the supernatant fluid containing 
the lysed red blood cells, ensuring the pellet does not dislodge 
4. Wash the pellet with 20-25ml cold sucrose-Triton-X lysing buffer and place the 
NUNC tube on ice for 5 minutes 
5. Centrifuge the NUNC tube for 5 minutes at 1000xg (~2400r.p.m.) at 4C in the 
Beckman GS-6R centrifuge 
6. Pour off the supernatant. These washes may be carried out several times until a 
white pellet is visible 
7. Add 3ml T20E5, 0.2ml (200l) 10% SDS and 0.5ml (500l) Proteinase-K mix. Mix 
the NUNC tubes well by inversion 
8. Incubate at 42C to 50C overnight (no need to agitate) 
Day 2: 
9. Add 1ml saturated NaCl to the lysate the following day. Agitate vigorously for 15 
seconds by inversion 
10. Chill the NUNC tube with the salt at -20C or on ice for 5-10 minutes 
11. Centrifuge the NUNC tube for 30 minutes at 1000xg (~2400r.p.m.) at 4C in the 
Beckman GS-6R centrifuge 
12. A white pellet should be visible. If no pellet is visible, spin again for 10-20 minutes 
13. Transfer the supernatant containing the DNA into a new NUNC tube 
14. Add two volumes absolute ethanol (Merck) kept at room temperature 
15. Agitate gently and spool the DNA. If no DNA is visible, precipitate DNA (see 
below) 
16. Wash DNA in 70% ice-cold ethanol. Transfer the DNA into a labelled Eppendorf 
tube 
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17. Air-dry the DNA and resuspend in an appropriate amount of 1xTris-EDTA (TE) 
buffer (usually between 200l and 1000l) overnight 
To Precipitate DNA 
18. If DNA is unable to be spooled, place NUNC tube containing the absolute ethanol 
at -20C overnight or at -70C for 30 minutes 
19. Centrifuge for 30 minutes (maximum) at 1000xg (~2400r.p.m.) at 4C in the 
Beckman GS-6R centrifuge 
20. Pour off the supernatant. Add about 15ml 70% ethanol. Centrifuge at 1000xg 
(~2400r.p.m.) at 4C for 15 minutes 
21. Pour off supernatant. DNA is the precipitate at the bottom of the NUNC tube. Allow 
the pellet to air-dry. Resuspend in appropriate amount of 1xTE buffer (between 50 
and 250l) overnight 
22. Transfer the DNA into a labelled Eppendorf tube. Label the tube "ppt" to indicate 
that it is a precipitate 
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B2 RNA EXTRACTION PROTOCOL 
QIAamp RNA Blood Mini Kit (QIAGEN) 
Notes before starting 
The RPE, RLT, EL and RW1 buffers, RNase free ddH2O and the QIAshredder and 
QIAamp spin columns are supplied with the kit 
Add 4 volumes absolute ethanol (Merck) to buffer RPE 
Add 10µl β-mercaptoethanol (Sigma) to 1ml buffer RLT. This solution is stable at room 
temperature for 1 month 
Cell lysates in buffer RLT (from step 6) can be stored at -70°C if necessary. Thaw 
products at 37°C for 10 minutes before continuing with protocol (step 7) 
Steps 3-5 use the Beckman GS-6R centrifuge at 400xg (~1657r.p.m.) at 4°C. Steps 7-
15 use the Eppendorf centrifuge 5415C, however the centrifugation speeds differ 
between the different steps. The vortex steps use the Vortex-Genie 2 (Scientific 
Industries) 
Protocol 
1. Mix 1 volume (0.5-1ml) fresh blood with 5 volumes (2.5-5ml) buffer EL. Incubate 
for 10-20 minutes on ice. Mix by vortexing twice. The cloudy suspension becomes 
clear 
2. Centrifuge in the Beckman centrifuge at 400xg (~1657r.p.m.) for 10 minutes at 
4°C. Discard supernatant 
3. Add 2 volumes (2ml) buffer EL to the cell pellet. Resuspend pellet by vortexing. 
Centrifuge in the Beckman centrifuge at 400xg (~1657r.p.m.) for 10 minutes at 
4°C. Discard supernatant 
4. Add 600µl buffer RLT. Vortex or pipette to mix and remove all clumps 
Cell lysate products can be stored at -70°c if needed. Thaw and incubate at 37°C for 10 
minutes before continuing with step 5 
5. Pipette lysate onto QIAshredder Spin Column (lilac column) in a 2ml collection 
column. Centrifuge in the Eppendorf centrifuge at maximum speed for 2 minutes to 
homogenise. Discard the QIAshredder and keep homogenised lysate 
6. Add 1 volume (600µl) 70% ethanol to homogenised lysate. Mix by pipetting. 
Pipette sample onto QiAamp spin column (clear column) in collection tube. 
Centrifuge at ≥8000xg (≥10000r.p.m.) for 15 seconds in the Eppendorf centrifuge 
7. Transfer QiAamp spin column into a new collection tube. Add 700µl buffer RW1 to 
the QiAamp spin column. Centrifuge at ≥8000xg (≥10000r.p.m.) for 15 seconds in 
the Eppendorf centrifuge 
8. Transfer QiAamp spin column into a new collection tube. Check ethanol was 
added to buffer RPE. Apply 500µl buffer RPE to the QiAamp spin column. 
Centrifuge at ≥8000xg (≥10000r.p.m.) for 15 seconds in the Eppendorf centrifuge 
9. Add 500µl buffer RPE to the QiAamp spin column. Centrifuge at ≥20000xg 
(≥14000r.p.m.) for 3 minutes in the Eppendorf centrifuge. Discard the flow through 
10. Centrifuge again at ≥20000xg (≥14000r.p.m.) for 1 minute in the Eppendorf 
centrifuge 
11. Transfer QiAamp spin column to a clean microfuge tube. Pipette 30-50µl RNase 
free ddH2O onto the QiAamp column membrane. Centrifuge at ≥8000xg 
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(≥10000r.p.m.) for 1 minute in the Eppendorf centrifuge to elute the RNA. Repeat if 
>0.5ml blood was used 
12. Store the RNA at -20°C or -70°C. Samples are stable for a year at these 
temperatures 
 
TRIzol RNA Stabilisation: 
The protocol for stabilisation of RNA in blood using TRIzol was received from Dr Marius 
Coetzee (Department of Haematology and Cell Biology, University of the Free State, 
Bloemfontein, 2009). This was to determine if TRIzol stabilised samples could be used 
for analysis in this project and considering future diagnostic use. 
1. Decant 20ml fresh whole blood into a 50ml centrifuge tube 
2. Add 30ml working lysis buffer and stand or mix for 10 minutes 
3. Centrifuge for 10 minutes at 3000xg to pellet the white cells 
4. Discard lysed red blood cells carefully without disturbing the white cell pellet 
5. Add 20ml working lysis buffer to the tube and resuspend pellet 
6. Stand or mix for 5 minutes and centrifuge for 10 minutes at 3000xg  
7. Discard supernatant carefully, without disturbing the white cell pellet 
8. Add 3.2ml TRIzol solution and mix by pipette action and ensure white cells are 
completely dissolved 
9. Store the TRIzol homogenate at -70°C 
 
TRIzol RNA extraction: 
1. Thaw frozen sample. Transfer the sample to a 50ml NUNC tube  
2. Add 0.2ml of chloroform:isoamylalcohol and shake vigorously for 15 seconds. 
Incubate at room temp for 3 minutes 
3. Centrifuge at 12000xg (~14000r.p.m.) in the Eppendorf centrifuge 5415C for 15 
minutes at 4°C 
4. The aqueous phase (clear layer) was removed and placed in a new tube 
5. Add 0.5 ml of isopropanol (propan-2-ol) (Sigma) to the aqueous phase and 
incubate at room temp for 10 minutes 
6. Centrifuge at 12000xg (~14000r.p.m.) in the Eppendorf centrifuge 5415C for 10 
minutes at 4°C. The RNA forms a pellet that may not be visible 
7. Add 1ml 100% ethanol (Merck) and centrifuge at 7500xg (~10000r.p.m.) in the 
Eppendorf centrifuge 5415C for 5 minutes at room temperature 
8. Remove the supernatant and air-dry the sample for 15 minutes 
9. Add 50µl of RNase-free ddH2O to resuspend the sample 
10. Store the RNA at -20°C or -70°C 
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B3 RADIOACTIVE LABELLING OF P482.6 PROBE PROTOCOL 
MegaPrime DNA labelling Kit (Amersham) 
Protocol 
1. Mix together: 10µl  p482.6 probe 
  5µl  primer (supplied with the kit) 
11µl  dH2O 
2. Incubate in a Hagar heating block at 95°C for 5 minutes, then cool on ice 
3. Add: 4µl  each dATP, dGTP, dTTP (supplied with the kit) 
5µl  buffer (supplied with the kit) 
5µl  10mCi/l 32P dCTP 
2µl  enzyme (supplied with the kit) 
4. Incubate in a Hagar heating block at 37°C for 30 minutes 
5. During the incubation step, prepare the spin columns as follows: 
a. Plug the bottom of a 1ml syringe with glass wool, up to the 0.1ml mark. Fill 
the syringe with 5% Sephadex (Appendix D) saturated with 1x TE buffer 
(Appendix D) 
b. Place the syringe in a 15ml falcon tube and spin in an IEC Clinical 
Centrifuge (International Equipment Company) at maximum speed for 5 
minutes to compact the Sephadex beads. Pour the liquid off at the bottom 
of the falcon tube 
c. Top up the syringe with more Sephadex and spin again for 5 minutes. 
Pour off the liquid at the bottom of the falcon tube 
d. Repeat the top-up and spin until the column is packed to approximately 
0.9ml 
e. Place a clean Eppendorf at the bottom of the falcon tube to make the 
collection of the probe easier 
6. Add 5µl of 0.2M EDTA (Appendix D) to stop the labelling reaction 
7. Add 50µl 1x TE buffer (pre-warmed to 37°C) 
8. Add 100µl of the labelled probe mix to the column (see preparation below) 
9. Spin at max speed for 5 minutes and collect eluted products into clean Eppendorf 
tube 
10. Add 100µl 1x TE buffer and spin at max speed for 5 minutes. Collect eluted 
products into same tube as first spin 
11. Dilute these products to 1ml with 1x TE buffer 
12. Diluted probe can be used immediately or stored at -20°C in lead peg until 
required 
13. To use labelled probe, denature in a Hagar heating block at 95°C for 5 minutes, 
then ice for 5 minutes 
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B4 REVERSE TRANSCRIPTION PROTOCOL 
ImPromII Reverse Transcription System (Promega) 
 
Notes before starting 
The oligo(dT)15 primer, nuclease-free ddH2O, ImPromII buffer, MgCl2, dNTP mix, 
RNaseIN and ImPromII Reverse Transcriptase enzyme are supplied with the kit. 
Thaw all reagents on ice 
Perform all steps on ice 
Incubation steps are performed in a heating block or a PCR machine without a heated 
lid 
 
Protocol 
RNA/primer mix 
Mix 4µl RNA with 1µl of 0.5µg/µl oligo(dT)15 primer, and spin samples briefly 
Incubate samples at 70°C for 5 minutes 
Place samples on ice for 5 minutes  
Spin for 10 seconds 
 
Reverse transcriptase mix 
Combine: 3.7µ  Nuclease-free ddH2O 
     4µl 5x ImPromII buffer 
4.8µl MgCl2 
   1µl dNTP mix 
0.5µl RNaseIN (40U/µl) (optional) 
  1 µl ImPromII Reverse Transcriptase enzyme 
Add 15µl reverse transcriptase mix to 5µl RNA/primer mix 
Anneal at 25°C for 5 minutes 
Extend at 42°C for 1 ½ hours 
Inactivate the reverse transcriptase at 70°C for 15 minutes 
Store cDNA products at 4°C until required 
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B5 PCR PRODUCT CLEAN-UP PROTOCOL 
NucleoSpin Extract II Kit (Macherey-Nagel) 
 
Notes before starting 
Add absolute ethanol (Merck) to buffer NT3 
All centrifugation steps performed at 11000xg in either the Eppendorf centrifuge 5415C 
(~11000r.p.m.) or the Beckman-Coulter Microfuge®18 centrifuge (~12500r.p.m.) for the 
specified time 
All incubation steps performed in the Bloer heating block 
 
Protocol 
1. For extraction from agarose gel: 
a. Excise the product of interest from the agarose using a clean scalpel and 
placed in a clean Eppendorf tube 
b. Add two volumes buffer NT to one volume agarose (approximately equal 
to the weight of the gel, in mg) 
c. Incubate at 50°C for 5-10 minutes until the agarose has completely 
dissolved 
OR For extraction directly from PCR products 
a. Make the volume of PCR products up to 50µl 
b. Add 100µl buffer NT 
2. Label the NucleoSpin Extract II column and place into a collection tube 
3. Add the sample to the NucleoSpin Extract II column. Centrifuge for 1 minute. 
Discard flow through 
4. Add 600µl buffer NT3 to the NucleoSpin Extract II column. Centrifuge for 1 minute. 
Discard flow through 
5. Centrifuge for 2 minutes. Discard collection column 
6. Incubate the spin column at 70°C for 2-5 minutes to remove all residual ethanol 
from the sample 
7. Place the NucleoSpin Extract II column into a clean, labelled 1.5ml Eppendorf tube 
8. Add 15-50µl ddH2O to the spin column membrane. Incubate at room temperature 
for 1 minute. Centrifuge for 1 minute to elute he cleaned sample 
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B6 CLEAN-UP OF CYCLE SEQUENCING PRODUCTS PROTOCOL 
DyeExTM 2.0 Spin Kit (QIAGEN) 
 
Notes before starting 
All centrifugation steps performed at 750xg using either the Eppendorf centrifuge 5415C 
(~3000r.p.m.) or the Beckman-Coulter Microfuge®18 centrifuge (~2500r.p.m.). 
 
Protocol 
1. Vortex sephadex column to remove all air bubbles 
2. Loosen screw cap and break off the bottom of the tube 
3. Place sephadex column into a collection tube 
4. Centrifuge the column for 3 minutes 
5. Discard the collection tube 
6. Add 20µl of cycle sequencing product onto the centre of the sephadex 
7. Place sephadex column into a clean, labelled 1.5ml Eppendorf tube 
8. Centrifuge for 3 minutes 
9. Discard sephadex column 
10. Collect the flow-through and dry in the vacuum drier to concentrate the products 
 
 
 
BigDye®X-TerminatorTM Purification Kit (Applied Biosystems) 
Notes: 
This clean up method is used for cleaning 20µl cycle sequencing products in a 96-well 
plate 
Halve the volumes of SAMTM Solution and BigDye® X-TerminatorTM Solution if cleaning 
10µl cycle sequencing products 
SAMTM Solution and BigDye® X-TerminatorTM Solution can be premixed in a 4.5:1 ratio 
up to 24 hours in advance 
1. Add 90µl of SAMTM Solution and 20µl of BigDye® X-TerminatorTM Solution to each 
well containing cycle sequencing product 
2. Seal the plate with heat seal film or AB adhesive cover 
3. Thoroughly mix the contents of the plate on a Vortex-Genie 2 (scientific Industries) 
for 30 minutes 
4. Centrifuge the plate at 1000xg for 2 minutes 
5. Run the plate on a 3130xl Genetic Analyser using the BigDye® X-TerminatorTM 
run module (refer to section 2.3.8) 
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B7 PROTEIN SYNTHESIS PROTOCOL 
EasyXpressTM Protein Synthesis Mini Kit (Promega) 
and 
 
EasyXpressTM Linear Template Kit (Promega) 
 
Notes before starting 
Once thawed, the E. coli extract should be stored on ice and used within 4 hours 
The EasyXpress Protein Synthesis kits are very sensitive to multiple freeze-thaw cycles. 
Do not refreeze and thaw more than two times 
Except for the actual transcription-translation incubation, all handling steps should be 
carried out on ice 
 
Protocol 
1. Thaw EasyXpress Reaction Buffer (blue screw-cap) and XE-solution (green 
screw-cap) on ice. Thaw RNase-free water (colourless screw-cap) at room 
temperature 
2. For each sample (including a positive- and no-template control reactions), prepare 
a premix containing 20µl EasyXpress Reaction buffer and 2.5µl RNase-free water 
in an RNase- and DNase-free reaction tube 
3. Thaw one tube E. coli extract (colourless snap-cap) on ice 
4. Add 22.5µl premix from step 2 to each tube of E. coli extract 
5. For each reaction add 2µl XE-solution to 0.7µg (~7µl) from the second PCR in a 
separate tube and mix by pipetting up and down 
6. Add the XE-solution-PCR product mix from step 5 to each reaction 
7. Bring the final reaction volume to 50µl with RNase-free water 
8. Mix and centrifuge briefly to collect reactions at the bottom of the tube 
9. Incubate at 37°C for 1 hour 
10. Stop the reaction by placing on ice and proceed with sample analysis 
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APPENDIX C 
PRIMER SEQUENCES 
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Table C3: The relative positions of the FVIII mRNA sequence and exons covered 
by each cDNA fragment. 
FVIII mRNA sequence covered Exons covered 
Fragment 
From To From To 
1a 102bp 866bp 1 6 
1b 739bp  1491bp 4 9 
2 1284bp 2458bp 8 14 
3 2332bp 3750bp 14 14 
4a 3730bp 4528bp 14 14 
4b 4444bp 5382bp 14 14 
5 5191bp 6328bp 14 20 
6a 6127bp 6767bp 18 24 
6b 6632bp 7295bp 23 26 
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APPENDIX D 
REAGENT PREPARATION 
1.5% agarose 
1.5g agarose (Hispanger) 
100ml 1xTBE 
Mix together, and boil until agarose is completely dissolved 
Allow to cool to ~60°C 
Add 3µl 10mg/ml Ethidium Bromide (Sigma) to the solution 
Pour into gel casting tray to set 
The gel can be stored at 4°C until needed, if covered in gladwrap and foil 
Other percentage gels can be used. An x% gel uses xg agarose 
 
3% agarose 
3g agarose (Hispanger) 
100ml 1xTBE 
Mix together, and boil until agarose is completely dissolved 
Allow to cool to ~60°C 
Add 3µl 10mg/ml Ethidium Bromide (Sigma) to the solution 
Pour into gel casting tray to set 
The gel can be stored at 4°C until needed, if covered in gladwrap and foil 
 
Depurinating solution (0.025M HCl solution) 
20ml Concentrated HCl (Saarchem) 
780ml ddH2O 
 
Denaturing solution 
87.66g NaCl (final concentration of 1.5M) (Saarchem) 
20g  NaOH (final concentration of 0.5M) (Analysed Analytical Reagent®) 
Made up to 1L with ddH2O 
 
12.5mM dNTP mix (for PCR) 
12.5µl 100mM dATP (Promega) 
12.5µl 100mM dCTP (Promega) 
12.5µl 100mM dGTP (Promega) 
12.5µl 100mM dTTP (Promega) 
950µl ddH2O 
Aliquot into smaller volumes and store at -20°C 
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70% Ethanol 
70ml absolute Ethanol (Merck) 
30ml  ddH2O 
 
0.5M Ethylenediamine Tetra-Acetic Acid (EDTA) 
93.06g EDTA disodium salt crystals (MW=372.24) (Saarchem) 
Adjust to pH8.0 with 5M NaOH to allow crystals to dissolve completely 
Make up to 500ml with ddH2O 
Autoclave and store at room temperature 
 
Ficoll-Bromophenol Blue Loading Dye 
50g  50% sucrose crystals (USB) 
0.1ml  0.5M EDTA (pH7.0)  
0.1g  0.1% bromophenol blue dye (Sigma) 
10g  10% Ficoll®-400 powder (Sigma-Aldrich) 
Make up to 100ml with ddH2O 
Aliquot into 1.5ml Eppendorf tubes 
Store at 4C 
 
1M MgCl2  
20.33g MgCl2 (MW = 203.31g/l) (Saarchem) 
Make up to 100ml with ddH2O 
Autoclave and store at room temperature 
 
1kb or 1kb+ Molecular Weight DNA Marker (1g/l) 
250l ladder (0.25g/l stock) (GIBCO BRL) 
125l  Ficoll-Bromophenol Blue Loading Dye 
2.1ml  1xTE 
Store in smaller aliquots at 4C 
 
Neutralising solution 
87.6g  NaCl (Saarchem) (final concentration of 1.5M)  
60.6g   Tris base (Roche) (final concentration of 0.5M)  
0.292g  EDTA (Saarchem) (final concentration of 0.01M)  
42ml  concentrated HCl (Saarchem) 
Make up to 1L with ddH2O 
pH should be close to 7.2. Adjust with HCl if necessary 
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0.144M NH4Cl 
77g NH4Cl 
1L  ddH2O 
Store at room temperature 
 
0.01M NH4HCO3  
7.95g NH4HCO3 
1L ddH2O 
Work in fume hood to avoid inhaling NH4HCO3 fumes during preparation 
Store at room temperature 
 
Prehybridisation buffer (modified Church and Gilbert Solution) 
12.78g  Na2HPO4 (AnalaR) 
9.75g  Na2H2PO4.2H2O (PAL Chemicals) 
17.5g   SDS (Sigma) 
5ml   0.5M EDTA (Saarchem) 
Make up to 250ml with ddH2O  
pH should be close to 7.2 (use 5M NaOH or NaOH pellets) 
Filter sterilise and store at room temperature 
Heat to 65C to dissolve crystals before use 
 
10mg/ml Proteinase-K 
10mg  Proteinase-K powder (Roche) 
1ml  ddH2O 
Dissolve and store at -20C until needed 
 
Proteinase-K mix 
850l    10% SDS (Sigma) 
34l     0.5M EDTA (Saarchem) 
1700l   10mg/ml Proteinase-K 
Make up to 8000l with ddH2O 
Use 500l per sample for DNA extraction 
 
ROX500-HiDi Formamide mix 
7l GeneScan Rox500 marker (Applied Biosystems) 
146l Hi-DiTM Formamide (Highly deionised formamide) (Applied Biosystems) 
This mix is sufficient for 1 run of 16 samples with an aliquot of 9l per sample 
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Saturated NaCl 
40g NaCl (Saarchem) 
100ml autoclaved ddH2O  
Add NaCl slowly until ddH2O is absolutely saturated 
 
Sephadex solution 
5g  Sephadex® G-50 fine beads (Fluka)  
100ml 1x TE buffer (pH 8.0) 
Swell the Sephadex beads in the 1x TE buffer 
 
10% Sodium dodecyl sulphate (SDS) 
100g SDS powder (Sigma) 
1L autoclaved ddH2O 
Weigh the SDS powder under a fume hood 
 
Southern blot washes 
 Final concentration Stock solution For 100ml 
 2x SSC 20x SSC 10ml 
 1x SSC 20x SSC 5ml 
 0.5x SSC 20x SSC 2.5ml 
 0.1x SSC 20x SSC 0.5ml 
 0.1% SDS 10% SDS 1ml 
 
Special Neutralising Solution 
60.6g Tris(hydroxymethyl)aminomethane (Tris) (Roche) 
175.4g  NaCl (Saarchem) (final concentration of 3M) 
Made up to 1L with ddH2O after adjusting the pH to 7.0 
Approximately 50ml of concentrated HCl (Saarchem) adjusts pH to 7.0 
 
20x SSC solution 
175.35g  NaCl (Saarchem) (final concentration of 3M) 
88.25g Tri-sodium citrate (Associated Chemical Enterprises) (0.3M final 
concentration) 
Made up to 1L with ddH2O 
 
Sucrose-Triton-X Lysing Buffer 
10ml  1M Tris-HCl (pH8.0) 
5ml  1M MgCl2 
10ml  Triton-X 100 (Merck) 
Make up to 1L with ddH2O, autoclave and keep at room temperature until needed 
Add 109.5g sucrose (USB) just before use. Stir until dissolved and keep the 
solution chilled at 4C 
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1.5M Tris (either pH8.8 or 6.8) 
Dissolve  121.14g Tris(hydroxymethyl)aminomethane (Tris) (Roche) 
in   800ml ddH2O. 
Adjust to required pH using concentrated HCl (Saarchem), approximately 4.2ml for 
pH8.0 
Adjust the volume to 1L with ddH2O 
Autoclave and store at room temperature 
 
10x Tris Borate EDTA buffer (TBE) 
109.02g  Tris base (Roche) 
55.64g  Boric acid (Promega) 
7.44g  NaEDTA (Saarchem) 
Dissolve all reagents in 1L ddH2O. Adjust the pH to 8.3 with HCl (Saarchem) 
Autoclave and store at room temperature 
Dilute 10-fold before use 
 
T20E5 
20ml 1M Tris-HCl 
10ml  0.5M EDTA 
Make up to 1L with ddH2O with a pH of 8.0 
Store at room temperature 
 
1x Tris-EDTA (TE) Buffer  
10ml 1M Tris-HCl (pH8.0) 
2ml  0.5M EDTA 
Make up to 1L with ddH2O 
Autoclave and store at room temperature 
 
Working Lysis Buffer 
100ml 0.144M NH4Cl 
100ml 0.01M NH4HCO3 
Make up to 1L with ddH2O 
Autoclave and store at room temperature 
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APPENDIX E 
PROTOCOL SHEETS FOR PCRS 
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E1 PCR PROTOCOL FOR DETECTION OF THE INTRON 1 INVERSION  
 
PCR components 
Component  Stock concentration Final concentration 1x mix 
DNA   1µl 
Amplitaq buffer  10x 1x 2.5µl 
MgCl2 25mM 2.5mM 2.5µl 
dNTP mix 10x 1x 2.5µl 
DMSO 100% 5% 1.25µl 
Primer: int1h-2F 20ρmol/µl 20ρmol 1µl 
Primer: 9F  20ρmol/µl 20ρmol 1µl 
Primer: 9cR 20ρmol/µl 20ρmol 1µl 
Amplitaq polymerase 5U/µl 2.5U 0.5µl 
ddH2O   11.75µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 5 minutes       1 cycle 
95°C – 30 seconds, 63°C – seconds; 72°C – 2 minutes  30 cycles 
72°C – 5 minutes       1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 15µl PCR products on a 1.5% agarose gel.  
PCR product size = 1.5kb (normal band) or 1kb (mutant band) 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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E2 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 1A 
PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
cDNA   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Betaine   5µl 
Primer: HPA-RNA-1a-F 10ρmol/µl 20ρmol 2µl 
Primer: HPA-1-seq-R 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   8.8µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 54°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 1.5% agarose gel.  
Expected PCR product size = 765bp 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
Improved Mutation Detection for Haemophilia A in South Africa 136 
E3 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 1B 
First round PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
cDNA   1µl 
High fidelity buffer 2 10x 1x 1.25µl 
dNTP mix 10x 1x 1.25µl 
Betaine   2.5µl 
Primer: HPA-RNA-1a-F 10ρmol/µl 20ρmol 1µl 
Primer: HPA-RNA-1b-R 10ρmol/µl 20ρmol 1µl 
High fidelity taq polymerase 3.5U/µl 0.35U 0.1µl 
ddH2O   6.9µl 
TOTAL   12.5µl 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 48°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
 
Second round PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
First round PCR product   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Betaine   5µl 
Primer: HPA-PTT1-seq-F 10ρmol/µl 20ρmol 2µl 
Primer: HPA-PTT-1d-R 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   8.8µl 
TOTAL   25µl 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 48°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl second round PCR products on a 1.5% agarose gel.  
Expected PCR product size = 737bp. 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
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E4 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 2 
First round PCR components 
Component  Stock concentration Final 
concentration 
1x mix 
cDNA   1µl 
High fidelity buffer 2 10x 1x 1.25µl 
dNTP mix 10x 1x 1.25µl 
Primer: HPA-RNA-2a-F 10ρmol/µl 20ρmol 1µl 
Primer: HPA-RNA-2b-R 10ρmol/µl 20ρmol 1µl 
High fidelity taq polymerase 3.5U/µl 0.35U 0.1µl 
ddH2O   6.9µl 
TOTAL   12.5µl 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 60°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
 
Second round PCR components 
Component  Stock concentration Final 
concentration 
1x mix 
First round PCR products   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Spermidine 1/40 dilution of 0.1M  2.5µl 
Primer: HPA-PTT-2c-F-new 10ρmol/µl 20ρmol 2µl 
Primer: HPA-RNA-2d-R 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   11.3µl 
TOTAL   25µl 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 64°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl second round PCR products on a 1.5% agarose gel.  
Expected PCR product size = 1243bp. 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
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E5 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 3 
PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
cDNA   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Primer: HPA-RNA-3c-F 10ρmol/µl 20ρmol 2µl 
Primer: HPA-PTT-3f-R-new 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   13.8µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 60°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 1.5% agarose gel.  
Expected PCR product size = 1483bp 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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E6 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 4A 
PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
cDNA   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Betaine   5µl 
Primer: HPA-RNA-4c-F 10ρmol/µl 20ρmol 2µl 
Primer: HPA-PTT4-seq-R 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   8.8µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 50°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 1.5% agarose gel.  
Expected PCR product size = 799bp 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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E7 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 4B 
PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
cDNA   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Betaine   5µl 
Primer: HPA-PTT4-seq-F 10ρmol/µl 20ρmol 2µl 
Primer: HPA-RNA-4f-R-new 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   8.8µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 50°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 1.5% agarose gel.  
Expected PCR product size = 983bp 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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E8 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 5 
First round PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
cDNA   1µl 
High fidelity buffer 2 10x 1x 1.25µl 
dNTP mix 10x 1x 1.25µl 
Primer: HPA-RNA-5a-F 10ρmol/µl 20ρmol 1µl 
Primer: HPA-RNA-5b-R 10ρmol/µl 20ρmol 1µl 
High fidelity taq polymerase 3.5U/µl 0.35U 0.1µl 
ddH2O   6.9µl 
TOTAL   12.5µl 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 60°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
 
Second round PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
First round PCR products   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Betaine   5µl 
Primer: HPA-RNA-5c-F 10ρmol/µl 20ρmol 2µl 
Primer: HPA-RNA-5d-R 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   8.8µl 
TOTAL   25µl 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 56°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 1.5% agarose gel.  
Expected PCR product size = 1275bp 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
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E9 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 6A 
PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
cDNA   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Betaine   5µl 
Primer: HPA-PTT-6-F 10ρmol/µl 20ρmol 2µl 
Primer: HPA-PTT6-seq-R 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   8.8µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 54°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 1.5% agarose gel.  
Expected PCR product size = 641bp 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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E10 PCR PROTOCOL FOR AMPLIFICATION OF CDNA FRAGMENT 6B 
First round PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
cDNA   1µl 
High fidelity buffer 2 10x 1x 1.25µl 
dNTP mix 10x 1x 1.25µl 
Betaine   2.5µl 
Primer: HPA-RNA-6a-F 10ρmol/µl 20ρmol 1µl 
Primer: HPA-RNA-6b-R 10ρmol/µl 20ρmol 1µl 
High fidelity taq polymerase 3.5U/µl 0.35U 0.1µl 
ddH2O   4.4µl 
TOTAL   12.5µl 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 48°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
 
Second round PCR components 
Component  Stock 
concentration 
Final concentration 1x mix 
First round PCR products   2µl 
High fidelity buffer 2 10x 1x 2.5µl 
dNTP mix 10x 1x 2.5µl 
Betaine   5µl 
Primer: HPA-PTT6-seq-F 10ρmol/µl 20ρmol 2µl 
Primer: HPA-PTT-6d-R 10ρmol/µl 20ρmol 2µl 
High fidelity taq polymerase 3.5U/µl 0.7U 0.2µl 
ddH2O   8.8µl 
TOTAL   25µl 
PCR conditions 
95°C – 10 minutes        1 cycle 
95°C – 1:30 minutes, 52°C – 1:30 minutes; 72°C – 2:30 minutes  35 cycles 
72°C – 20 minutes        1 cycle 
15°C – hold 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 1.5% agarose gel.  
Expected PCR product size = 664bp 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
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E11 PCR PROTOCOL FOR AMPLIFICATION OF DNA EXONS 
The primers, annealing temperatures and product size specific for each exon of the FVIII 
gene can be found in Appendix C, Table C4. 
 
PCR components 
Component  Stock concentration Final concentration 1x mix 
DNA   2µl 
Amplitaq buffer  10x 1x 2.5µl 
MgCl2 25mM 2.5mM 2.5µl 
dNTP mix 10x 1x 2.5µl 
Primer: ________-F 10ρmol/µl 10ρmol 1µl 
Primer: ________-R 10ρmol/µl 10ρmol 1µl 
Amplitaq polymerase 5U/µl 1U 0.2µl 
ddH2O   14.3µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 5 minutes       1 cycle 
95°C – 1 minute, ____°C – 1 minute; 72°C – 1 minute  _____ cycles 
72°C – 10 minutes       1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 3% agarose gel.  
Expected PCR product size = _______bp 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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E12 PCR PROTOCOL FOR AMPLIFICATION OF INTRON 13 INTRAGENIC 
MARKER 
 
PCR components 
Component  Stock concentration Final concentration 1x mix 
DNA   2µl 
Amplitaq buffer  10x 1x 2.5µl 
MgCl2 25mM 2.5mM 2.5µl 
dNTP mix 10x 1x 2.5µl 
Primer: 1A-F (FAM) 10ρmol/µl 10ρmol 1µl 
Primer: 2A-R 10ρmol/µl 10ρmol 1µl 
Amplitaq polymerase 5U/µl 1U 0.2µl 
ddH2O   14.3µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 5 minutes       1 cycle 
95°C – 1 minute, 45°C – 1 minute; 72°C – 1 minute   30 cycles 
72°C – 10 minutes       1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 5µl PCR products on a 3% agarose gel.  
Expected PCR product size = 137-155bp 
Analyse products further using microsatellite analysis. Run 1µl undiluted PCR products 
with 9µl Rox500-HiDi mix (for 16 samples use 146µl HiDi formamide and 7µl Rox500) on 
the 3130xl genetic analyser. 
 
Interpretation of results 
Number of AC repeats = (PCR product size – 108bp)  2  
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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E13 PCR PROTOCOL FOR AMPLIFICATION OF INTRON 22 INTRAGENIC 
MARKER 
 
PCR components 
Component  Stock concentration Final concentration 1x mix 
DNA   2µl 
Amplitaq buffer  10x 1x 2.5µl 
MgCl2 25mM 2.5mM 2.5µl 
dNTP mix 10x 1x 2.5µl 
DMSO 100% 10% 2.5µl 
Primer: 1B-F (HEX) 10ρmol/µl 10ρmol 1µl 
Primer: 2B-R 10ρmol/µl 10ρmol 1µl 
Amplitaq polymerase 5U/µl 1U 0.2µl 
ddH2O   10.8µl 
TOTAL   25µl 
 
PCR conditions 
95°C – 5 minutes       1 cycle 
95°C – 1 minute, 45°C – 1 minute; 72°C – 1 minute   30 cycles 
72°C – 10 minutes       1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 25µl PCR products on a 3% agarose gel.  
Expected PCR product size = 69-87bp 
Analyse products further using microsatellite analysis. Run 1µl undiluted PCR products 
with 9µl Rox500-HiDi mix (for 16 samples use 146µl HiDi formamide and 7µl Rox500) on 
the 3130xl genetic analyser. 
 
Interpretation of results 
Number of AC repeats = (PCR product size – 32bp)  2  
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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E14 PCR PROTOCOL FOR AMPLIFICATION OF P39 EXTRAGENIC MARKER 
 
PCR components 
Component  Stock concentration Final concentration 1x mix 
DNA   2µl 
Amplitaq buffer  10x 1x 2.5µl 
MgCl2 25mM 2.5mM 2.5µl 
dNTP mix 10x 1x 2.5µl 
Primer: p39-F (HEX) 10ρmol/µl 10ρmol 1µl 
Primer: p39-R 10ρmol/µl 10ρmol 1µl 
Amplitaq polymerase 5U/µl 1U 0.2µl 
ddH2O   14.3µl 
TOTAL   25µl 
 
PCR conditions 
94°C – 45 seconds, 65°C – 50 seconds; 72°C – 30 seconds 30 cycles 
72°C – 10 minutes       1 cycle 
15°C – hold 
 
PCR machine: Perkin Elmer GeneAmp 2720: PCR machine #:____ 
Check 5µl PCR products on a 3% agarose gel.  
Expected PCR product size = ~152-166bp 
Analyse products further using microsatellite analysis. Run 1µl undiluted PCR products 
with 9µl Rox500-HiDi mix (for 16 samples use 146µl HiDi formamide and 7µl Rox500) on 
the 3130xl genetic analyser.  
 
Interpretation of results 
Allele size = PCR product size (results are not reported as repeat numbers as with intron 
13 and intron 22 microsatellites) 
 
Samples 
Lane Patient name HPA code Result 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
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APPENDIX F 
SUMMARY TABLE OF RESULTS 
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Table F1: Mutations in the FVIII gene identified in South African haemophilia A patients. 
Mutation 
type Code Ethnicity Severity Inhibitors 
Intron 22 
inversion DNA change 
Observed cDNA 
change 
Predicted protein 
change 
FVIII 
position 
Novel 
mutation 
Polymorphisms 
identified 
Inversion HPA007 White Moderate No Positive – type I - - - Intron 22 No  
Inversion HPA041/204 White Severe No Positive – type I  - - - Intron 22 No  
Inversion HPA127 White  Severe No Positive – type I  - - - Intron 22 No  
Inversion HPA169 White Severe No Positive – type I - - - Intron 22 No  
Inversion HPA174 White Severe No Positive – type I - - - Intron 22 No  
Inversion HPA182 White Severe No Positive – type I - - - Intron 22 No  
Inversion HPA199 White Severe No Positive – type I - - - Intron 22 No  
Inversion HPA270 White Severe No Positive – type I - - - Intron 22 No  
Inversion HPA031 Black Severe No Positive – type I - - - Intron 22 No  
Inversion HPA159 Black  Severe No Positive – type I - - - Intron 22 No  
Inversion HPA189 Black Severe No Positive – type I - - - Intron 22 No  
Inversion  HPA191 Black Severe No Positive – type I - - - Intron 22 No  
Inversion HPA193 Black Severe No Positive – type I - - - Intron 22 No  
Inversion HPA213 Black Severe Yes Positive – type I - - - Intron 22 No  
Inversion HPA237 Black Unknown Unknown Positive – type I - - - Intron 22 No  
Inversion HPA271 Black Severe No Positive – type I - - - Intron 22 No  
Inversion HPA277 Black Unknown Unknown Positive – type I - - - Intron 22 No  
Inversion HPA167 Indian Severe No Positive – type I - - - Intron 22 No  
Inversion HPA227 Mixed ancestry Severe Yes Positive – type I - - - Intron 22 No  
Inversion HPA035 White Severe No Positive – type II - - - Intron 22 No  
Inversion HPA138 White Severe No Positive – type II  - - - Intron 22 No  
Inversion HPA170 White Severe No Positive – type II - - - Intron 22 No  
Inversion  HPA195 White Severe No Positive – type II  - - - Intron 22 No  
Inversion HPA203 White Severe No Positive – type II - - - Intron 22 No  
Inversion HPA196 Black Severe Yes Positive – type II - - - Intron 22 No  
Inversion HPA206 Black Severe No Positive – type II - - - Intron 22 No  
Inversion  HPA207 Black Severe Yes Positive – type II  - - - Intron 22 No  
Inversion HPA211 Black Severe No Positive – type II - - - Intron 22 No  
Inversion HPA235 Black Severe No Positive – type II - - - Intron 22 No  
Inversion HPA239 Black Severe Yes Positive – type II - - - Intron 22 No  
Inversion HPA240 Black Severe No Positive – type II - - - Intron 22 No  
Inversion HPA275 Black Unknown Unknown Positive – type II - - - Intron 22 No  
Inversion HPA198 Mixed ancestry Severe No Positive – type II - - - Intron 22 No  
Inversion  HPA107 White Severe No Positive – atypical  - - - Intron 22 No  
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Table F1: Continued 
Mutation 
type Code Ethnicity Severity Inhibitors 
Intron 22 
inversion DNA change 
Observed cDNA 
change 
Predicted 
protein change 
FVIII 
position 
Novel 
mutation 
Polymorphisms 
identified 
Inversion HPA177 Black Severe No Positive – atypical - - - Intron 22 No  
Inversion HPA265 Black Unknown No Negative - - - Intron 1 No  
Inversion  HPA266 Black Severe No Negative - - - Intron 1 No D1241E 
Inversion HPA273 Indian Severe Yes Negative - - - Intron 1 No  
Missense HPA186 Black Severe No Negative 29618AT 431AT D125V Exon 4 Yes M2238V 
Missense HPA091 White Moderate ? Negative 29700GA 514GA V162M Exon 4 No D1241E 
Missense HPA172 White Moderate No Negative 56198CT 1171CT R372C Exon 8 No  
Missense HPA205 Black Severe No Negative 56267AG 1241AG T395C Exon 8 Yes  
Missense HPA084 Black Severe No Inferred negative 56716GA 1406GA G450E Exon 9 Yes M2238V 
Missense HPA183 Black Severe No Inferred negative 56716GA 1406GA G450E Exon 9 Yes A544A, M2238V 
Missense HPA261 Indian Mild No Inferred negative 61568AC 1457AC N467T Exon 10 Yes  
Missense HPA112 White Severe No Negative  68826TC 1898TC M614T Exon 12 Yes  
Missense HPA037 White Moderate No Negative  91100GA 2167GA A704T Exon 14 No   
Missense HPA218 Black Severe  Inferred negative 91927TG 2994TG H979Q  Exon 14 Yes D1241E 
Missense HPA241 Black Severe No Inferred negative 93692GA 4759GA D1568N Exon 14 Yes  D1241E 
Missense HPA272 Black Moderate No Negative 116283GA 5353GA E1766K Exon 14 Yes D1241E 
Missense HPA201 White Moderate No Inferred negative 117871GA 5544GA E1829K Exon 16 No ¥  
Missense HPA247 Black Severe No Inferred negative 118700TA 5881TA W1942R Exon 18 Yes  
Missense HPA232 White Mild No Inferred negative 160972CG 6690CG R2209G Exon 24 No  
Missense HPA234 White Moderate No Inferred negative 162135GT 6744GT W2229C Exon 25 No  
Missense HPA248 White Mild No Inferred negative 185027CT 6956CT P2300L Exon 26 No  
Nonsense  HPA033 White Severe No Negative 56262-56263 GGAC 1236-1237 GGAC WD393-394XH Exon 8 
W393X = 
No ¥  
Nonsense  HPA254 White Moderate No Inferred negative 56646CT 1336CT R427X Exon 9 No  
Nonsense  HPA175 Black Severe No Negative  91220CT 2287CT Q744X Exon 14 Yes  
Nonsense  HPA269  Black Severe Yes Inferred negative No result 2440CT R795X Exon 14 No  
Nonsense HPA225 White Severe No Negative 92024AT 3091AT K1012X Exon 14 Yes D1241E 
Nonsense HPA115 White Severe No Negative 92676TG 3743TG L1229X Exon 14 Yes  
Nonsense HPA164 White Severe No Negative 93875CT 4942CT Q1629X Exon 14 Yes D1241E 
Nonsense HPA060 Black Severe No Negative 94077CT 5144CT R1696X Exon 14 No  
Nonsense HPA184 Indian Severe No Negative 162270AG 6879AG W2271X Exon 25 No  
Deletion  HPA202 Black Severe No Negative ? 1445-1538del Ex10-11 deletion Exon10&11 ●  
Deletion  HPA258 Black Severe No Inferred negative 74927delTTC 2014delTTC ΔF652 Exon 13 No  
Deletion  HPA274 White Severe No Inferred negative 92482delAA  3548delAA  K1164fsX13 Exon 14 No  
Deletion  HPA194 Black Moderate No Negative 92571delA 3637delA I1194fsX5 Exon 14 No D1241E 
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Table F1: Continued. 
Mutation 
type 
Code Ethnicity Severity Inhibitors Intron 22 
inversion 
DNA change Observed cDNA 
change 
Predicated 
protein change 
FVIII 
position 
Novel 
mutation 
Polymorphisms 
identified 
Deletion HPA160 Black Severe No Negative 92679delCTGA 3745delCTGA L1230fsX6 Exon 14 Yes P1481P 
Deletion  HPA256 White Severe No Negative 93052delA 4118delA Q1354fsX1 Exon 14 Yes  
Deletion  HPA068/215 White Severe No Negative 93255delAGAA 4321delAGAA K1424fsX20 Exon 14 No  
Deletion  HPA013 White 
Carrier 
(dad 
severe) 
Unknown Negative 93313delA 4379delA N1441fsX5 Exon 14 No  
Deletion HPA128 White Severe No Negative 93854delA 4920delA E1621fsX1 Exon 14 Yes S1269S 
Insertion HPA011/129 White Severe No Negative 92571insA 3637insA I1192fsX27 Exon 14 No  
Insertion HPA015 White Severe No Negative 92571insA 3637insA I1194fsX27 Exon 14 No  
Insertion HPA050 White Severe No Negative 92571insA 3637insA I1194fsX27 Exon 14 No  
Insertion HPA118 White Severe No Negative 92571insA 3637insA I1194fsX27 Exon 14 No  
Insertion  HPA230 White Severe No Inferred negative 92571insA 3637insA I1194fsX27 Exon 14 No  
Insertion  HPA249 White Severe No Negative 92571insA 3637insA I1194fsX27 Exon 14 No  
Insertion HPA029 White Severe No Negative 93135insC 4201insC P1381fsX5 Exon 14 Yes S1269S 
Splice site HPA236 White Moderate No Inferred negative 75023CT 1904-2113del (ex13 del) 
P687L = ex13 
deletion Exon 13 Yes  
Splice site HPA176 Black Severe  No Inferred negative 91048GC = IVS13-1GC 
2114-2143del 
(partial ex14 del) 
686-696del (partial 
ex14 deletion)  Intron 13 Yes  
Complex  HPA219 * Mixed ancestry Severe Yes Inferred negative ? 1445-1538del (ex10 del) 
463-494del  
(ex10 deletion) 
Exon 10 ● M2238V 
Complex HPA020 * White Moderate No Inferred negative ? 113bp ins@2120 Insertion of 37.3amino acids Intron 13 ●  
Complex HPA223 White Severe No Inferred negative ? 5373-5419del Partial ex16 del (del1773-1788) Exon 16 ● IVS16+37delT  
Complex HPA017 * White Severe No Negative ? 6005-6121del 
Exon 19 deletion 
(1981-2020del) 
Exon 19 ●  
Complex HPA210 * Black Severe No Negative ? 6005-6121del 
Exon 19 deletion  
(1981-2020del) 
Exon 19 ● IVS19-103TC 
Nomenclature of the FVIII mutations in this study is as follows (as per standard nomenclature used by the HAMSTeRS mutation database):  
The DNA change is determined where the “A” of the start codon is the first base; 
The cDNA sequence starts 171bp into the FVIII mRNA and  
The amino acid sequence of the mature protein starts 19 amino acids into the native protein sequence. 
* In these patients, a mutation was identified on one amplified product of cDNA. However, these mutations could not be confirmed on repeat cDNA sequencing, due to unsuccessful amplification 
or a mutation that was outside the region sequenced on DNA.  
● The exact DNA change could not be elucidated. We were therefore unable to determine if these mutations were previously reported. 
¥ These mutations were not previously reported on the HAMSTeRS mutation database, but were reported by Green, et al. (2008). 
 These changes are assumed to be polymorphic as no evidence could be found for pathogenicity in the respective patients. They could be useful in linked marker analysis for at-risk relatives. 
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